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ABSTRACT

The objectives of this research were to test treatment and survival differences
between women and men with lung cancer as there is minimal investigation in the
literature. Three research questions were developed with statistical testing for gender
differences based on similar cancer type, stage, treatment assignment and survival. Data
for 44,863 primary lung cancer cases were collected from eight U.S. state-based cancer
registries to investigate the research questions. The lung cancer incidence data included
the morphological cell-types of adenocarcinoma (AC); squamous cell carcinoma (SCC);
large cell carcinoma (LCC) and small cell carcinoma (SCC). Stage, grade, treatment
type, as well as, individual characteristics such as gender, age at diagnosis, marital status
at diagnosis and race were other variables obtained to be included in the statistical
models.
Reporting the overall effect for lung cancer gender specific treatment differences
or survival has not been demonstrated in the literature to the author’s knowledge. By
convention, main effects and interaction effects are reported in the literature; without
including an evaluation the overall effect of a variable on the outcome, possible
misinterpretations could be made. For example, utilizing the Cox’s Proportional Hazards
model when the interaction effect of gender and treatment type received was examined,
females were at an increased risk for death by as much 29% as compared to males (HR =
1.18, 95% CI 1.09 – 1.29). But when the gender effect on survival was assessed, there
was an increase in females survivorship as compared to males by as much as 28% (HR =
xv

0.80, 95% CI 0.72 – 0.97 ).
In conclusion, by using a unique statistical approach, statistically significant Odds
Ratios and Hazard Ratios were demonstrated for the research data set when the overall
interaction effect on the outcome was examined. Recommendations to health care
practitioners include adhering to current guidelines, e.g. American Medical Association,
for lung cancer treatments. Standard treatment protocols were not always followed for
early stage disease, e.g. females versus males with stage I lung cancer were 1.71 times
more likely to receive chemotherapy in combination with radiation therapy versus a
standard first treatment course of surgery (OR = 1.71, 95% CI 1.06 – 2.78). Also,
depending on the lung cancer morphology and lung cancer treatment, females as
compared to males could exhibit an increase in survivorship by as much as 28%. To
improve the results of medical care decisions for lung cancer, clinicians may find the
information presented in this study useful and encourage further research on which
treatment increases survival for both men and women.

xvi

CHAPTER I: INTRODUCTION
Background
There are many histological types of lung cancer and finding an optimum
treatment regimen is a challenge. Lung cancer typically is classified into two major
divisions: small cell lung cancer (SCLC or oat cell carcinoma) and non-small cell lung
cancer (NSCLC) 2-5. SCLC accounts for approximately 20% of all the lung cancer cases,
whereas about 80% of all lung cancer cases are NSCLC. There are many types of
NSCLC but the three major histological classifications are adenocarcinoma, large cell
carcinoma, and squamous cell carcinoma 6, 7. The treatment modalities for small cell
lung cancer versus non-small lung cancer are different due to the biological response of
the particular cancer cell type to various treatment regimens 8-11. The medical
interventions for each histological type can include any combination of treatment
modalities such as surgery, radiation therapy, and/or chemotherapy. Adding to the
complexity of lung cancer is that the incidence, prevalence, and survival rates are also
dissimilar for the specific histological type 1, 2, 12, 13.
One prognostic factor for lung cancer ―in terms of treatment treatment/modality
received‖ that requires further exploration is the relationship between lung cancer
treatment(s) and gender. There is limited research regarding if the treatment modality,
e.g. radiation therapy, surgery, chemotherapy, received is dependent upon being a woman
with lung cancer as compared to a man with lung cancer. This is of particular interest
because of all the various types of cancers and treatments available, lung cancer has
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become the leading cause of death for women as there has been a 600% increase for
women with lung cancer from 1930 to 1997 44. Any effect which gender exerts in the
decision regarding which lung cancer treatment modality decided upon must be
disentangled from other prognostic factors. The study question(s) of this research
attempted to enumerate the risk of being a woman with lung cancer and type of treatment
received compared to a man with lung cancer and the type of treatment modality that he
receives. An assessment was made to determine if a statistically significant association
between gender and treatment modality exists. Another aspect of gender differences that
was investigated included the impact on survivorship between women and men with lung
cancer. Stratified analysis was based on the histological type, stage, grade, gender and
the treatment modality or treatment modalities received in an attempt to investigate
treatment effects on survival. Much of the scientific literature on lung cancer research
does not address survival and the relationship gender has to play due to the effects of
specific histological lung cancer types, stage or progression of LC, and grade on gender
and survival. The purpose of this research study is to provide a quantitative assessment
of the outcome (survival) for women as compared to men based on the particular
treatment received for lung cancer 14-17.
Minorities will also be included in the subject selection; it is important not to
exclude minorities as they can provide valuable epidemiologic information. In an
attempt to facilitate minority research, United States government agencies, e.g. the
National Cancer Institute (NCI), now mandate the inclusion of women, children, and
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minorities if government funding is provided for the study 18-20. For the purposes of this
research, minorities are being included since the treatment modality selected for the
treatment of lung cancer may be dependent upon race as well as gender 21. In other
words, race may or may not play a role in the treatment modality utilized for lung cancer.
Although this research is primarily focused on what treatment modalities are
utilized for men as compared to women, the impact of gender on lung cancer survival
will also be considered. There are several reasons why is gender important as risk factor
for lung cancer. First, according to the 2001 report by the Surgeon General 44, female
lung cancer mortality increasing by 600% since 1930 noting that this is a ―full blown
epidemic‖ 44. Secondly, the causal pathways of lung cancer development are blurred for
women 8, 13. For example, the causes of lung cancer among women seemingly different
from men, are still not resolved 3, 8, 13. One possible answer to this question is much of
the current knowledge and treatment patterns for lung cancer are based on research
primarily done on men. Previously, the association between being a woman and the risk
of lung cancer was considered negligible as reported in the 1964 Report of the Advisory
Committee to the Surgeon General DHEW Publication Number PHS 110323. But as
behavior and other temporal changes, such as cigarette smoking have occurred over the
past several decades for women, lung cancer incidence and increased mortality rates of
lung cancer 24, 76, 77. Women historically have been excluded from clinical trials or if
included, the data was not analyzed22. If women are at a greater risk for lung cancer than
men at the same level of smoking one result of women being excluded historically from
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research studies is even there is no evidence in the literature to support this; results have
been conflicting and limited 22. A 1964 report of the ―Surgeon General on Women and
Smoking‖ 23 did not reach any conclusions concerning what role gender difference may
play in the development of lung cancer. The 1964 report did conclude that although
smoking was risk factor for lung cancer in men, smoking was not a risk factor for lung
cancer in women as there was not enough scientific evidence to establish causality 24.
What was not known at the time of the 1964 report was the temporal effect due to when
women started smoking on a large scale and the development of lung cancer (lag time of
approximately twenty years).
Hypotheses have been developed based on possible physiological responses to
carcinogens and hormonal related differences in women as compared to men but
inconsistent results in the literature remains 8, 15, 17, 25-27. Lung cancer is the leading cause
of death of all cancers in both men and women in the United States 28. The overall
lifetime risk in women is 1 in 17 and for men 1 in 13 for lung cancer development 27, 29,
30

. Lung cancer has an extremely low 5 year survival rate of 15%. The primary cause of

lung cancer is due to smoking cigarettes; smoking is estimated as being a causal factor in
80 – 90 % of all lung cancer cases 14, 15. Some of the literature reports the susceptibility
for lung cancer in women is different when compared to men with women by
demonstrating an increased risk for lung cancer

8, 14, 15, 31, 32

. Another source for concern

for women is second hand smoke; of the individuals that die from that exposure, 65 % are
women 33. This could possibly indicate hormonal differences may make women more
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susceptible to smoke. Sex differences in survival and susceptibility have been linked to
estrogen as a lung cancer risk factor 229.

Research Questions
Given what present day research has and has not found concerning the treatment
of lung cancer and the role gender has played in the selection of the treatment modality,
the following research questions will be addressed in this dissertation:
Question One: Do men and women with the same histological type and
stage/grade of lung cancer receive the same treatment modality?
Question Two: Are there differences in survival between men and women
regardless of the treatment modality received?
Question Three: Do men and women with the same histological type, stage/grade
of lung cancer, and same treatment modality, have comparable survival?

As stated in the abstract and in the background, the study or research question(s)
will focus on the association between the treatment received by women with lung cancer
as compared to that received by men. The study will investigate the overall survival
patterns based on the treatment that a woman with lung cancer receives versus a man.
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CHAPTER TWO: LITERATURE REVIEW
Overview of the Lungs
Anatomy and Physiology
The lungs, part of the respiratory system, are coned shaped, sponge-like, and
highly elastic organs located in the chest. The functions of the respiratory system and in
particular, the lungs, include gas exchange, moisturizing the inhaled air, stabilizing the
temperature of all air to body temperature, and filtering harmful substances 34, 35. As
shown in Figure 5, the respiratory system includes the nasal cavity, the windpipe or
trachea, and two lungs. The upper tract of the respiratory system includes the mouth or
oral cavity, the nasal cavity, and the trachea 36. The lower tract of the respiratory system
consists of lungs, bronchi, and alveoli. Inspiration and expiration are the two phases of
respiration or breathing. During each phase of respiration, the volume or dimensions of
the chest cavity is changed, i.e. increased lung volume (inspiration) or decreased lung
volume (expiration) 36, 37.
Air entering into the body via the nose or mouth, contains approximately 21%
oxygen with no carbon dioxide. The air is drawn into the trachea and bronchi, and then
enters the lungs through the left or right bronchi. Air entering into the main branch of the
bronchi will travel into smaller bronchi which further divide into smaller, complex tubes
called the bronchioles 36, 37. Mucus is secreted by the inner lining of the larger bronchial
tubes. One of the purposes of the secretion is to filter or trap dirt from the air. In a
continuous, sweeping process, the mucus is expelled from the lungs by cilia; cilia are

6

similar to hair or brush-like structures 38. Coughing is another method by which mucus is
removed from the lungs. The final or most distal ends of the bronchioles are connected
to small air sacs called alveoli. The exchange of gases occurs in the alveoli. T he alveoli
are very thinly walled, balloon-like structures that expand upon inspiration and relax or
deflate upon expiration 37, 38. Each alveolus is surrounded by small blood vessels called
capillaries. When the concentration of dissolved oxygen is greater in the alveoli than in
the capillaries, oxygen diffuses across the alveoli walls into the blood plasma contained
in the capillaries. An increased concentration of CO2 in the blood results in carbon
dioxide diffusing from the capillaries into the alveoli. At the time air is exhaled, it
contains approximately 16% oxygen and 4.5% carbon dioxide 37, 38.
As previously described, the exchange of oxygen and carbon dioxide occurs in the
lungs. Each lung is identified by the apex, lobes, and base. The left lung is comprised of
2 lobe or sections; typically weighing 625 grams 34, 39. The right lung has three lobes,
approximately 567 grams. The left lung is smaller than the right to accommodate the
heart and other structures in the mediastinum. The lungs have a surface area
approximately equal to the size of a tennis court and while at rest, the entire body blood
supply or blood volume, five liters, passes through the lungs each minute 38.
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Figure 1: The Respiratory System
Source: webschoolsolutions.com/patts/systems/lungs.htm

The Disease of Interest: Lung Cancer
Any obstruction of air flow through the bronchial tree or at the alveoli can cause
serious functional limitations or even death 37, 38. Besides the various diseases which can
obstruct airflow and affect the cellular respiration, the lungs can become cancerous 10.
Physiological changes in the lung tissue where the lung becomes cancerous can be
defined as an uncontrolled cell growth in the lung forming clumps of tissue referred to as
malignant tumors 37. Exposure to carcinogens, such as those present in tobacco smoke,
immediately causes changes to the tissue lining the bronchi of the lungs (the bronchial
mucous membrane), the more cumulative damage to the lung tissue, the greater the
probability a tumor will develop 9, 10. The non-small cell lung cancers (NSCLC) are
grouped together because their prognosis and management is roughly identical 2, 9, 54.
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There are 3 major subtypes of NSCLC: squamous, large cell, and adenocarcinoma 1, 2, 55.
Squamous cell carcinoma starts in the larger breathing tubes but grows slower, this means
that the size of these tumors vary when the diagnosis is made. Adenocarcinoma (the
slower growing type forms alveolar cell cancer) starts near the gas-exchanging surface of
the lung 56. It is less closely associated with smoking. Large cell carcinoma is a fastgrowing form that grows near the surface of the lung 4, 57. It is primarily a diagnosis of
exclusion, and when more investigation is done, it is usually reclassified to squamous cell
carcinoma or adenocarcinoma 56. Small cell carcinoma (SCLC, also called "oat cell
carcinoma") is the less common form of lung cancer. Approximately 20% of all primary
lung cancer diagnosed are small cell lung cancer and account for 30,000 to 35,000 cases
per year in the United States 13, 28. Small cell LC tends to start in the larger breathing
tubes and progresses rapidly becoming quite large 6, 10, 58, 59. SCLC is more sensitive to
chemotherapy, but carries a worse prognosis and is often metastatic at presentation 2, 3, 33.
This type of lung cancer is strongly associated with smoking 4. Exposure to carcinogens,
such as those present in tobacco smoke, immediately causes cumulative changes to the
tissue lining the bronchi of the lungs (the bronchial mucous membrane) and the more
tissue that gets damaged, the greater the probability a tumor will develop 4, 37. Squamous
cell carcinoma usually is diagnosed after the disease has spread 1, 5, 12, 13. The overall
prognosis for all non-small cell lung cancers is poor, with a five-year survival rate of
about 15% 11, 13, 60. The survival rate is higher (close to 50%) when the cancer is detected
and treated early 13. Survival rates after surgery vary 7, 43, 54, 61-63. For those with stage I
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disease, the five-year survival rate is about 47% 13, 64. For those with stage III disease,
the five-year survival rate is 8% 2, 13, 33, 64. Even when surgery and other therapies are
initially successful, there is a high risk of the cancer reoccurring 4, 27, 32, 65. This reflects
the fact that squamous cell carcinoma is rarely restricted to just one area. Squamous cell
carcinoma readily spreads to other parts of the body 4, 30, 66.
Cancer is a multistep progression of changes or phases that occur in the genes 43,
52, 67-71

. The genotypic changes are characterized by the loss of normal cellular

differentiation and an alteration in tissue morphology due to an increase of unrepaired
DNA damage and the formation of abnormal genomic variants 10. Lung cancer can
result from an exposure of a susceptible host to carcinogenic agents; these exposures
cause progressive changes in the cell from metaplasia, to atypia and dysplasia, then
developing into a carcinoma in situ and invasive cancer 72. The changes that occur on the
cellular level are variable from individual to individual, and not all neoplasms follow the
same progress 4. Metaplasia, the first phase of cancer development, is the transformation
of a mature differentiated cell type into a different mature differentiated cell type 4. This
transformation is in response to an injury or insult at a cellular level which can make the
tissues more susceptible to a malignant alteration. Atypia is defined as an abnormality
associated with a precancerous process. An atypical cell (atypia) can also be an
indication of an infection or irritation 4, 37. Atypia can be caused by a chronic irritation
and this has been shown increases the probability of premalignant lesions 9. Dysplasia is
typically an irreversible condition or change in the cell that is a precursor of invasive
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epithelial tumors. There levels or grades of dysplasia and high grade dysplasia can be
difficult to distinguish from carcinoma in situ during histologic examination 4, 37.

Exposures of Interest: Gender and Lung Cancer Treatment Modality
There is limited research regarding the survival of women with lung cancer and
the treatment received compared to the survival of men with lung cancer and the
treatment men receive 12, 40-45. Presently, there are no quantitative results that show
whether there is a statistically significant difference regarding survival due to a particular
treatment for women as compared to men having the same histological type and stage of
lung cancer 46-48. The goal of this research is to investigate the exposures, gender and
treatment modality and their effect on the outcome, survival. Several research questions
must be answered in order to evaluate the relationship between these variables. Belani
et.al., 2007, in the article ―Women and lung cancer: Epidemiology, tumor biology, and
emerging trends in clinical research‖, noted that ―emerging findings in the scientific
literature reveal gender specific differences in cancer prognosis‖ 41. The authors
expressed an urgent need to increase research and funding to improve lung cancer care,
women in particular 41. Ringer et al. (2005) in the article "Influence of sex on lung
cancer histology, stage, and survival in a Midwestern United States Tumor Registry."
identified differences between men and women with regard to lung cancer type, stage at
diagnosis, and survival in a single hospital system cancer registry. The study design was
a retrospective cohort with a target population based on case information from a lung
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cancer tumor registry at a single hospital system composed of 2 independent hospitals in
the Midwestern United States27. This database included all patients from 1996 to 2002
with known lung cancer or abnormal findings on chest radiography or computed
tomography (N=2618). Patients with adenocarcinoma or squamous cell, small-cell, or
large-cell carcinoma were included in the study. A total of 1216 men and 997 women
were included in the study. The authors found no significant difference in age between
sexes at diagnosis27. Women were significantly more likely to have adenocarcinoma or
small-cell carcinoma but less likely to have squamous cell carcinoma compared with
men. There were no significant differences between sexes in the incidence of large-cell
carcinoma. No significant differences were found between men and women in terms of
cancer stage at diagnosis 27. There were significant differences in survival between the
histologic types at years 3, 4, and 5. Only patients with stage I disease showed a
difference between sexes and only for years 2, 3, 4, and 5. This study did not investigate
the impact of treatment modality on survival, gender, histological type and stage of lung
cancer. Women were found to have a decreased survival with late stage lung cancer as
compared to men 27 but there was no expansion of the results based on the type of
treatment received for women and men.
In the article by Ouellette, et. al. (1998), ―Lung Cancer in Women as Compared to
Men: Stage, Treatment, and Survival‖ 8, gender differences in survival were examined.
The authors8 cited several articles that reported on cardiovascular disease and the survival
advantage for men as compared to women; Ouellette, et. al.’s research attempted to
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identify gender disparities in lung cancer survival. To test the hypothesis of a gender
difference in lung cancer survival, a retrospective cohort study of 104 women and 104
men was conducted. Women were found to have a higher incidence of small cell lung
cancer (25% versus 12% as compared to men); whereas men had a greater percentage of
squamous cell carcinoma (51% versus 38% as compared to women) 8. The authors noted
there were no statistically significant survival differences between women and men but
women were found to live, on average, 6 months longer then men (mean survivalwomen =
24 months, mean survivalmen = 18 months). Ouellette, et. al. reported when stratified
analysis based on the stage of lung cancer (Stage I, II, IIIa, IIIb, and IV) was assessed, ―
these two groups with a coefficient according to stage, there was a survival advantage in
women, and they seem to live 12 months longer than men‖ 8. The authors reported that
this increase in women’s survivorship may be contributed to an intrinsic factor, e.g.
hormones. Ouellette, et. al. concluded the overall survival between men and women was
not statistically significant but that there was a significant survival difference between
men and women with lung cancer when stratified on stage.
The question about gender differences and lung cancer survival has not been
resolved in the literature as conflicting results still exist 40, 41, 49-52. A recently published
article investigating gender differences and survival by Wisnivesky and Halm, 2007,
―Sex-Differences in Lung Cancer Survival: Do Tumors Behave Differently in Elderly
Women‖ examined women’s responses to treatment and their survival as compared to
men 53. The study was based on SEER data collected from men and women diagnosed
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between 1991 and 1999 (N = 18,967) with stage I and stage II non-small cell lung cancer.
It was shown that for early stages of lung cancer, that women have a better overall and
relative survival as compared to men (p = 0.001). The authors noted women as compared
to men had a greater probability of being diagnosed with adenocarcinoma, tended to be
diagnosed at an earlier age, and when the disease had not metastized (localized) 53.

Epidemiology
Epidemiology is utilized to monitoring the consequences of an intervention and is
used in the development of hypotheses for risk factors 73, 74. Epidemiological methods
are used to study lung cancer for the identification of the disease frequency, determinants,
and distribution of lung cancer in human populations 73, 74. For example, there has been
an increase of 600% in mortality for women with lung cancer since 1930 28, 40, 60 and
without monitoring or the identification of the disease frequency in epidemiological
terms ―this epidemic rise in lung cancer mortality44‖ 24, 75-77 may not have been identified.
Alberg et. al, (2005) reported that in the 20th century of the United States the lung cancer
epidemic ―peaked and began to declined by century’s end, a decline that continues today‖
40

. The rates of lung cancer in women were shown to have a differential increase in lung

cancer incidence and mortality over time as compared to men 40. Lung cancer rates have
peaked for men but the rates for women are still increasing in many regions of the world
5, 16, 30, 65, 78, 79

. While the gap between lung cancer gender differences is narrowing, the

differences for in incidence and mortality rates are declining 45, 46, 66, 80, 81. According to
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the International Agency for Research on Cancer (IARC), rates of all lung cancer types
among women and adenocarcinoma of the lung in men continue to rise in many Western
countries 5. Worldwide, lung cancer is the 10th leading cause of death and is the leading
cause of death for all types of cancer 5. The 5-year relative survival remains low;
approximately 10% in Europe. In Developing Countries, the incidence of smokingrelated lung cancer is rising rapidly 5, 30, 82. Countries such as China are expected to see a
marked increase in lung cancer cases as smoking is exceedingly common 5, 78. Devesa
and Bray, 2005, reported recent total lung cancer incidence rates among males varied by
4-fold, from 83.6 among U.S. Blacks to 21.1 in Sweden 30. Rates in the Nordic countries,
which varied by 2-fold from a high in Denmark to a low in Sweden, still were generally
lower than in other parts of Europe, where the incidence rate was highest in the
Netherlands 30. Lung cancer rates in Italy, Slovenia and France were higher as compared
to U.S. Whites or Canadian LC incidence. The authors also noted that among females,
recent incidence rates varied by almost 8-fold, with the highest among U.S. Blacks (35.8)
and the lowest in Spain (4.6) 30. The ranking of rates among females paralleled that in
males, with the exception of Switzerland. Lung cancer rates everywhere were higher
among males than females 30. Male to female rate ratios varied from less than 2 in
Iceland, U.S. Whites, Canada, Denmark and Sweden to more than 6 in Slovenia, Italy,
and France and more than 10 in Spain 13, 30. Henschke et. al. (2006) reported that the US
cancer rates for men and women in their research showed a dose (pack-years) – incidence
(lung cancer) threshold as there was a biological gradient associated with increased pack-
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years with an increased risk of lung cancer 174.
In the United States, the American Cancer Society estimated that there were
92,305 new cases of lung cancer in men and 79,544 new cases among women in 2006 2.
The majority of cancer deaths among women and men are attributed to lung cancer 2.
According to the American Cancer Society, approximately 60% of newly diagnosed lung
cancer cases die within the first year of diagnosis 2. The 5- year relative survival rate is
approximately 15% in the United States. The prevalence rates of smoking as reflected in
the National Health Interviews, Current Population Survey, notes that smoking
attributable cancer mortality for males is approximately 90% and 78% for females 84-86.
Current literature about smoking habits (age when started smoking, number of cigarettes
daily, duration frequency of inhalation, use of dark tobacco, and non-filter cigarettes) 8789

, notes that a smoker is twenty two times more likely to die from lung cancer than a

nonsmoker 86. In Chapter Three ―The Descriptive Epidemiology of Lung Cancer‖ from
the book Epidemiology of Lung Cancer: Academic Press; 1998, a study from the
Saskatchewan Cancer Foundation (a population based cancer registry) was referenced by
Thomas J. Mason. He noted endogenous and exogenous factors may contribute to the
development of primary lung cancer in women 83. Endogenous factors can be produced
or can be synthesized within an organ in the body; exogenous factors are agents or factors
from outside the body (cigarette smoke) 37.
Zang and Wynder conducted a hospital-based prospective, case-control study on
data collected from 1995 through 1995 that included 21,057 males as controls and 14,448
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female controls that were originally diagnosed with non-smoking related diseases 81. The
authors found that at the same level of lifelong exposure to cigarette smoke, women had a
1.5 times greater risk of developing lung cancer as compared to men 90. There was a
statistically significant difference in the incidence of adenocarcinoma; females were at a
higher risk of developing adenocarcinoma versus males independent of tar yield per
cigarette 90. Zang and Wynder noted a statistically significant difference between
squamous cell carcinoma for women as compared to men, dependent upon the level of
total tar per cigarette (> 6 kg). Women were found to develop primary lung cancer at
earlier age as compared to men, yet women smoked fewer cigarettes for a shorter time
than men 81.
Smoking patterns have changed over the past thirty years and the change in the
dominant histologic lung cancer classifications, possible differences between gender
emerges 83. Lung cancer has a multivariable etiology and there are specific risks
associated with the type of lung cancer 3, 91-95. These secular trends can provide a clue to
the understanding of lung cancer and future research for the impact on diagnosis,
treatment, and outcome 48. Other studies that identify patterns of risk by the histologic
types include an article by Devesa, et al., 2005, utilizing data from the International
Agency for Research on Cancer (IARC) databases 30. Morphology-specific incidence
data noted that the rates of all lung cancer types are increasing for women and
adenocarcinoma is rising for men 30. This trend continues even with the decrease in
prevalence of smoking and the use of filtered and low tar cigarettes 13. These finding are
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consistent with current literature as the secular trends in histologic type with the annual
rise in the incidence of adenocarcinoma 10, 96-98. Govindan et al., 2006 in the article
―Changing Epidemiology of Small-Cell Lung Cancer in the United States over the Last
30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database‖, found
that the proportion of women with SCLC increased from 28% in 1973 to 50% in 2002 99.
When SCLC was compared to all lung cancer histologic types there was a decreased of
SCLC from 17% in 1986 to 13% in 2002 99. The authors also noted that although there
was an overall decrease in small cell carcinoma, survival had not improved. Stockwell, et
al., 1990, found the histological type of lung cancer varied by age, sex and the use of
cigarettes; this was based on observations from a population based cancer registry in
Florida 96. A dose threshold for the amount of cigarettes smoked and the risk of lung
cancer was not statistically significant. The authors noted that adenocarcinomas were
more frequent in the younger aged population (< 60 years of age) for both genders. Men
who smoked had a higher risk for squamous cell carcinoma whereas females very more at
risk for small cell carcinoma 96. Adenocarcinoma was the most frequently encountered
histological type for women who were nonsmokers 96.
As there are differences in the incidence of histologic lung cancer types
based on smoking patterns, the rates of incidence and mortality for lung cancer differ
according to regional areas across the United States 4. Geographic mapping of lung
cancer incidence and mortality was introduced by Mason in the 1960’s while at the
National Cancer Institute in Atlanta, Georgia 83. This novel approach allowed for the
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identification of regional differences in lung cancer rates; with this information Public
Health resources were directed to areas with increased rates for purposes of prevention
and monitoring of trends. There are differences in smoking attributable risk between
males (>90%) and females (<80%) although ratio between male smoking rates and
female smoking rate approach unity 83. These homogeneous and heterogeneous patterns
of lung cancer etiology require further identification of factors other than smoking as to
quantify the risk for the four major histologic types of lung cancer.
Currently, lung cancer incidence in women is approximately equal to that of men
as reported by the American Cancer Society (see Figure 6 below) 2. Lung cancer in the
United States is the most common cause of cancer death in women; today the mortality
rate is more than two times what it was 25 years ago 2. In Figure 7 below, the estimated
number of U.S. lung cancer deaths is given for 2006. Cancer of the lung and bronchus is
the most common and most fatal cancer in men (31%), followed by prostate cancer
(10%), and colon & rectum cancer (10%) 2. The major killer of women from a cancer
specific cause is lung cancer (27%), breast cancer (15%), and colon & rectum (10%) are
the leading sites of cancer death 2.
As women began smoking in increasing numbers during the 1930’s and 1940’s,
the death rate due to lung cancer steadily increased with a dramatic rise in mortality rates
in 1965 (see Figure 8) 2-4, 79, 100, 101. Lung cancer mortality rates in women have reached a
plateau since 1998 102. As shown in the Figure 9 below, the death rate from lung cancer
appears to have peaked in 1990 for men 2. The age-adjusted lung cancer death rate in
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men has been decreasing since 1990. Prior to 1990, the major increase in cancer death
rates for men was attributable to lung cancer 2. When comparing the mortality rates
between men and women (Figure 8 and Figure 9), the temporal effect of gender specific
smoking patterns associated with the increase in lung cancer mortality is clearly
demonstrated 2, 102.
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Figure 2: 2006 Estimated US Cancer Cases

Figure 3: 2006 Estimated US Cancer Deaths
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Figure 4: US Women Cancer Death Rates
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Figure 5: US Men Cancer Death Rates

There are many other aspects of the association of the risk factor (gender) to the
outcome of lung cancer. These aspects of a woman’s overall susceptibility to lung cancer
can include but are not limited to: smoking patterns (cigarette type, depth of inhalation,
number of pack years), gender, occupation, dietary factors, nutrition, hormonal factors,
air pollution, obesity, and radiation effects 45, 49, 62, 67, 81, 103-110. Incidence and prevalence
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rates are used in the evaluation of the overall disease (lung cancer) trends. These
statistics are available on government sponsored data bases such as the National Cancer
Registry SEER registries, state cancer registries, e.g. members of the North American
Association of Central Cancer Registries, Inc. or other state registries, such as the
Washington State Department of Health Occupational Mortality Data Base 1, 13.

Impact on Health Care Resources
Lung cancer has a devastating impact an individual’s quality of life but has also
has direct and indirect costs associated with lung cancer diagnosis and treatment. Some
of the direct costs are medical care which include hospitalization, doctors visits, home
health care, hospice care, and treatment modalities such as radiation therapy, surgery, and
chemotherapy 10. Direct non-medical costs associated with lung cancer can consist of
transportation to and from the hospital/physician’s office, housekeeping services and any
additional costs incurred due to changes necessary in the living conditions of the patient.
Other considerations are the indirect costs which can be difficult to grasp the scope of
exactly what can be involved with patient care 111-113. These costs such as time spent
seeking medical attention, time lost from work (lost productivity), or job replacement
costs cannot be directly measured in some instances 111-113. The costs associated with
lung cancer care are enormous according to the National Heart Lung & Blood Institute
(NHLBI). In 2003, there were 1.5 million deaths representing 47% of all deaths in the
United States 111, 113, 114. These deaths were as result mainly of three disease processes;
lung, cardiovascular, and blood diagnosis. By 2006, these three diseases are expected to
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exceed $560 billion of medical costs 115. Lung cancer costs in 2004, shows medical
expenditures as approximately 10 billion annually, according to the Centers for Medicare
and Medicaid Services (CMS) 115. Lung cancer represents over 13% of the total cancer
care costs for 2004. The non medical total or personal care exceeded 250 billion for the
same time period.
Lung cancer is one cancer which is more expensive to diagnose and treat because
of the histologic types 64, 116-118. Many successfully treated cancer types have an early
detection program or screening program for the early diagnosis of cancer 4, 117, 119.
Unfortunately, lung cancer does not have an effective screening tool and typically is not
diagnosed until it has spread outside the diseased organ 64, 116-118. As the majority of lung
cancer is diagnosed at later stages, the associated healthcare costs and resources required
are increased 111, 113. In 2007, it is estimated that the total healthcare cost (HCC) for lung
cancer will be 21 billion. According to CMS, lung cancer care and treatment accounts for
10% of the total US healthcare costs 115. The United States Federal Office of the Actuary
estimates that by 2016 every 20 cents of every dollar will go towards health care by 2016
115, 120

. The annual forecast by a division of the Centers for Medicare and Medicaid

Services (CMS) predicts a 10-year increase of approximately 2 trillion dollars (2.1 trillion
to $4 trillion) for spending on health care in the United States 115, 120. This represents an
ever increase amount of healthcare resources going to the detection and treatment of lung
cancer. Using the estimated 4 trillion which is expected in 2016 with the total HCC
being 400 billion, the lung cancer portion of 13.3% would make the projected lung cancer
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portion over 53 billion 115. If the same relationship as seen in medical costs, estimated
non medical costs could exceed over 1 trillion. The projected lung cancer incidence and
mortality rates are expected to increase as 77 million baby boomers will move into their
60’s; the age that has the highest risk for lung cancer incidence. This march to retirement
of those who were heavy tobacco use will be responsible for even higher costs after 2016
115, 120

.

Origin
The site of origin of lung cancer refers to the type of tissue from which the cancer
cells develops 9, 121. Lung cancer is categorized by site of origin into hilar and peripheral
types; as the structures where the disease originates are different 37. The majority of early
cancers in the hilar region are squamous cell types, whereas many early stage lung
cancers in the peripheral areas are adenocarcinoma 121. Adenocarcinoma originates in
glandular tissue; whereas a carcinoma originates in the tissue that lines the organs and
tubes of the lungs called epithelial tissue 122. NSCLC adenocarcinoma and large cell
carcinoma typically are located in the peripheral of the lungs and can present as solitary
nodules or masses 37. Squamous cell carcinoma and small cell carcinoma are normally
found in the central portion of the lungs and can be misdiagnosed as a collapsed lung
(atelectasis) or pneumonia (an inflammation of the lungs) 37. Small cell carcinoma is
normally located in the mainstem bronchi; this cancer originates in the Kulchitsky’ cells
which are a component of the bronchial epithelium 35.
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The tissue layers are comprised of cells that are similar in their structure and
perform common functions. The intercellular material, e.g. RNA, DNA, are contained
within the cells; genetic material is found within the intercellular material for that cell
type. As a human embryo develops, three primary germ layers provide the basis for body
tissue and organ formation 35. The three germ layers are the ectoderm, the endoderm,
and the mesoderm. The ectoderm and endoderm layers are considered epithelial tissue.
The epithelial tissue from the endoderm lines the respiratory tract (the lungs and the air
passageways from the pharynx to the lungs).

Clinical Signs and Symptoms of Lung Cancer
Early detection of cancer is credited with an increased survival; unfortunately for
lung cancer, there is no early detection program that has clinically proven long-term
success 4, 117, 118, 123. One impact due to the lack of early detection for lung cancer is that
lung cancer has become one of the most lethal of all cancers; mortality rates for lung
cancer have surpassed colorectal, breast and prostate cancer combined 4. The main
difficulty in the diagnosis of lung cancer is that the majority of lung cancer cases do not
have symptoms (asymptomatic) until the disease has progressed to an advanced stage 4, 64,
119, 124

. It is estimated by the American Cancer Society that only 15% of all lung cancer

cases are diagnosed in the early stage, i.e. Stage I 4. The average five year survival rate
for lung cancer patients is 15%, this low survival rate is consistent with the current lack
of an early diagnosis program 4, 64, 119, 124.
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Common clinical lung cancer symptoms include a new or persistent cough,
hemoptysis or blood in the sputum, chest pain, wheezing, hoarseness, shortness of breath,
and repeated respiratory infections, e.g. bronchitis, pneumonia 4. The symptoms of lung
cancer can vary according to the tumor type and the extent of the disease or metastases.
Recent articles in the literature have identified another area of concern in the diagnosis of
lung cancer 4, 9, 125-128. Lung cancer diagnosis is currently done based on the symptomatic
criteria outlined in textbooks that were written ten to twenty years ago 125. As physicians
may not be aware of the changing patterns of lung cancer, this may add to the difficultly
of a diagnosis, let alone an early diagnosis 125. Collins, et. al., 2007, noted that there have
been epidemiologic changes or differences in the lung cancer patient population 4. Some
of the current differences include an increased number of females with lung cancer; the
most frequently encountered histological lung cancer type for males and females has
changed to adenocarcinoma, and temporal differences in the age of diagnosis 4, 10. These
epidemiologic differences may decrease the identification of specific symptomatic
patterns in lung cancer cases which in turn could negatively impact the rate of early
diagnosis 4.
Approximately thirty to forty percent of lung cancer cases that are diagnosed have
symptoms of metastatic disease 28; some of the most common organs that the cancer
spreads to are the liver, the brain, the bones, spinal cord, and the adrenal glands. The
symptoms of metastatic disease include bone pain, personality changes, confusion,
elevated alkaline phosphatase level, seizures, weakness, weight loss, nausea, vomiting,
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and palpable lymphadenopathy 4. There are several clinical manifestations of the skeletal
and endocrine systems due to lung cancer spread. Some of the endocrine manifestations
include Cushing’s syndrome and hypercalcemia. Common clinical symptoms of the
skeletal system consist of digital clubbing and hypertrophic pulmonary osteoarthropathy;
these symptoms occurs in approximately ten percent of lung cancer cases 4.
Clinical presentation and radiographic results are first steps in the differentiation
or diagnosis of lung cancer type, i.e. small cell lung cancer (SCLC) or non-small call lung
cancer (NSCLC) 9. Small cell lung cancer is recognized by lymphadenopathy or the
swelling of the lymph nodes and tumor invasion of the mediastinum 9. A characteristic of
small cell lung cancer is the tumor or mass is seen in the hilum in approximately 78% of
the cases. Patients with small cell lung cancer can present with paraneoplastic
syndromes. Paraneoplastic syndromes are a collection of clinical signs and symptoms
resulting from the byproducts of the tumor interrupting normal biological function 4.
Some of the syndromes resulting from small cell lung cancer include Lambert-Eaton
syndrome (muscle weakness), inappropriate antidiuretic hormone, and ectopic
adrenocorticotrophic hormone production 9.

Procedures for Diagnosing Lung Cancer
Early detection and treatment is credited with increased survival for early stage
lung cancer 13, 28. Early stage lung cancer is defined ICD-9 code as Stage I; which is less
than 3 cm and with no evidence that the disease has may has spread outside the lung. There are
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several early detection technologies providing diagnosis of lung cancer. These include are
Computerized Tomography (CT), Magnetic Resonance Imaging (MRI) and Positron
Emission Tomography (PET) Scans 113, 129. Early treatment choices for lung cancer include
chemotherapy, surgery, Radiation Therapy and combined modalities 4, 48, 130. In
Radiation Therapy, there have been advancements in computer technology allowing the
scanning results of CT, MRI and PET to be merged into a three dimensional (3-D) treatment
planning system for more precise Radiation Therapy treatments 72. The technological
treatment advancement of Intensity Modulated Radiation Therapy can focus the radiation
beam into very specific treatment fields that are created or simulated on the treatment
planning system by using CT scan and/or by merging of CT and PET scans 72. Literature
has shown that staging of cancer patients has vastly improved with the aid of PET 131-133. In
many instances, the patient treatment plan has been changed drastically. Cancer patient cases
thought to be primary and hence the patient would have received a very aggressive treatment
become palliative with less cost, physically, emotionally and economically, to the patient and
community at large 131-133.
The gold standard for diagnosing lung cancer is with a tissue diagnosis. There are
several diagnostic methods in order to obtain a tissue which include 1) sputum cytology,
2) a thoracentesis, 3) excisional biopsy of an accessible node, 4) flexible bronchoscopy
with or without transbronchial needle aspiration, 5) transthoracic needle aspiration, 6)
video-assisted thoracoscopy, and 6) thoracotomy 4. In order to select the most
appropriate test or procedure the physician, e.g. pulmonologist, interventional radiologist,
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or thoracic surgeon, must make a determination of which lung cancer type is suspected.
Patients with suspected early stage non small cell lung cancer who are surgical
candidates, commonly have a surgical procedure known as a thoracotomy 4, 9, 54, 59, 125, 134,
135

. A patient can be staged as well as having a tissue diagnosis from this procedure 4, 9.

Sputum cytology involves the collection of at least three samples of sputum; it is
noninvasive, but if the results are negative, further testing may be required 4, 9, 135. This
technique is recommended if the patient has hemoptysis; sputum cytology is indicated for
centrally located tumors in the chest cavity. The specificity for this test is 99% and the
sensitivity for central tumors is 71%, peripheral tumors are less than 50% 4, 125, 127. If the
patient has pleural effusion (fluid between the lung and the chest cavity); a thoracentesis
can be performed. Sampling of the fluid can give an indication of the presence of lung
cancer. The sensitivity for this procedure is 80% with a specificity of less than 90%. In
the case of palpable lymphadenopathy, a biopsy of an accessible node can be a method to
obtain a tissue sample. Sputum cytology, flexible bronchoscopy, and transthoracic
needle aspiration are procedures employed when the stage and the cancer type are
unclear. Flexible bronchoscopy involves passing a scope along the bronchial tract and
taking samples of tissue via bronchial washings and/or biopsies. The sensitivity of this
procedure or ability to correctly detect the presence of the disease is 88%. Computerized
tomography (CT) of fluoroscopic guidance can be utilized while placing the catheter into
the patient’s lungs. The sensitivity and specificity of this test depends upon where the
tumor is located or where the tissue sample is taken. The sensitivity for diagnosis of
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centrally located tumors utilizing flexible bronchoscopy is 88% and the specificity is
90%. The sensitivity for peripheral tumors drops to 60 to 70% with this technique. The
procedure of choice for peripheral tumors (sensitivity of 90%) under CT or fluoroscopic
guidance is the transthoracic needle aspiration; its’ specificity is 97%. It is indicated in
nonsurgical candidates with peripheral tumors when the transbronchial needle aspiration
is inconclusive. One drawback or complication of this procedure is a pneumothorax
(collapsed lung) in 25 to 30% of the patients undergoing the procedure 4, 9. Videoassisted thoracoscopy is a more recent procedure 4 and is used for small peripheral tumors
less than 2 centimeters in diameter, pleural effusion , or pleural tumors. The major
advantage of a video-assisted thoracoscopy is it can prevent an unnecessary surgical
procedure, i.e. the thoracotomy. Lastly, the surgical procedure recommended for the
treatment and the diagnosis of early stage non-small cell lung cancer is a thoracotomy in
cases with a clearly resectable tumor 4, 9, 126, 136.

Screening
There are many histological types of lung cancer and finding a single biomarker
or screening tool is a challenge. Several biomarkers are being evaluated as screening or
predictors for lung cancer. An effective screening program for lung cancer is important for
early detection of the disease which could increase survival. One of the research projects at
the Moffitt Cancer Research Center, has the objective of finding a biomarker that will be
used to develop an early screening and detection program for those people at risk for lung
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cancer 137, 138. Present research includes microscopic examination of sputum sample
staining patterns. One of the possible biomarkers is monoclonal antibodies (Mabs). The
pattern and stain intensity of the Mabs and varying cell characteristics are being
investigated as a possible screening tool. The understanding of tumor biology has
increased with the recognition of genetic and protein markers which precede malignancy
137

. Mutations of particular genes contribute to the process of epithelial carcinogenesis.

These mutations modify the control of abnormal cell growth. Heterogeneous nuclear
ribonucleoprotein (hnRNP) has been linked as a marker with sputum cytology for early
detection of lung carcinogenesis. Data demonstrate that hnRNP is expressed in most lung
cancer cases before any morphologic abnormality.
Other biological markers that are found in lung tumors include: tumor suppressor
genes (p53, Rb, p16, p21), proto-oncogenes (K-ras, c-myc, c-erB-1 and 2, HGF, HER-2),
Telomerase (hTERT), hypermethylation and growth factors (GRP/BN, TGF-b, FDGF,
PTHrP, IGF-I and II), apoptosis and angiogenesis (Bcl-2, VEGF), and gene amplification
(HER-2) 137. These molecular markers can be important markers for pulmonary
carcinogenesis, used as an early diagnosis tools, and can be determinants in prognosis of
a lung cancer treatment regimen. As shown in the Table 1 (Chart 2) below from Duarte,
et. al, 2005, several biological markers are found with greater frequency with respect to
the tumor type 139. The molecular marker Rb is found 30% in NSCLC but approximately
100% of the time it is detected in SCLC.
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Table 1: Molecular Biomarker for Lung Cancer (LC)

Presently, the National Cancer Institute is conducting a large scale clinical trial
known as the Prostate, Lung, Colorectal, and Ovarian Screening Trial (PLCO) 140, 141.
The objective of this study is to determine the efficacy of screening tools utilized during
the trial and evaluate the death or mortality rate associated with that particular cancer
under study 142. The major disadvantage with this trial for the early detection of lung
cancer is the screening tool, a conventional chest x-ray, does not detect lung neoplasms at
early stages 140. Another research study known as the National Lung Screening Trial
(NLST) is sponsored by the National Cancer Institute for women and men and women at
risk for lung cancer. This particular trial is comparing spiral CT scans and conventional
chest x-rays and making a determination which is a more effective screening tool in an
effort to reduce death due to lung cancer. Spiral CT scans are effective in the
visualization of lung nodules that cannot be seen in conventional chest x-rays; this does
creates moral and ethical issue as a spiral CT is proven to detect lung cancer in the early
stages as compared to a chest x-ray 143. Presently, the literature does not show that a
spiral CT scan or a conventional chest x-ray has not been demonstrated in the literature to
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reduce the risk of lung cancer mortality 9, 135, 140, 144.

Pathology/Histology
There are two major categories of lung cancer; small cell carcinoma and non-small cell
carcinoma. NSCLC includes adenocarcinoma, squamous cell carcinoma and large-cell
undifferentiated carcinoma 3, 40. Each histological type has its own medical intervention
that can include any combination of surgery, radiation therapy, and/or chemotherapy 7, 51, 67.
The incidence and survival rates are also different for the lung cancer type. There are many
causal factors for lung cancer such as lifestyle, occupational risks, and environmental
factors 10. The primary cause of lung cancer is smoking 9, 13, 145-151. Lung cancer remains a
major public health problem lacking an early prevention and intervention program 4, 9, 125, 136.
As far as Public Health consequences, lung cancer is the most lethal of all cancers as it has
the highest mortality rate both among men and women 2, 13 with the average ―5 Year
Survival Rate‖ of 13 percent.
The four major types of lung cancer are adenocarcinoma, squamous cell
carcinoma, large cell, carcinoma, and small cell carcinoma. The four major lung cancer
types comprise 95% of a lung cancer cases 72. Adenocarcinoma is a malignant neoplasm;
it originates in the epithelial cells of glandular tissue, and forms glandular structures.
This particular cancer is very commonly found in the periphery and accounts for 30 40% of all lung cancer types. Squamous cell carcinoma accounts for 20-30% of lung
tumors and the origin is usually hilar 7, 152. 95% of all small cell lung cancer is attributed
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to smoking. SCLC metastasizes early and has a five year survival rate of less than 15%.
Large cell carcinomas account for 10-15% of all lung neoplasms and are comprised of
undifferentiated or immature cells. Large cell is the most aggressive of the NSCLC as
they difficult to diagnose due to its’ undifferentiated nature. These are commonly located
in the central portion of the lung.
The ICD-O code for lung cancer pathology is classified by the morphology code
and the topography code as shown below in Figure 6.

Figure 6: Structure of a Morphology Code
Source: http://training.seer.cancer.gov

The topography code identifies the site and the sub-site for the disease of interest.
The complete ICD-O code contains ten digits with the first four digits being the topography
and the last six digits the morphology identifiers. Figure 7 is an example of the coding
scheme for a squamous cell lung cancer.
Diagnostic term:
Poorly differentiated squamous cell
carcinoma, upper lobe of lung
C34.1 M-8070/33

Figure 7: Structure of a Complete ICD-O Code
Source: http://training.seer.cancer.gov
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The complete site specific topography code for lung cancer is shown in Figure 8
from SEER. Figure 9 displays the anatomy of the lungs with the associated ICD-O code.
The codes range from C34.0 as found in the main bronchus to C34.9 NOS (not otherwise
specified).
ICD-O

TERM

C34.0

Main bronchus

C34.1

Upper lobe, lung

C34.2

Middle lobe, lung (RIGHT LUNG ONLY)

C34.3

Lower lobe, lung

C34.8

Overlapping lesion of lung

C34.9

Lung, NOS

C33.9

Trachea, NOS

Prior to the Second Edition of ICD-O, trachea and lung had the same ICD-O
code. With the advent of ICD-O-2, trachea has a separate code (C33.9) from lung (C34._). The ICD-O
four-digit subsites of C33.9 through C34.9 are considered part of a single primary site. Since lung is a
paired organ, laterality must be coded.

Figure 8: ICD-O-3 Site (Lung) Codes
Source: http://training.seer.cancer.gov/ss_module03_lung/unit03_sec01_icdo_codes.html

Figure 9: Lung Anatomy with ICD-O-2/3 Codes
Source: http://training.seer.cancer.gov/ss_module03_lung/unit03_sec01_icdo_codes.html
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Staging/Extent of Disease
There are several purposes why it is necessary to stage a cancer case. First, the
medical professional must assess the extent of the disease adequately 1, 4, 40. Correct
ascertainment of the extent of the disease is crucial as the appropriate treatment regimen
must be determined 10. A curative or palliative approach in disease management will be
based on the stage of lung cancer the patient has. Secondly, staging can one of the
indicators of patient’s prognosis and projected survival. Other indicators of prognosis
include tumor histology, grade of disease, and patient demographics, e.g. age, gender,
race, socioeconomic status, and martial status 55, 139, 153, 154. Finally, with a
comprehensive and standardized staging protocol, the exchange of information between
the scientific communities can be accomplished. Staging or coding data are use for
research and general health care information. The extent of the disease can be classified
by the use of a number or coding system with increasing values representative of
increasing disease severity. The anatomic coding system allows for analysis of similar
cases with comparable characteristics based on disease extent 11. Cancer cases are
described by the site of origin called the primary site and how far the cancer has spread
from the primary site. Other essential variables include tumor size, the number of tumors
(multiplicity), the depth of the tumor invasion, regional or distant tissue extension,
regional lymph node involvement, and distant metastases 13.
Coding information began on an international level in 1893 for mortality data.
The League of Nations’ World Health Organization (WHO) introduced the concept of
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staging a disease in 1929. One of the first descriptions of the extent or the stage of the
disease was for carcinoma of the cervix 13. After World War II, the World Health
Organization established guidelines for the classification of disease. In 1948 the
International Statistical Classification of Diseases, Injuries, and Causes of Death (ICD),
manual was published; the coding scheme was used to code and tabulate morbidity and
mortality data. The American Cancer Society 2, in 1951, developed the first code manual
for the classification of tumor morphology. The tumor codes were comprised of the first
two numbers being the indicator of the tumor type with a third number representing the
behavior of the neoplasm 2, 29. WHO adopted a coding system based on the ACS in 1956
2, 29

. The International Agency for Research on Cancer (IARC) was commissioned by the

World Health Organization to help develop a world wide classification scheme for
oncology. The first edition of this manual was in 1976 called the International
Classification of Disease for Oncology (ICD-O) 2, 29. There have been several updates
and revision for the classification scheme but morphology code uses standardized threeand four- character categories 1, 2, 29.
In the United States, the Surveillance, Epidemiology, and End Results (SEER)
Program of the National Cancer Institute routinely gathers data on cancer statistics from
designated population based cancer registries 11, 13, 60. SEER has developed a two stage
classification system, extent of the disease and a summary stage. Summary staging is
based in how the cancer advances or grows and there are five main categories 11. The
Commission on Cancer (CoC) of the American College of Surgeons uses the American
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Joint Committee on Cancer (AJCC) staging system. An earlier version of the AJCC
classification scheme was first introduced in 1958 by the Union Internationale Contre le
Cancer (UICC) 29. In 1959, the American Joint Committee on Cancer Staging and End
Results Reporting (AJC) was organized and adopted the UICC coding system 29. The
AJC changed their name to The American Joint Committee on Cancer in 1980. This
system classifies the tumor in terms of the primary tumor (T), the regional lymph nodes
(N), and distant metastasis 155. T is the indication for size and the invasiveness of the
primary tumor. It (T) describes the size of the tumor in millimeters or centimeters with
the extension of the disease into the adjacent tissue, e.g. mucosa, submucosa, muscularis,
subserosa, serosa. T0 indicates there is no tumor; T1 indicates carcinoma in situ and
limited to surface cells, and T1-4 reflects increasing tumor size and disease extension 1, 11.
The N component is indicative of nodal involvement or no lymph node involvement. An
increasing numerical value represents increasing disease extension into the lymph nodes.
M is used in the identification of metastatic disease and distant lymph node involvement
1, 11

.
Another numeric system commonly in cancer registries used to describe or

classify the extent of the disease is Stage 0 through Stage IV 1, 11. Stage 0 limits the
disease to the surface and is also known as cancer in situ, Stage I confines the cancer
growth to the tissue of origin and gives evidence of cancer growth, Stage II describes the
cancer as limited local spread, Stage III is extensive local and regional spread, and Stage
IV is used to classify distant metastasis 29.
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The ICD-O coding system uses a morphology code based on the histology (cell
type), behavior code, and grade 1, 11. The behavior indicates if the tumor is malignant,
benign, in situ, or if the diagnosis is uncertain. Grading is determined by microscopic
examination of the tumor cells 1, 11. The cells are classified Grade I through Grade IV;
Grade I, the cells are slightly abnormal and well differentiated, Grade II cells are
moderately differentiated and the cells appear more abnormal, Grade III cells are very
abnormal and poorly differentiated, and Grade IV are undifferentiated and immature.
Immature or primitive cells are undifferentiated and highly abnormal in appearance. If a
cell is well differentiated, it can appear like a mature or specialized cell. Table 2 below
summarizes the AJCC staging system originally based on clinical data or surgical
findings 11.
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Table 2: AJCC TNM Staging System for Lung Tumors
American Joint Committee on Cancer (AJCC) TNM Staging System for Lung Tumors
Tx

Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum
or bronchial washings but not visualized by imaging or bronchoscopy
T0
No evidence of primary tumor
Tis
Carcinoma in situ
T1
Tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without
bronchoscopic evidence of invasion more proximal than the lobar bronchus† i.e., not in the main
bronchus
T2
Tumor with any of the following features of size or extent:
• More than 3 cm in greatest dimension
• Involves main bronchus, 2 cm or more distal to the carina
• Invades the visceral pleura
• Associated with atelectasis or obstructive pneumonitis that extends to the hilar region
but does not involve the entire lung
T3
Tumor of any size that directly invades any of the following: chest wall (including superior
sulcus tumors), diaphragm, mediastinal pleura, parietal pericardium; or tumor in the main
bronchus less than 2 cm distal to the carina, but without involvement of the carina; or associated
atelectasis or obstructive pneumonitis of the entire lung
T4
Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea,
esophagus, vertebral body, carina; or separate tumor nodules in the same lobe; or tumor with a
malignant pleural effusion‡
†The uncommon superficial tumor of any size with its invasive component limited to the
bronchial wall, which may extend proximal to the main bronchus, is also classified T1. ‡Most
pleural effusions associated with lung cancer are due to tumor. However, in a few patients,
multiple cytopathologic examinations of pleural are negative for tumor. In these cases, fluid is
not bloody and is not an exudate. Such patients may be further evaluated by videothoracoscopy
(VATS) and direct pleural biopsies. When these elements and clinical judgment dictate that the
effusion is not related to the tumor, the effusion should be excluded a staging element and the
patient should be staged T1, T2, or T3. §M1 includes separate tumor nodule(s) in a different lobe
(ipsilateral or contralateral).
NX: Regional lymph nodes cannot be assessed
N0: No regional lymph node metastasis
N1: Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, and intrapulmonary nodes
N2: Metastasis to ipsilateral mediastinal and/or subcarinal lymph node(s)
N3: Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or
supraclavicular lymph node(s)
Stage 0: Carcinoma in situ
Stage IA: T1, N0, M0
Stage IB: T2, N0, M0
Stage IIA: T1, N1, M0
Stage IIB: T2, N1, M0, T3, N0, M0
Stage IIIA: T1, N2, M0, T2, N2, M0, T3, N1, M0, T3, N2, M0
Stage IIIB: T4, N0, M0, T4, N1, M0, T4, N2, M0, T1, N3, M0, T2, N3, M0, T3, N3, M0, T4, N3, M0
Stage IV: Any T, any N, M1
Source: American Joint Committee on Cancer (AJCC)
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Lung Cancer Prognosis
There are certain factors that affect prognosis, i.e. quality of life, chance of
recovery, survival, for a disease. In particular, the prognostic factor of interest for this
research is to expand the scientific knowledge concerning gender differences in women
and men with lung cancer and survival. The literature has cited several prognostic factors
that affect lung cancer survival 49, 55, 139, 154. The prognosis can be dependent upon 1) the
stage of lung cancer (the size of the tumor, whether the cancer is confined to the lungs or
has spread to other places in the body, i.e. metastized), 2) the histologic type of lung
cancer, 3) if there are respiratory symptoms, e.g. coughing, difficulty breathing, and 4)
the patient’s general health or well-being 4. Early stage disease (Stage I, Stage II,
resectable Stage III) prognostic factors most critical to decreased survival have been
shown to include large tumor size and presence of lymph node metastasis, male gender,
age greater than 60 years, and having a wedge resection versus a lobectomy or
pnumonectomy 55, 61, 156. In advanced stage lung cancer, poor performance status, weight
loss, male gender, elevated serum lactate dehydrogenase, and liver/bone metastasis are
key prognostic factor for poor survival 17, 61, 157, 158.
Clinical research has identified more than 150 risk or prognostic factors according
to Blanchon, et. al., 2006 153. Prognostic factors investigated by Blanchon, et. al., 2006’s
research included age, gender, socioeconomic status, possibility of occupational origin of
the cancer, stage of cancer at time of diagnosis, smoking history (pack-years, duration,
discontinuation, date of discontinuation), geographic location, histology, stage, vital
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status, treatment modality, and performance status at time of diagnosis 153. Performance
status was based on the classification as given by the Eastern Cooperative Oncology
Group 158, 159, based on a 0 to 4 scale. The final univariate model included age, sex,
performance status, histologic types, and stage of disease. Patients younger than 50 years
had a greater probability of survival as compared to those greater than 70 years. Men had
a decreased survival (Hazard Ratio (HR) = 1.17; 95% CI: 1.05-1.31) versus women. The
HR for risk of death increased with increasing stage of disease (Stage IV HR = 3.53; 95%
CI 3.05-4.09) and performance status (Performance Status 4 HR = 4.97; 95% CI: 3.836.43) 153. These five predictor variables served as the most important prognostic factors
for Blanchon’s research. Other medical research has reported similar individual
characteristics (prognostic factors) such as gender, sex, stage of disease, performance
status, molecular biologic markers, marital status, smoking status, and psychosocial
factors as predictors for lung cancer survival 61, 156, 157, 160, 161; similar to Blanchon et al.
(2006).
In the article ―The Lung Cancer Database Project at the National Cancer Center,
Japan: Study Design, Corresponding Rate and Profiles of Cohort‖, Nakaya, et. al., 2006,
reported the importance of having a database with available prognostic factors for lung
cancer survival 160. The authors stressed the epidemiologic, psychosocial, and molecular
biology data as to improve lung cancer patient outcome by increase treatment efficiency.
In this particular study, biologic material was collected and several questioners at
baseline and subsequent follow-up intervals 160.
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Epidemiologic studies have shown that there is a causal relationship between
smoking and lung cancer 149, 162, 163. Smoking patterns and status serves as a prognostic
factor in survival after the diagnosis of lung cancer but the majority of heavy smokers do
not develop lung cancer 139. Duarte, et. al. 2005 has suggested that genetic factors affect
an individual’s susceptibility to the development of lung cancer. Molecular changes in
lung cancer may serve as an indicator (prognostic factor) for survival. Several genetic
factors have been investigated, but presently there is no evidence that a single parameter
has sufficient treatment efficiency 139, 153. Principle molecular markers primarily found in
lung cancer will be expanded upon in the section on Genetic Risk Factors in this chapter.
Biologic or molecular markers can be important as prognostic variables but also in the
identification of treatments targeting the cancer cell based on the patient’s genetic code
for an effective cancer cell kill. This is becoming increasingly important for the treatment
of lung cancer and survival

Lung Cancer Survival and Risk Factors
Gender
Why is gender important as risk factor for lung cancer survival? Although lung
cancer mortality has reached epidemic levels for women (an increase of 600 % since the
1950’s), the causal pathways are blurred for women 40. The exact etiology of a woman’s
susceptibility (reported in the literature as different from men ) to lung cancer, still not
resolved 49. One potential reason for the current deficit of knowledge for gender
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differences in the etiology and subsequent susceptibility is that the treatment patterns for
lung cancer are based on research done on men. Previously, the association between
being a woman and the risk of lung cancer was considered negligible by the medical
community as referenced by published reports by the US Surgeon General 24, 76 . But as
behavior and other temporal changes, such as cigarette smoking have occurred over the
past several decades, the incidence of lung cancer has increased with a resultant increase
in mortality 2, 29. Women historically have been excluded from clinical trails or if
included, the data was not analyzed 18. As one result of this disparity of being excluded
from research studies, women may be at a greater risk of lung cancer than men at the
same level of smoking but the evidence in the literature has be conflicting and is limited
22

. A report of the Surgeon General 24, 76 on women and smoking did not reach any

conclusions concerning what role gender difference may play in the development of lung
cancer (US Department of Health, and Human Services, 2001). Hypotheses have been
developed based on possible response to carcinogens and hormonal related differences in
women as compared to men (Ryberg et al., 1994) but conflict in the literature remains 27,
40, 45, 50, 107, 164

.

Lung cancer incidence and mortality rates are higher in men as compared to
women 3, 10. The fact that women have a lower prevalence of smoking may account for
this difference. The primary cause of lung cancer in women and men is due to smoking
tobacco products, in particular cigarettes 23, 75, 165, 166. In 2006, it is estimated lung cancer
will account for 30 percent of all cancer deaths in the United States. Among men, lung
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cancer incidence and mortality have been declining since the early 1980s and 1990s. The
peak death rate in men in the 1990s coincided with a lag period of approximately 25
years after the highest per capita cigarette consumption. Women started smoking
approximately 20 years after men, lung cancer incidence rates did not begin to fall in
women until 1998. For the first time in 1995, mortality rates in women have stabilized,
after increasing for several decades. There has been an increase of 600% in mortality for
women with lung cancer since 1930 28, 40, 60. Lung cancer has overtaken breast cancer as
the number one cause of cancer related deaths of women in the United States.
In the next several articles cited in this chapter, epidemiological studies were
designed to quantify the differences in lung cancer risk between men versus women 8, 15,
17, 27, 167

. In the paper, "Lung cancer in women compared with men: stage, treatment, and

survival", Ouellette et al., 1998, conducted a retrospective cohort study, to test the
hypothesis of a survival difference among men and women with lung cancer 8. The target
population consisted of 104 women and 104 men with incident cases of lung cancer
diagnosed between March 1998 and June 1990 at a university hospital in Montreal,
Canada. The authors concluded there was no difference in mean age of lung cancer
diagnosis for females (60.97+ 10.89 years of age) and for male patients (61.49 +10.29
years of age). There was a statistically significant difference in the distribution of the
different histologic types of lung cancer between men and women (p = 0.028). When
Ouellette et. al. stratified on lung cancer stage, the stage of the disease positively
influenced survival between the women and men 8. After adjustment, women appeared
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to live 12 months longer than men at any stage and a statistically significant survival
advantage in women was found (p = 0.02) 167.
The authors (Ouellette et. al. ) found that women did received less surgical
interventions than men; although not statistically significant 8. Twenty-four women
received chemotherapy compared with fourteen men, although this was not found to be
statistically significant according to the authors. A limitation in this study could be due to
the small number of lung cancer cases contributing to the non-significant finding
(decreased power). Ouellette et al., 1998 reported men and women received similar
treatments for their disease in this study. This differs from studies on coronary artery
disease in which it was thought that physicians may pursue less aggressive management
in women as noted by Steingart et al., 1991 8. Unlike Ouellette, et. al., 1998, Aitakov et.
al., 1998, found that more men in Russia underwent surgery with a ratio of men to
women of 7.4:1.0 167. Ouellette et al. did not find such a disparity; the ratio was 1.17:1.0
men to women, and noted that is probably reflected the tendency to offer similar
treatments to both sexes in the Western world.
A population-based study by Radzikowska et al., (2002), investigated
demographic factors (gender, age, and smoking) and factors connected with the disease
(histology, performance status, stage, treatment and survival) for lung cancer patients.
The target population was comprised of members of community-based cancer registries.
Approximately 20,561 lung cancer cases from all parts of Poland, from 1995 to 1998,
were registered with the National Tuberculosis and Lung Diseases Research Institute
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(NTLDRI), as well as being registered with the Polish Cancer Register. From this
population, 2,875 women and 17,686 men were selected 15. It was determined that
women developed lung cancer at a younger age, were more likely to be lifetime nonsmokers, consumed fewer cigarettes per day and smoked for a short period of time 15.
The authors commented that all those factors suggested that women are more susceptible
to the carcinogenic compounds of cigarette smoke and environmental noxious conditions
that possibly damaged the genetic distribution for the population 15. Women were found
to be more likely to have adenocarcinoma and SCLC as compared to men. Squamous
cancer was the predominant type of lung cancer among men, and less than ten percent of
men had adenocarcinoma. Different patterns of histological types of lung cancer were
observed in Poland as compared to the USA, China or Denmark, where overrepresentation of adenocarcinoma has been noted. The distribution of main histological
types of lung cancer in Poland was similar to that described in Finland and Scotland. The
most important prognostic factors for lung cancer patients were performance status,
clinical stage of the disease and surgical treatment. The authors did not evaluate different
treatment modalities and the effect on survival. Radzikowska et al., found that females
with lung cancer had a survival benefit compared with males, taking into account age,
histology, performance status, extension of the disease and treatment. This overall
survival advantage of women was described first in data based on Danish Register
information. Although Radzikowska, et al., found an increased survival based on gender
the other researchers found the opposite. Kirsh et al., in their 1982 article ―Carcinoma of
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the Lung in Women‖ found that the survival among women in a younger age group was
significantly lower than for both groups of women in the older age group (p = 0.0335)
and men in the younger age group (p = 0.0033). This was believed to be due to the
higher incidence of both Stage III disease and adenocarcinoma in younger women.
Visbal et al. (2004) "Gender differences in non-small-cell lung cancer survival: an
analysis of 4,618 patients diagnosed between 1997 and 2002 evaluated the magnitude of
the gender effect on non-small-cell lung cancer (NSCLC) survival across disease stage,
tumor histology, and therapies 17. The target population of 4,618 newly diagnosed
NSCLC were patients at the Mayo Clinic in Olmsted County, Minnesota between 1997
and 2002. There were 2,724 men (59%) and 1,894 women (41%), with a median age at
diagnosis of 68 years in men and 66 in women (p < 0.01). Women were diagnosed on
average two years younger than men 17. As compared to men, women began smoking at
a later age, smoked less cigarettes per day and fewer years. More men smoked and were
heavier smokers than women17. Adenocarcinoma was the common subtype in both
genders; 59.5% of the women and 48.2% of men. The difference between women and
men with adenocarcinoma was significant with a p-value of <0.001. For the other
histological types (squamous, unclassified NSCLC, large cell, adenosquamous) of lung
cancer the difference was not significant between men and women with. The estimated
relative survival in men was 51% (95% CI: 49%, 53%) at one year and 15% (95% CI:
12%, 17%) at five years. The estimated one year relative survival in women was 60%
(95% CI: 58%, 62%) and 19% (95% CI: 16%, 22%) at five years 17. Men were at a
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significantly increased risk of mortality compared to women following a diagnosis of
NSCLC (adjusted relative risk: 1.20, 95% CI: 1.11, 1.30), particularly for patients with
stage III/IV disease or adenocarcinoma. Male gender was found an independent
unfavorable prognostic indicator for NSCLC survival 17. This particular study by Visbal
et. al. was of interest to this research as Visbal studied treatment types, stage and
histology of the disease; as noted previously reports on stage, grade, histology, and
treatment are limited. Some of the weaknesses of this study included the lack of
interaction terms in the model as without evaluating interaction any significant effects
could be masked.
The 2005 article by Ringer et al., ―Influences of Sex on Lung Cancer Histology,
Stage, and Survival in a Midwestern Untied States Tumor Registry‖ 27 attempted to
expand the current knowledge of gender differences in men and women with lung cancer
and survival (N= 2618). Squamous cell carcinoma was the predominant histologic type
of lung cancer for men; women had an increased likelihood of having adenocarcinoma or
small cell lung cancer. There was no statistically significant difference for men with
large call carcinoma versus women with large call carcinoma. The stage of disease at
diagnosis for men as compared to women was not significant27. Differences in survival
were demonstrated between the lung cancer types during the cutpoints of 3, 4, and 5
years. A very pronounced survival difference existed between men and women for stage
IV squamous cell carcinoma (274 mean days for men versus 153 mean days for women,
p = 0.005). Women diagnosed with squamous cell carcinoma stage II again had

49

decreased survival versus men (636 mean days for men, 379 mean days for women, p =
0.043). This study demonstrated the important effect histologic type and stage at
diagnosis plays in overall survival when comparing gender differences 27. It has been
hypothesized that women are more susceptible to tobacco products as compared to men.

Tobacco
The number one cause of lung cancer, approximately 80% of lung cancer cases
can be attributed to smoking tobacco products, and the subsequent decrease in survival
for lung cancer cases is due to tobacco smoke 10, 168. The etiology of lung cancer is multicausal with a complex pathway of development that includes carcinogen exposure,
metabolism, and genetics 48. Tobacco smoke is recognized as the chief risk factor for
lung cancer 25, 67, 92, 169. It has been estimated by the International Agency for Research
on Cancer (IARC) to contain at least 80 known mutagens and carcinogens, e.g.
polycyclic aromatic hydrocarbons (PAH’s), N-nitro amines, and aromatic amines. Yach
and Wipfli stress the importance of tobacco-control efforts as tobacco kills five million
people annually with an estimated increase of 100% (10 million) by mid 2020 170. Today
the population attributable risk percent (PARP) for men is approximately 90% and for
women the PARP is approximately 80% 10. The effects of tobacco smoking were
demonstrated in the 1950’s with an epidemic rise of lung cancer in US males. The
increase in lung cancer rates were first attributed to factors other than tobacco smoke
such as atmospheric pollution 170. As the rise in lung cancer rates and the increase in
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mortality rates for lung cancer, clinical evidence and case series were reported in the
literature during the 1930’s for a suspected link between tobacco smoke and an increased
risk of lung cancer. In 1938, Raymond Pearl, M.D. from Johns Hopkins University
reported that smokers do not live as long as nonsmokers 170. There were two classic
epidemiologic studies that demonstrated a strong association between the risk of lung
cancer and smoking by 1) Sir Richard Doll and 2) Sir Bradford Hill 10. Sir Richard Doll
conducted a case control study in 1947 and compared hospitalized patients with and
without lung cancer. He collected information on smoking history and found a greater
than 20 percent increased risk for lung cancer. Zang and Wynder found that women were
at an increased risk (1.2 to 1.7 times) for lung cancer than men independent of tobacco
smoking level 171 with an associated decrease in survival.
Passive smoke, also known as second hand smoke or environmental tobacco
smoke (ETS) has been shown to increase the risk of lung cancer 10, 172. Stockwell et al.
(1992) demonstrated an increased risk, OR = 2.4; 95%CI = 1.1-5.3, for women with 40 or
more smoke-years of household (ETS) exposure as an adult. The authors also found a
statistically significant association with women exposed to ETS during childhood or
during adolescence for 22 smoke-years with an OR = 2.4; 95%CI = 1.1-5.4 173.
Investigators for the International Early Lung Cancer Action Program found that women
have an increase susceptibility to lung cancer as compared to men, OR = 1.9; 95%CI =
1.5-2.5 yet women had a decrease hazard ratio for survival versus men, HR = 0.48;
95%CI= 0.25-0.89 174. The study population was comprised of 1202 men and women
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from New York City undergoing a baseline screening at Weill Medical College of
Cornell University 174.

Race and Ethnicity
Worldwide statistics for lung cancer obtained from the International
Agency for Research on Cancer, IARC, and GLOBOCAN 2002 demonstrate that lung
cancer incidence and mortality rates are less in women than men 5. The decreased rates
for women are not dependent upon ethnicity and race as reported by IARC. Some of the
variation in the incidence rates may be attributed to the quality of the data collected by
the cancer registries and diagnostic methods employed.
Gadgeel and Kalemkerian (2005) reported that race is not a biologically relevant
parameter but racial differences in lung cancer characteristics and outcomes have been
reported 21. Blacks consistently have higher rates of lung cancer incidence as compared
to whites. African-Americans in the United States have the greatest incidence of lung
cancer (8.5% risk of lung cancer diagnosis); they also have the highest lung cancer
mortality rates (7.6% risk of death form lung cancer) 10. Racial differences in smoking
habit sand SES, have been associated with an increased risk of lung cancer 21.
Willsie and Foreman (2006) in the article ―Disparities in Lung Cancer: Focus on
Asian Americans and Pacific Islanders, American Indians and Alaska Natives, and
Hispanics and Latinos‖ evaluated lung cancer incidence and mortality based on racial and
ethnic groups 175. The authors noted racial and ethnic differences in smoking habits,
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presentation, stage at diagnosis, metabolism of nicotine, treatment received, and
outcomes will impact lung cancer survival and health care over the next several decades
in the United States 175.
The identification of ethnic groups is an important aspect of lung cancer research
for possible gender differences based on ethnicity and lung cancer survival. The
Multiethnic/ Minority Cohort study was established to study diet and cancer in the United
States 176. The data can be and is utilized to evaluate lung cancer patterns of incidence
and mortality and the effect gender, race, and ethnicity play. The cohort consisted of
215, 251 living in California (primarily in Los Angeles County) and Hawaii with the
cohort consisting of 16.3% African-American, 22.0% Latino, 26.4% Japanese-American,
6.5% Native Hawaiian, 22.9% White, and 5.8% of other ancestry. African American had
the highest rate of smoking, 28.5%, followed by Native Hawaiian at 20.1%. The lowest
groups of smokers were Japanese Americans, 15.5%, and whites, 15.9%. Both females
and male African American and Native Hawaiian females had the highest prevalence of
smoking as compared to male and female Japanese Americans and Latinas. Lung cancer
incidence was 54.0% lower for Japanese American men (p-value < 0.001) and 71.0%
lower for Latina women (p-value < 0.001) as compared to African Americans 176.

Genetics
Prior to 1970, scientific evidence about the etiology of lung cancer was
unavailable. A pathway of understanding the complex route of lung cancer development
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with the consequent effects of gender differences and survival became accessible with
advances in molecular genetics 83. Cancer is a complex process which involves an initial
damage of the genetic material (DNA, RNA) of a cell; this leads to a mutation or change
in the chromosomes19, 67, 69, 71, 177-180. The mutations can be inherited (germ cells) or may
occur ―somatically‖ in the stem cells; resulting in clone cells of the original cell that may
become cancerous (malignant and uncontrolled cell growth). Although identification of
biologic materials provides evidence of genetic susceptibility; inter-individual variation
can modify the effects of carcinogenic exposures and the resultant effects. For an
example, the majority of long term smokers will not develop lung cancer. A predictive
model for lung cancer genetic susceptibility among smokers was developed by Bach et al.
(2003) 92, 117, 118. Utilizing data from the CARET trial, 18, 172 individuals, the statistical
model predicted only a quarter of the lung cancer cases based on genetics predisposition;
individual variation of metabolism, DNA repair, cell cycle, inflammation and
microenvironment would be a possible explanation for the inability to calculate an
accurate and precise model of behavior 92.
Several genetic and epigenetic mutations of tumor suppressor genes have been
observed in lung cancer 48. Thomas et al. (2006) noted in 95% of small cell lung cancers
and 40 to 70% of NSCLC, the most frequently encountered genetic alteration was p53.
The p53 affects the biological pathway in G1 and G2 cell cycle regulation; p53 stops the
cell division that occurs when there is damage to the DNA 48. The p53 mutation leads the
formation of DNA adducts (abnormal piece of DNA bonded to a cancer causing agent) as
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a response to the effects of smoking; this mutation inhibits the normal cell repair and is
involved in carcinogenesis. Women have been found to have increased DNA adducts per
pack years versus men. K-ras (a proto-oncogene) is another biomarker and forms DNA
adducts when damaged; women are three times more likely than men to have the K-ras
mutation; this mutation is associated with adenocarcinoma.

Family History
Another risk factor impacting lung cancer survival can be associated with family
history or familial aggregation 10, 172. Familial aggregation can serve as a surrogate
(indirect measure) for lung cancer etiology and resultant survival rates based on genetic
predisposition 181. Etzel et al. (2003) examined risks for smoking related cancers for
relatives of lung cancer patients 169. Siblings were found to have a statistically significant
association, RR = 1.85; p-value = 0.003, of lung cancer risks as well as an increased risk
for smoking-related cancers, RR = 1.29; p-value = 0.01 169. When stratification on age of
disease onset was done, there was no association between familial aggregation and lung
cancer risk for ages less than 55 years. The authors did find evidence of familial
aggregation, RR = 1.71; p-value < 0.001, for lung cancer risk between relatives of lateonset cases of lung cancer. Schwartz et al. (1999) found evidence that common
susceptibility genes may increase the risk for lung cancer among relatives of nonsmoking
lung cancer cases 182. The study population was obtained from families of nonsmoking
lung cancer cases (257 population-based) and nonsmoking controls (277 population-
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based), residing in metropolitan Detroit. The first-degree nonsmoking lung cancer cases
relatives were (OR = 1.5; 95% CI = 1.02-2.27) at increased risk for cancer of the
digestive system after adjustment for each relative's gender, race, age, and smoking
status. There was an elevated OR of 1.12 for an increased risk for lung cancer for first
degree relatives but the findings were not statistically significant, i.e. 95% CI = 0.65-1.93
182

.

Genetics and the Environment
A powerful design to disentangle the interplay between genetics and
environmental influences in the studies of human disease incidence, mortality, and
survival can be accomplished by the use of twin studies 10, 172. Twin studies serve to
separate the affects of an individual’s biological makeup and environmental influences.
Identical twins (monozygotic (MZ)) develop from fission of single fertilized egg and
have inherited identical genetic material; fraternal (dizygotic (DZ)) twins derive from two
distinct fertilized eggs meaning they have the same genetic makeup comparable to
siblings 10, 172. Genetic effects would be determined significant if there was concordance
for cancer among MZ twins as compared to DZ twins (on average share 50% of their
separated genes). Environmental factors would be the determining factor for increased
lung cancer risk if the concordance was similar for both types of twins 183. Lichtenstein
et al, (2000) combined data from three different national twin and cancer registries
(44,788 pairs of twins from Swedish, Danish, and Finnish twin registries) 183. The
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authors found that there were statistically significant risks associated with colon and
breast cancer, lung cancer was not. This implies the inherited genetic factors do not
make an individual susceptible to lung cancer and survival but environmental factors play
the major role 183.
Braun et al. (1995) concluded that genetic susceptibility had influence on lung
cancer mortality 184 in men. There was an excess risk of lung cancer mortality for
dizygotic twin pairs (DZ SMR = 2.2; 95%CI = 1.3-3.4) but the risk was not statistically
significant for monozygotic twin pairs (MZ SMR = 2.1; 95%CI = 1.0-3.7). This suggests
a predisposition for lung cancer in males.

Geographic Variation
Survival rates based on lung cancer incidence and mortality cluster in geographic
regions that have a high prevalence of smoking 10. Devesa et al. (1999) examined data
from the IARC cancer registries of morphology specific lung cancer. Squamous cell
carcinoma had declined by 30% in North America 30. Rates in the Nordic countries,
which varied by 2-fold from a high in Denmark to a low in Sweden, still were generally
lower than in other parts of Europe, where the rate was highest in the Netherlands 30. The
lung cancer incidence rates among males varied by 4-fold: 83.6 among U.S. Blacks to
21.1 in Sweden. Among females, recent rates varied by almost 8-fold, with the highest
among U.S. Blacks (35.8) and the lowest in Spain (4.6). Incidence rates among females
paralleled that in males, with the exception of Switzerland. Rates everywhere were

57

higher among males than females. Male to female rate ratios varied from less than 2 in
Iceland, U.S. Whites, Canada, Denmark and Sweden to more than 6 in Slovenia, Italy,
and France and more than 10 in Spain.
Developing countries demonstrate a higher ratio of lung cancer incidence and
mortality for men versus women. As shown below in Table 3, developing countries,
have a higher ratio of male and female lung cancer incidence and mortality rates.

Table 3: Incidence and Mortality Rates
Incidence and Mortality Rates, Crude and Age-Standardized (World) rates, per 100,000
Incidence
Mortality
Crude
Crude
Country/Region Cases
Rate ASR(W) Deaths
Rate
ASR(W)
World
1352132 43.5
47.6
1178918
37.8
41.5
More developed
regions
676681 114.7
72
584979
99.2
61.2
Less developed
regions
672221
26.7
35.3
591162
23.4
31.2
Females
World
386891
12.6
12.1
330786
10.7
10.3
More developed
regions
194731
31.7
17.1
161472
26.3
13.6
Less developed
regions
191192
7.8
9.4
168481
6.8
8.3
Males
World
965241
30.9
35.5
848132
27.1
31.2
More developed
regions
481950
83
54.9
423507
72.9
47.6
Less developed
regions
481029
18.9
25.9
422681
16.6
22.9
Source: GLOBOCAN 2002, IARC

In the United States, Kentucky had the highest incidence of lung cancer, 40 per
100,000, and lung cancer mortality, 115 per 100,000 for the years 1997-2001 for males
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10

. Utah has the lowest incidence and mortality rates for lung cancer for males and

females based on data from the American Cancer Society.

Alcohol
Another risk factor associated gender differences and lung cancer survival is
alcohol 10. The causal relationship between lung cancer and alcohol is complicated and
remains controversial 10. Confounding by smoking is a major consideration and tobacco
smoking commonly exists in setting where alcohol is consumed 185. Nine studies were
identified by Wakai et al. (2007) and in the authors’ examination of alcohol and lung
cancer; they found only five of the studies adjusted for smoking 185. This meta-analysis
concluded that methodological issues explain the elevated risks in the studies of alcohol
as misclassification errors based of smoking status were common in the nine studies.
Prescott et al. (1999) found a protective association between lung cancer risk and
wine drinking 186. This was based on the results of three prospective cohort studies in
Denmark. Men who consumed more than 13 glasses of wine per week had an RR of
0.78; 95%CI 0.63-0.97 compared to nondrinkers of wine. The RR’s were elevated and
statistically significant for beer drinkers (RR = 1.36; 95%CI 1.02 -1.82) and ―spirits‖
(more than 41 drinks per week RR = 1.57; 95%CI 1.06-2.33). The study made the
determination that the type of alcohol consumed impacted the association between lung
cancer and alcohol after adjustment for smoking status 186.
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Diet and Micronutrients
Scientific evidence from the literature exists pointing to dietary factors as
protectors against lung cancer induction 83, 187, 188. This risk factor, diet, may prove to
increase survival as it may serve as a protector against lung cancer for men and women.
Some of the dietary factors include fruits, vegetables, carotenoids, vitamin C, phenols,
flavones, vitamin E, selenium, isothiocyanates, folate, fat, and alcohol 10. The article by
Smith-Warner et al., 2003, ―Fruits, Vegetables and Lung Cancer: A Pooled Analysis of
Cohort Studies‖ found that after controlling for smoking, there was a sixteen to twentythree percent reduction in lung cancer risk (RR = 0.77; 95% CI 0.67-0.87; p-value (test
for trend) =0.001) for men and women that had an increased consumption of vegetables
and fruits versus study participants that had a limited intake of fruits and vegetables.
Table 4 (Table 1 from Smith-Warner et al. (2003)), lists the prospective cohort studies
used in the pooled analysis used for the research.
The American Institute for Cancer Research presented a summary of seventeen
case-control and seven cohort studies and concluded evidence existed that with an
increased intake of fruits, vegetables, and in particular dark, leafy, green vegetables, lung
cancer risk was decreased 189. Brennan et al., 2005 studied whether cruciferous
vegetables were protective against lung cancer in a case-control study 190. Cruciferous
vegetables contain isothiocyanates, non-nutrient compounds found to be effective
inhibitors of tumorigenesis 10 . The authors found that weekly consumption of
cruciferous vegetables decreased lung cancer (OR = 0.78; 95% CI 0.64-0.96) as
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compared to men and women that consumed cruciferous vegetables less than monthly 190.
One of the weaknesses of the study by Brennan et al., was there was no identification or
analysis by gender and the possible gender effect of cruciferous vegetables consumption
on lung cancer.
Insufficient adjustment for smoking has been examined as a possible residual
confounder 191 to explain the protective effects demonstrated by an increased intake of
fruits and vegetables for a decreased lung cancer risk and subsequent increase in survival.
The results of the research done by Skuladottir et al., 2004, found that there was an
inverse relationship between an increased intake of fruits, vegetables, and lung cancer
risk even after the influences of smoking as a confounder analyzed via stratified analysis.
Men and women in the highest quartile of intake of fruits and vegetables demonstrated a
thirty-five percent lower risk of lung cancer as compared to individuals in the lowest
quartile of fruits and vegetable intake 191. The lung cancer risk and fruits and vegetable
intake association was decreased when stepwise adjustment for smoking status, duration
of smoking, and the number of cigarettes smoked per day was done but the relationship
remained statistically significant for study participants that had the highest intake of all
plant food (fully-adjusted rate ratio = 0.65; 95% CI 0.46-0.94) 191.
Dietary carotenoids have been identified as the possible micronutrients in fruits
and vegetables that may decrease lung cancer risk 84, 192-195. When this effect was tested
utilizing clinical trials with high doses of carotenoids, in particular beta-carotene, a
reduction in lung cancer risk was not demonstrated 196, 197. One particular clinical trial,
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the Alpha-Tocopherol, Beta-Carotene Cancer Prevention 198 Trial, was stopped early due
to the unexpected result of a statistically significant increase of lung cancer after
receiving beta-carotene as compared to participants receiving the placebo 197, 198. Stram
et al., 2002 suggested that biases introduced from the method of smoking assessment
resulted in the failure of three prospective beta-carotene clinical trials: CARET, ATBC,
and the PHS 199-202.
Gender specific lung cancer survival may be influence by a dietary factor, fat.
There has been extensive research into the association between dietary fat and lung
cancer risk 203-211. Alavanja et al. (2001), Goodman, et al. (1992), and De Stefani et al.
(1997) (study restricted to men) reported an elevated risk of lung cancer with an
increased consumption of fat 204, 206, 212. A non-statistically significant association was
demonstrated by Swanson et al., 1997210 for intake of red meats and increased lung
cancer risk after adjusting for confounders. Conflicting results in the literature as cited in
this chapter could be suggestive of inaccurate reporting and possible recall bias 10.

62

Table 4: Lung Cancer and Food Intake Cohort Studies

Obesity and Body Mass Index (BMI)
The major controversies concerning the exposure disease relationship between
gender, obesity, BMI, lung cancer risk and lung cancer survival exist in the literature.
There are conflicting opinions in the scientific community concerning the association 40,
213

of low BMI and elevated lung cancer risk. In case-control studies, the literature 26, 108,

214-219

cite that low body mass index or ―leanness‖ is associated with the increased risk of

lung cancer. The scientific unit for BMI is 1 kg/m2 220. The three levels of exposure are:
low BMI (> 25 kg/m2), normal or the reference group BMI (> 21.9 kg/m2to <25 kg/m2),
and the high BMI group (> 25 kg/m2). As noted in a report from the January-February
2005 FDA Consumer Report, the average or median BMI has increased from 25 kg/m2 in
1960 to 28 kg/m2 in 2002 for the general US population. BMI can serve as a proxy
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measure for overweight and obesity. It is widely cited in the literature 220 that a high BMI
(> 25 kg/m2) is associated with an increased risk to hypertension, diabetes mellitus,
ischemic heart disease and in particular most cancers. A contradiction exists with lung
cancer and low BMI (> 25 kg/m2) 40, 218, 219 where there is an inverse relationship. As
pointed out previously, the evidence based on BMI and cancer is blurred due to the
progression of lung cancer and that effect on mortality 106, 220. Weight loss may occur
(which affects BMI) due to the cancer process prior to the disease being diagnosed
adding to the difficulty associated with making a definitive causal inference in the
BMI/Lung Cancer association 5, 106, 108, 220, 221.
Some of the limitations of previous obesity, BMI, and lung cancer risk study
designs may have served to mask a true association. Kanashiki 218 mentioned in his
article that the previous case-control studies investigating the relationship between low
BMI and lung cancer were based on participants with symptomatic lung cancer. This
may have caused a misinterpretation of the relationship between the exposure and the
disease because weight loss may be a sign or clinical symptom of the disease, lung
cancer. Kanashiki 218 further reported that there is a statistically significant association
between low BMI and lung cancer for men; women did not demonstrate a statistically
significant association between low BMI and lung cancer (increased lung cancer risk).
Previous cohort studies 108, 219, 222 such as Kabat and Wynder used self-reported body size
during data collection. Using a method of self-reported body size has been noted to be
problematic in the literature 223; as overestimates of height and underestimates of weight
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can be reported with this method. As noted by Henley 213, another issue with all previous
prospective studies is that the numbers were not large enough to exclude those that were
smokers or that have preexisting diseases that may reduce body weight. This may have
resulted in a spurious association between low BMI and lung cancer. The main effect of
BMI and lung cancer has been shown by Rauscher 26 to have an increased Odds Ratio of
1.33 (95% CI 1.13, 1.57) in matched analysis for men and women with high BMI and
being a non-smoker. This conflicts with other studies that associate a low BMI with an
increase in the risk of cancer as compared to a normal BMI group. These conflicting
results serve as an example for the need for the additional clarification that the proposed
research study will provide. Biologic plausibility defined by Gordis 224 as a consistency
of the epidemiologic findings with existing biologic knowledge. Therefore, without
biologic plausibility, interpreting the data or making a definitive statement about the
association between the exposure and the disease becomes problematic. In the case of
suspect biologic plausibility, Gordis 224 suggests that the requirements for the sample size
and the significance of any differences that may be observed may have to be escalated,
e.g. increase the sample size to decrease the variability in the sample 155. Hennekens 73
states that biologic plausibility is a causal criterion for an association and that a known
biologically plausible mechanism enhances the cause and effect relationship.
From the literature review in the section above, the disease process in lung cancer
has been shown to influence BMI levels or visa versa. Changes in the association
between the exposure and the disease, for example, could be a result of changes in
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physiology during the preclinical phase of the disease; which would provide a
biologically plausible mechanism. The ―exact‖ biological mechanism of how lung cancer
changes BMI or how BMI influences lung cancer has not been clearly established.

Occupation
Several occupational exposures are known carcinogens and have been classified
by IARC (an international agency) and the Occupational Safety and Health
Administration (OSHA) in conjunction with the National Institute of Safety and Health (a
US based agency) 225. The list of substances considered by NIOSH include arsenic and
inorganic arsenic compounds, dintrotoluenes, beryllium and beryllium compounds,
cadmium compounds, nickel compounds, and crystalline forms of silica 225. Diesel
exhaust, coal tar pitch volatiles, coke oven emissions, and environmental tobacco smoke
are other substances of variable chemical composition and are considered carcinogens by
NIOSH. Other occupational risk factors (agents) include radon, vinyl chloride,
polycyclic aromatic compounds, asbestos, and bischoloromethyl ether 10. Epidemiologic
studies estimate a range of attributable risk percent associated with lung cancer and
occupational exposure of 9% to 15% 10. Hessing and Hartung explored the excessive
rates of respiratory cancers for European underground metal miners in 1879 226. Radford
and Renard (1984) examined the increased dose-response relationship for radiation and
lung cancer 227. The expected death rate for nonsmoking miners with lung cancer was 1.8
but the observed mortality rate for nonsmoking miners due to lung cancer was 18 227.
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Deposits of uranium and radium and the subsequent by-products of radioactive decay
(radon) were determined to be the causative agent for the development of lung cancer for
miners. Other occupational investigational studies included Doll (1952) who
demonstrated an increased risk of lung cancer for gas workers and Morgan (1992)
reported that mortality from lung cancer had a standardized mortality ratio SMR of 1.65
226

. Hinds et al. (1985) determined risk factors for lung cancer based on excessive

relative risks for a number of occupational groups exposed to coal and tar pitch, diesel
fuel and exhaust, arsenic, chromium, asbestos, nickel, and beryllium 228.

Hormones
Sex differences in susceptibility and survival have been attributed to estrogen as a
lung cancer risk factor and prognostic factor 229. Gender specific estrogen receptor
(ER) expression may offer a biologically plausible influence in female lung
carcinogenesis 230. Schwartz et al. (2005) conducted a study of lung cancer tissue
samples from two population based, case-control studies (214 women and 64 men) 229.
Normal lung tissue was obtained for comparison from subject during autopsy that did not
have lung cancer. The association between the ER receptor status, subject characteristics,
and survival were analyzed. The lung tissue was tested for the presence of nuclear
estrogen receptor (ER)-alpha and ER beta with immunohistochemistry. Lung tissue
sample for tumor and normal tissue did not stain positive for ER. Nuclear ER
receptors were found in 61% of the lung tumor samples (70% of the men and 58% of the
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women) and in 20% of normal tissue. Females were less likely to have positive ER
tumors than males (OR = 0.54; 95%CI = 0.27-1.08). When the analysis was stratified on
histologic type, women with adenocarcinoma were less likely to have positive ER
tumors than males ((OR = 0.40; 95%CI = 0.18-0.89).
Han et al. (2005) found that the gender specific estrogen receptor  (Er) may
offer a plausible explanation that inter-individual difference in Er expression (present in
the lung) impact carcinogen metabolism and mutation. The research was based on
genome studies of genes (CYP1A1, CYP1B1) key in carcinogen metabolism; those genes
were the most responsive to cigarette smoke extract (CSE) in normal bronchial epithelial
(NHBE) cells 230.

Socioeconomic Status
The risk of lung cancer and socioeconomic status patterns can be dependent upon
a country’s industrialization. In Canada, Mao et al. (2001) reported males with a lower
socioeconomic status had an increased risk of lung cancer as compared to individuals at a
higher SES level 231. Females did not show an association between lung cancer risk and
SES after adjustment for occupation, education level, income, and social class was made
10

. Singh et al. (2002) reported on changing US area socioeconomic patterns for lung

cancer mortality for the years 1950 through 1998 232. Temporal changes in the
distribution of lung cancer mortality were shown for women in all age groups with a 7
times increased risk between 1950 and 1998 with an overall higher mortality of women
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with lung cancer in higher socioeconomic groups. Lung cancer mortality for men (25-64
years) was 56% (95%CI = 49%-64%) higher in the lowest socioeconomic groups 232.
The authors concluded that lung cancer mortality risk based on socioeconomics reversed
for males from 1950 to 1998 with women demonstrating an increased risk for lung cancer
mortality independent of socioeconomic status 232.

Environment
Environmental factors play a distinct role in lung cancer etiology and
survival patterns. Passive or environmental tobacco smoke (ETS) and occupational
exposures are risk factors for lung cancer and causal associations have been established.
Veneis et al. (2007) investigated ETS and traffic related air pollution 233. Attributable
risk percents for the proportion of lung cancer cases of never smokers and former
smokers were 16 to 24%. The authors concluded that a reduction in air pollution levels,
as measured by nitrogen dioxide (NO2) levels less than 30 g/m3, would prevent 5 to 7 %
of all lung cancer cases 233. Indoor air pollutants have been studied as risk factors for
lung cancer in developed and developing countries 234. In a recent article by
Ramanakumar et al. (1997) the risk of lung cancer and residential heating and cooking
fuels was assessed for a North American population. The odds ratio for women as
compared to men exposed to both traditional cooking and heating sources was 2.5; 95%
CI = 1.5-3.6. Oriental women have been shown to be at increased risk for lung cancer, in
particular adenocarcinoma, which is attributed to prolonged and concentrated exposures
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to cooking and heating sources 172, 234.

Diseases Associated with Lung Cancer
An individual’s previous history of respiratory disease has been shown to modify
the risk of lung cancer incidence and mortality 10, 235. Cigarette smoking and chronic
respiratory diseases play a key role is carcinogenesis due to a continued cycle of injury
and repair. Schabath et al. (2005) compared the medical histories of 1,375 health
controls and 1,553 lung cancer cases in a case control study (1995 through 2003) with a
focus on respiratory diseases (asthma, emphysema, bronchitis, hay fever, pneumonia, and
TB). Two biologically relevant biomarkers for lung cancer, polymorphic genes (matrix
metalloproteinase-1 and myeloperoxidase) were also assessed. Those with emphysema
had an elevated for the risk of lung cancer (OR = 2.87; 95%CI = 2.20-3.76). Individuals’
positive for the adverse genotype had a significantly higher risk of lung cancer; OR
metalloproteinase-1 +

= 4.98; 95%CI = 2.94-8.44) and OR myeloperoxidase + = 4.23; 95%CI = 1.84-

9.73 235. A previous history of hay fever was found to be protective with an OR of 0.32;
95%CI = 0.21-0.50.
Alavanja et al. (1992) examined preexisting lung disease in nonsmoking women
and the risk of lung cancer. The OR = 1.7 for the risk of adenocarcinoma and previous
lung disease; the overall OR for all lung cancer types was 1.8. The OR’s for nonsmokers
were significant for lung cancer risk; OR asthma = 2.7and OR pneumonia = 1.5. The OR for
emphysema was 2.6 and tuberculosis, OR = 2.0, for former smokers. The authors found
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an attributable risk percent (16%) among women that were nonsmokers and had a
previous history of emphysema, asthma, pneumonia, and tuberculosis 235. Further
investigation is warranted as the biologic role of respiratory diseases in lung cancer
etiology is unclear as the evidence is not consistent.

Treatments for Lung Cancer
How lung cancer spreads throughout the body can be classified into three
categories: intrathoracic (local), lymphatic (regional), and hematogenous (distant). The
sequence of the cancer growth is sporadic and does not necessarily follow any particular
order 72. Small cell carcinoma (oat cell) has the greatest probability of distant spread as
compared to non small cell lung cancer; adenocarcinoma of the three NSCLC types has
the highest incidence of distant spread or metastasis 2, 4, 40. Depending upon the diagnosis
of the lung cancer histologic type, stage, grade and the health of the patient, a clinical
decision is made by the physician how the treatment will proceed. These treatment
decisions are based on years of empirical data, research, and clinical trials; the standards
of care established by the medical community are overseen by several organizations such
as the American Medical Association, the American College of Surgeons, the National
Cancer Institute, and the American College of Radiology 33.

Confined to the Lungs
NSCLC confined to the lung is considered early stage disease and is treated with a
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surgical resection 72. Postoperative radiation therapy with or without chemotherapy is
recommended for the treatment of microscopic disease 135. The patient’s health and comorbidities are other considerations if the patient is a surgical candidate. Radiation
Therapy is then the treatment of choice if the patient cannot tolerate surgery. Early stage
small cell lung cancer is considered limited disease spread and the primary treatment is
chemotherapy plus concurrent radiation therapy. There has been current interest in
surgical procedures for limited stage SCLC; according to Anraku and Waddell (2006) when
the disease is confined, surgery improves the local control and increases survival 54. The authors
also note that continued research via clinical trials is warranted to confirm long term results.
Local Spread
Once the tumor has spread beyond the hemithorax and there is mediastinal lymph
node metastasis, the treatment options include chemotherapy and radiation therapy; at
this stage surgery is contraindicated. Surgery could be an option in cases of limited
mediastinal lymph node involvement in combination with chemotherapy or radiation
therapy 72. Prior to the advent of CT scans and the ability to detect mediastinal lymph
node metastasis, it has been estimated in the literature that 30% of all NSCLC patients
would have received a surgical resection unnecessarily by current medical standards 72.

Distant Spread
Extrathoracic, distant, or hematogenous spread involves the growth of lung cancer
into multiple organs. Treatment of extensive disease for non small cell lung cancer and
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small cell lung cancer is chemotherapy alone 135. The anticancer agents treat the disease
systemically or throughout the body. The future direction for treatments includes
targeting therapies, i.e. the treatment of cancer cells treated with bio-agents that attack the
cells at the molecular level 135.

Lung Cancer Relapse
In the case a lung cancer relapse, the stage, grade, histologic type, and patient
condition once again determines next steps in treatment options. Angeletti, et. al. (1995),
noted that surgery is warranted in the case of an early stage lung cancer relapse or a
second locally confined primary in the lung 236. Although long term survival and local
control has not been validated, the authors suggest this as a viable option to increase
patient survival. Another approach suggested by Johnson, et. al. (1990) suggested a
combination of cyclophosphamide, doxorubicin, and vincristine or etoposide or both
vincristine and etoposide for SCLC.

Complications of Lung Cancer
The lungs are highly vascular and are supplied by a system of lymphatic glands so
the greatest complication of lung cancer is the spread of cancer through different tissue
and organs of the body (metastasis). Another major complication of lung cancer is the
reappearance of the disease in the form of another primary neoplasm or the development
of a secondary tumor 72. According to the American Cancer Society, lung cancer relapse
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commonly occurs within two years even in the event of a positive treatment course 2.
Complications are associated with each treatment regimen; in particular chemotherapy
agents have been shown to decrease survival resulting in the early termination of clinical
trials 237. Venuta, et al., 2006, found in a retrospective study based on one hundred and
thirty-nine patients (100 males and 39 females), preoperative functional parameters, type
of operation, associated disorders, staging, induction regimen (chemotherapy alone or
combined with radiation therapy), all added to the complication rate for surgical
procedures 238. After multivariate analysis for morbidity and mortality and controlling
for age and lung functional volume; the results were not statistically significant.
The complications for radiation therapy lung cancer treatments include decreased
ventilation function, hemoptysis, and local relapse. Historically, the major disadvantage
to the use of radiation therapy was the amount normal tissue that had to be irradiated
thereby reducing lung function in a lung already compromised by cancer. Advances in
radiation therapy treatment modalities, e.g. Intensity Modulated Ration Therapy (IMRT),
Image Guided Radiation Therapy (IGRT), Respiratory Gated Radiation Therapy
(RGRT), all allow for techniques to minimize motion and to increase the precision of the
target or tumor coverage 239-241. Underberg, et. al., 2005 found a 50% reduction in the
primary tumor volume irradiated with the new treatment techniques. This means that the
newer radiation therapy techniques can offer a consistently smaller irradiation volume so
decreased toxicity can be expected; any longer term effect on survival would have to be
investigated 242.
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Lung Cancer Treatment Modalities
The type of lung cancer treatment modality is dependent upon several factors that
include the histological type of lung cancer, the size of the tumor, the location, extent or
degree of regional spread of the disease, and the general condition of the patient. Many
of the treatment modalities, e.g. radiation therapy, surgery, chemotherapy, photodynamic
therapy, can be used separately or combined to treat the cancer239-241. As there are
several treatment options, there are at the very least two main goals that are anticipated
upon completion of the treatments. First, there is an expectation that if a complete cure is
not achieved, the progression of the tumor has been confined. This should have an
overall effect of increased survival. Secondly, there is an expectation that the symptoms
of the disease will be diminished for the patient, thereby improving quality of life issues.
In the next several sections in this chapter, current and emergent technologies will be
expanded upon.

Radiation Therapy
Radiation therapy or radiotherapy utilizes high energy rays to kill cancer cells 4,
47

. The radiation is delivered to a very specific region of the diseased lung, with the goal

of a minimal radiation dose given to normal tissue. Prior to a surgical procedure,
radiation can be given to decrease the tumor size and destroy peripheral, microscopic
disease surrounding the tumor 4, 239-241. Radiation therapy can also be used for the relief
of lung cancer symptoms, such as shortness of breath. There are several radiation therapy
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treatment options for lung cancer; external beam therapy and radioisotope therapy
(brachytherapy) 6. External beam is the application of a radiation beam from an external
source, e.g. linear accelerator, cyclotron, to the affect site of cancer. Recent
advancements as discussed in ―Complication of Lung Cancer‖ section of this chapter
reviewed the newer technologies to reduce radiation damage of the normal tissue, thereby
preserving lung function 72. One of the newest and most costly (1.2 billion US dollars)
radiation therapy treatment involves treating with a proton beam to reduce radiation
induced morbidities. Protons deposit their energy maximally at a specific distance from
the patient surface 72. This maximum deposition occurs at the Bragg Peak of the proton;
the amount of radiation deposited is dependent upon the energy of the proton (a charged
ionizing particle) and the medium or material of interaction. There is minimal interaction
with normal tissue and decreased lung function toxicity.
Endobronchial brachytherapy involves the application of a radioactive material to
the affect site in the lung; a commonly used radioisotope is Iridium-192 72. Normally the
treatment is done for a more circumscribed area of the lung (less than 10 centimeters in
length) as compared to external beam radiation. The application of the radioactive source
can be done by two methods; either a high dose rate application (taking several minutes)
or by the low dose method (can take several hours) 72. For the high dose rate (HDR)
method, the radioactive source is introduced into the lung tumor via a flexible catheter.
This catheter is place prior to the HDR during a bronchoscopic procedure. The treatment
goal is to minimize any normal tissue damage and deliver a therapeutic dose (3 to 10
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Gray per fraction) 72. The advantage of this technique is an increased local control of the
tumor progression and it is less invasive than a surgical procedure with the associated
postoperative morbidities. The main disadvantages to this technique is fistula formation
and fatal hemoptysis 243.

Chemotherapy
Chemotherapy is another lung cancer treatment option, as shown in Table 5,
which uses drugs to obliterate cancer cells. The purpose of chemotherapy is to kill the
cancerous cell or interrupt the cancer cell cycle, thereby preventing the growth of the
tumor. One of the harmful effects of chemotherapy agents is the drug(s) destroy normal
cells in the process of destroying the cancer cells. The destruction of normal cells/tissue
can cause various side effects that include nausea, vomiting, diarrhea, increased
susceptibility to infections, and in some instances, death 9. The various chemotherapy
drugs are administered either by infusion, orally, or as a combination of both during a
treatment. NSCLC and SCLC can both be treated with chemotherapy agents; the
optimum or most effective drugs for the treatment of lung cancer are platinum-based
drugs, cisplatin and carboplatin 135. Other non-platinum based chemotherapy agents
include docetaxel, paclitaxel, gemcitabine, and irinotecan; these can be used in
conjunction with cisplatin and carboplatin during the treatment regimen. For further
information, Appendix III Table 75 contains a listing with chemotherapy drugs typically
used in the treatment of lung cancer, the type of agent, and major side or adverse effects.
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Typically, chemotherapy is used as an adjunct or secondary treatment to surgery
or radiation therapy, dependent upon the histological type and stage of the disease. In the
case of small cell lung cancer, chemotherapy is the treatment of choice because the
procession of the disease is typically widespread throughout the body when the diagnosis
of lung cancer is made 4, 135. Small cell lung cancer accounts for approximately 20 to
25% of incident lung cancer cases diagnosed 13. Of all SCLC diagnosed, only 40% of the
cases have the disease limited to the chest cavity (thorax). The regimen of choice is
chemotherapy plus radiation therapy. In some instances, prophylactic irradiation of the
brain is given to treat micrometastasis; which is the early spread of the cancer to the
brain. The five year survival rate for limited stage SCLC is 15 – 25%. The median
survival for patients that do not receive chemotherapy in combination with radiation
therapy is 6 to 12 weeks 237. If the SCLC has developed into an extensive stage, the
recommendation is to use chemotherapy alone; these cases account for 60% of all the
newly diagnosed SCLC 237. When a case of SCLC is diagnosed at this stage, the disease
has normally progressed or metastized to the brain, liver, bone, and/or bone marrow.
According to Carney in his New England Journal of Medicine article,‖ Lung Cancer Time to Move on from Chemotherapy‖, he states that over the past twenty years, all the
chemotherapy drugs combinations and varying treatment regimens, the most significant
improvement in survival was on average two months 244. At advanced stages of lung
cancer, clinical trials are still being evaluated for efficacy 54, 59, 245-249.
Gerold Bepler of the H. Lee Moffitt Cancer Center and Research Institute, noted
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that there is a renewed interest in the development of new strategies for chemotherapy to
increase survival for NSCLC patients 250, 251. This has come about due to advances in
genetic research and the identification of genes on the chromosomes that have been
identified as prognostic factors in the treatment of lung cancer. The level of the genetic
material present in a lung cancer case’s biological makeup can determine which specific
chemotherapy drug or combination of chemotherapy drugs will be most effective to treat
the cancer 250. An increased level of two genes, RRM1 and ERCC1, has been shown to
decrease the effectiveness of chemotherapeutic drugs 251. In the clinical trial, the
International Adjuvant Lung Cancer Trial, Olaussen et al. (2006), demonstrated that
patients with ERCC1- negative tumors had increased survival (adjusted hazard ratio =
0.65, 95% CI 0.50 – 0.86; p-value = 0.002); whereas patients with ERCC1 – positive
tumors (adjusted hazard ratio = 1.14; 95% CI 0.84 – 1.55; p-value = 0.40) 252.
Table 5 gives a summary of the recommendations found in Collins, et al 20074
and describes the primary or first choice of treatment for a particular lung cancer type, i.e.
Non Small Cell Lung Cancer and Small Cell Lung Cancer, and stage of the disease. The
secondary treatment modality recommendations and the associated five year survival
rates are also listed in Table 5.
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Table 5: Lung Cancer Treatment Recommendations
Stage

Primary
Treatment
Modality

Secondary
Treatment
Modality

Survival Rate

Non Small Cell Lung Cancer (NSCLC)
I
II

III A (resectable)

III A (unresectable)

III B (pleural effusion)
or IV

Surgery
(Resection)
Surgery
(Resection)

Preoperative
chemotherapy followed
by surgical resection
(preferable) or surgical
resection
Chemotherapy plus
concurrent radiotherapy
(preferable) or
chemotherapy followed
by radiotherapy
Chemotherapy with 2
agents for 3 or
4 cycles (preferable)

Chemotherapy†
Chemotherapy
with or without
Radiation
Therapy†
Chemotherapy
with or without
Radiation Therapy

None

Surgical resection of
solitary brain metastasis
and surgical resection of
primary (T1) lesion

5-Yr survival rate,
> 60 – 70%
5-Yr survival rate,
> 40 – 50%

5-Yr survival rate,
15 -30%

5-Yr survival rate,
10 – 20%

None

Median survival, 8–10 mo
1-Yr survival rate, 30–35%
2-Yr survival rate, 10–15%

None

5-Yr survival rate , 10–15%

None

5-Yr survival rate,
15 – 25%

Small Cell Lung Cancer (SCLC)
Limited Disease‡

Extensive Disease‡

Chemotherapy and
concurrent Radiation
Therapy
Chemotherapy

None

5-Yr survival rate,
< 5%

* All chemotherapy regimens include either cisplatin or carboplatin. A complete list of clinical trials is available at
http://www.cancer.gov. and up-to-date approaches to the treatment of non–small-cell and small-cell lung cancer are
available from the National Comprehensive Cancer Network at http://www.nccn.org.
† This regimen is based on data from the International Adjuvant Lung Cancer Trial, which demonstrated a small but
significant survival advantage with cisplatin-based adjuvant therapy. Physicians should strongly consider such therapy
for appropriate patients.
‡ Prophylactic cranial irradiation is recommended for all patients with a complete response to initial therapy.
Source: Adapted from Collins, et. al., 2007
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Surgery
Surgery removes lung cancer or the tumor during an operation. The operation or
surgical procedure is based on the histology or type of lung cancer and where the tumor is
located. A surgical procedure is not recommended for small cell lung cancer, unless the
disease is very circumscribed and is not too advanced at the time of diagnosis 4. Surgery
is recommended by the American College of Chest Physicians and the American Joint
Commission on Cancer 4, 9, 253 for NSCLC. According to Rivera, et. al., (2003), Stage I
and Stage II have the optimum prognosis, with a average five year survival rate of 60% to
70% for Stage I and a greater than 40 – 50% for Stage II 9. Other considerations for a
surgical procedure for the excision of a lung tumor include the location of the tumor, i.e.
the tumor may be too close to the heart or the trachea, if the patient is a surgical candidate
and can withstand the surgical intervention, and the stage or extent of the disease 135. If
the disease is too extensive throughout the body, a surgical procedure to remove the lung
tumor is not recommended. Radiation Therapy and/or chemotherapy may be other
options if surgery is not indicated 4, 9, 135.
Different types of surgical procedures include 1) wedge resection, 2)
segmentectomy, 3) lobectomy, 4) lymph node removal, and 5) pnumonectomy. A wedge
resection consists of the removal of part of the lung; it is used when the tumor is confined
to a particular location in the lung. When the tumor is removed, a portion of the healthy
or non diseased lung is also removed. This is done in an attempt to eliminate any
microscopic disease around the periphery of the tumor bed. A segmentectomy is the
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procedure where a greater margin is taken around the tumor bed. A lobectomy entails the
removal of one of the five lobes of the lung; the right lung has three lobes and the left
lung has two lobes. This type of surgical resection involves the surgeon making an
incision on the patient’s side between the ribs. Once the incision has been made the
surgeon then spreads the ribs apart; this makes the lung tumor accessible for removal. A
video-assisted lobectomy (VATS) employs a small video camera (a thorascope) inserted
into the chest cavity; the images received form the thorascope guides the surgeon to the
operative area in the chest. This particular procedure minimizes the bleeding and
complications of the surgery; the patient stay is reduced from five to seven days to two to
three days. A lymphectomy or lymph node removal can be accomplished during the
surgical procedure. The lymph nodes are examined by the pathologist for signs of
disease; if the nodes were positive, this would be an indication of disease spread. In the
case of positive nodes, the surgeon may opt not to remove any of the tissue as the stage of
the disease has progressed and surgery is not an indication 4, 54, 59, 253.
A pnumonectomy is the complete removal of the entire lung. This procedure can
only be performed if the patient’s physical condition and breathing capacity can tolerate
this extensive surgical procedure and would not compromise the patient’s quality of life.
A pnumonectomy is recommended for centrally located tumors and tumors that involve
more then one lobe. The removal of the lung is warranted when the tumor has spread
throughout the lung but has not metastized to other parts of the body. The complications
from surgery may include internal bleeding, infection, lymohocytopenia (low white
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count), and possible reoccurrence of the disease.

Combination Therapy
Treatment modalities are combined in an effort to increase the length of survival
for lung cancer patients. The standard of practice for small cell lung carcinoma with
limited disease (no evidence of spread) is chemotherapy drugs concurrent with radiation
therapy 4, 135. According to Anraku and Waddell (2006), surgery can be warranted under
certain conditions for early stage SCLC. Chemotherapy with a combination of surgery
for patients with T1-2 N0 SCLC may enhance local control but the authors also note that
clinical trials are needed to validate these results 54. Surgery and chemotherapy can be
offered to patients that have a mixed tumor type (SCLC and NSCLC components) as the
anticancer agents are less effective against NSCLC in the limited or early stages of the
disease 54. Stage I and Stage II NSCLC use the combination of surgical resection,
radiation therapy, and/or chemotherapy. Surgery is the primary treatment with radiation
and/or chemotherapy as the adjuvant therapy. Other treatment regimens include surgery
with or without preoperative chemotherapy for resectable Stage IIIA with the adjuvant
therapy of chemotherapy with or without radiation therapy. The five year survival rate is
15 to 30% for this course of therapy4, 9. The recommendation for Stage IIIA unresectable
NSCLC is chemotherapy with concurrent radiation therapy or radiation therapy
treatments after the course of chemotherapy treatments. The five year survival rate
declines for this combination of modalities to 10 to 20% 4, 9, 135. Patients with Stage IIIB
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(pleural effusion) or IV are given chemotherapy, resection of a primary T1 tumor and
primary brain metastasis.

Emergent Modalities
The optimum treatment for lung cancer is based on stage and grade of the
disease4, 144, 243, 249, 253, 254. There are several recently developed endoscopic modalities for
the treatment of early stage lung cancer. 243. Although the newer treatment techniques
offer a less invasive technique, decreased perioperative morbidity and reduced cost as
compared to conventional modalities, the techniques and methods require validation 4, 243.
Endoscopic therapies such as photodynamic therapy, brachytherapy, neodymium yttrium
aluminum garnet laser, electrocautery, and cryotherapy; offer an alternative in the
treatment of early stage lung cancer. These modalities can be applied during a procedure
known as a fluorescence bronchoscopy. Pathological changes in the appearance of
normal lung tissue can be detected during bronchoscopy utilizing fluorescence. Normal
tissue fluoresces (emission of light) at varying energy levels when compared to cancerous
tissue; this difference in energy levels is seen by the human eye as differences in color
243

.

The main disadvantage to this detection method is the high false-positive rate;

inflammatory processes or trauma can cause changes in the light patterns that could be
perceived as cancerous 243, 255. Lam, et al., 1993, reported a sensitivity of 72.5% and a
specificity of 94% in the detection of advanced dysplasia 243, 255. When comparing
fluorescence bronchoscopy to conventional bronchoscopy, the conventional technique
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had a sensitivity of 48.4% 255. A multicenter trial comparing the two techniques found
fluorescence bronchoscopy detection rate of invasive lung carcinoma of 95% as
compared to conventional bronchoscopy with a 65% detection rate 256. Photodynamic
therapy (PDT), as a treatment for lung cancer, has been used in conjunction with
fluorescence bronchoscopy 243. PDT involves targeting the lung tumor cells with a
photo-sensitizing agent and an application laser light to the affected area during a
bronchoscopy. The laser light, typically 630 nanometers, activates the chemical
sensitizer producing a photochemical reaction at the cellular level. This results in the
destruction of the tumor cells by an oxidative process 243.
Lung cancer treatments can be done by a neodymium yttrium aluminum garnet
(Nd: YAG) laser. This treatment has been done for palliation purposes but the literature
does not support a significant contribution in the treatment of early stage lung cancer 243.
Gerasin et al. (1990), did report success with this technique for early stage lung cancer in
the contralateral lung when a lobectomy is contraindicated 257.
Scientific advancements in the fields of chemotherapy, surgery, and radiation
therapy involving tumor development (carcinogenesis) and lung cancer progression have
been possible with the discovery of genetic materials that are involved in the disease
process 4, 9. There has been recent evidence that a drug, epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor, has been effective in the treatment of bronchialveolar
cell carcinoma (a NSCLC type). This particular cancer type is common in women and in
non smokers. The drug causes the shutdown of the epidermal growth factor receptor
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protein, thereby preventing the development of the cancer.

Conclusions and Assessment of the Literature
The purpose of this research is to test the hypothesis of a survival
difference in women with lung cancer as compared to men, dependent upon treatment
modality (surgery, chemotherapy, radiation, or combination), histological type, and stage
of disease. An extensive literature search and review was preformed to investigate the
variables that could be involved in the associated lung cancer treatment received and how
that treatment decision influences women’s survival as compared to men. There is
limited research regarding the risk of being a woman with lung cancer and the treatment
received as compared to men. As described in the literature review, there are no studies
combining the specific treatment modality received or combinations of treatment
received, gender, stage, grade, morphology and demographic factors with respect to
survivorship. Visbal et.al. (2004) noted the Relative Risks between males and females
and survival adjusting for stage, histological, and treatment type. Although there were
significant results for stage (Stage IIIB RR = 1.22, 95% CI = 1.02, 1.46 and Stage IV RR
= 1.29, 95% CI = 1.15, 1.44), there was no significant results for treatment type received.
Also the authors did not mention if there were any combined treatments of chemotherapy,
radiation, or surgery 17. In the article by Radzikowska et. al. (2002), (n = 11,479) a
multivariate survival analysis was performed based on age (categorized into two groups;
group I < 50 years old, group II > 50 years old), gender, performance status, clinical
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stage of lung cancer (four stages), histology (adenocarcinoma, squamous, SCLC, and
other) and two treatment types (surgery and non-surgical) 15. In the Cox-Proportional
Hazard’s model, the relative risk of death was adjusted to age, gender, histological type
of lung cancer, performance status, and stage of the disease. The RR’s were given with
no confidence intervals; any truly significant results could not be evaluated. The reported
RR’s were all greater than 1.0 (squamous cell RR = 1.09, SCLC RR = 1.42, Other
Histological Type RR = 1.46) with the exception of the reference group (RR = 1.0).
There were significant p-values, all values < 0.004 with the exception of the histological
type for squamous cell (p-value = 0.29). Lung cancer was six times more frequent in
males versus females and women with lung cancer were younger and smoked less than
males with lung cancer.
There are many histological types of lung cancer, finding an optimum treatment
regimen that will increase survival for a particular lung cancer type is challenging. Each
histological type has its own medical intervention that can include any combination of
surgery, radiation therapy, and/or chemotherapy. Gender-specific incidence and survival
rates were shown to be different for the lung cancer types. In the article by Thomas et. al.
(2005), ―Lung Cancer in Women: emerging differences in epidemiology, biology, and
therapy‖ 48, as the authors noted ―women are at an increased risk for lung cancer than
men‖. The gender differences placing women at a greater risk were reported to include
molecular variables such as different metabolism of tobacco-related carcinogens, possible
association with human papilloma virus (HPV) infection, and that women have less DNA
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repair capacity (DRC); the authors also noted that women had better survival outcomes
stage for stage than men 48.
Presently, there are no published quantitative results that show whether there is a
statistically significant difference regarding survival due to a particular treatment for
women as compared to men having the same histological type, grade and stage of lung
cancer. The statistical methods performed in the articles cited in the literature review did
not evaluate interaction effects of the independent variables; this is a major limitation as
any gender specific differences based on any moderating variables could not be
evaluated. Performing this research provides the scientific evidence to answer the
question concerning gender, stage, grade, morphology, age, martial status and race and
their impact on survival. Findings of treatment differences by major histological types are
presented in this dissertation. In conclusion, the goal of this research was to provide a
statistical and biologically plausible model demonstrating gender differences in lung
cancer survival exist based on the treatment received.
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CHAPTER III: PROCEDURES AND METHODS
Introduction
The purpose of the research presented in this dissertation was to determine if
gender differences exist for a treatment(s) utilized for lung cancer and if that treatment(s)
received impacts gender specific survival. The epidemiologic study design was based on
a historical cohort of lung cancer cases drawn from population based state-wide cancer
registries. Each cancer registry were members of the North American Association of
Central Cancer Registries, NAACCR 258. The participants were men and women with
newly diagnosed/incident primary lung cancer diagnosed between January 1, 2000 and
December 31, 2004. All lung cancer cases selected were pathologically confirmed and
classified on the four major histological types of the disease, i.e. adenocarcinoma,
squamous cell carcinoma, large cell carcinoma and small cell carcinoma.

Aims/Hypothesis
Aim 1: The first aim was to determine if men and women with the same
histologic type, stage, and grade of lung cancer received the same treatment type. Any
effect, such as any interaction that the covariates (histologic type, stage, and grade) may
exert on the relationship between gender and treatment received must be evaluated. It
was important to establish if there were treatment differences’ dependent upon gender.
If the lung cancer treatment is gender dependent, this may impact gender specific
survivorship.
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Hypothesis 1: Women with the same histological type, stage and grade of lung
cancer will receive the same treatment modality as compared to men with the same
histological type, stage and grade of lung cancer.
Aim 2: The second aim is to evaluate the overall relationship between survival
and gender for the lung cancer cases. The goal is to obtain an assessment of the overall
survivorship by gender.
Hypothesis 2: There is a statistically significant difference in survival in women
with lung cancer as compared to men with lung cancer.
Aim 3: The third aim of this study is to expand the investigation of treatment
modality differences and gender-specific survival. The goal is to determine if men and
women with lung cancer grouped or stratified by treatment modality, histologic type,
stage, and grade exhibit or demonstrate gender-specific survivorship.
Hypothesis 3: Women with the same histological type, stage, grade of lung
cancer, and the same treatment modality differ significantly in survival as compared to
men with the same histological type, stage, and grade of lung cancer, and the same
treatment modality.

Participant Description and Case Identification
The study participants in this research are primary lung cancer cases drawn from
population based state-wide cancer registries. Data on cancer cases and cancer deaths are
collected, managed, and analyzed by a system of state-based cancer registries 1. The
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majority of state cancer registries are members of the National Program of Cancer
Registries 259; the NPCR was established in 1992 by the Cancer Registries Amendment
Act 259. The NPCR is administered by the Centers for Disease Control and Prevention
(CDC) and is under the Division of Cancer Prevention and Control 259. Prior to the
establishment of the National Program of Cancer Registries, there were ten states with no
cancer registry; today there are forty-five states with cancer registries to include the
Virgin Islands, the Republic of Palau, Puerto Rico, and the District of Columbia 258.
Another international cancer registry organization that certifies NPCR is the North
American Association of Central Cancer Registries 258. NAACCR was established in
1987; it represents state cancer registries and professional organizations such as the
American College of Surgeons, the American Cancer Society, and the Public Health
Agency of Canada 258. Other responsibilities of the NAACCR or known as the ―central
cancer registry‖ are to monitor and certify state cancer registries; this ensures the data
collection methods used by each state registry are complete, accurate, and done on a
timely basis. The each state registry that is a member of NAACCR submits cancer case
data obtained from medical facilities, e.g. hospitals, surgical centers, laboratories,
outpatient facilities, physician offices, and radiation therapy centers, to the central cancer
registry. Cancer information is collected or abstracted in a standardized format into
highly specified field arrangements 258. The standardization of field information allows
for the intercomparison of data within the state, with other states, and on a national level
258, 259

.
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One of the first steps in the selection of the primary lung cancer cases for this
research study was to identify the eligible cancer registries. The criteria for the state/state
cancer registries selected had to be established. Each selection parameter or criterion was
critical; the ultimate goal being selection criteria that could be utilized to generate a
dataset free from bias. The criteria for selection of a state/state cancer registry (Table 6)
for this research were as follows:
Table 6: Criteria for State/State Cancer Registry Selection
1. The registry must exist in a state in the United States of America,
2. The registry must be population based,
3. Each registry must be selected from the four US regions as defined by the US Census
Bureau,
4. The individual lung cancer cases must be randomly selected, as each lung cancer case
in the state cancer registry must have an equal chance of being included or excluded
in the registry,
5. The cancer registry must be defined as a ―passive‖ registry,
6. The data must include primary lung cancer cases diagnosed between 1-1-2000 and
12-31-2004, a five year time frame,
7. The state registry must be a member of NAACCR,
8. Each state registry must meet the criteria of the ―Standards for Cancer Registries:
Standards for Completeness, Quality, Analysis, and Management of Data‖ 258 , and
9. The state cancer registry must have achieved NAACCR certification (a minimum of
3 years gold certification and maximum of 2 years silver certification – see Table 6.
10. Each state must be randomly selected as not to introduce selection bias,
11. The data must be accessible and retrievable to the researcher conducting the study.
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The NAACCR guidelines for certification are measurable standards and each year
state registries obtaining the goals for ―Completeness of Data‖ are awarded a gold or
silver designation (if the goals were achieved) by NAACCR. The selection of states for
the research study began with a process as outlined in Figure 10.

50 USA States

37 USA States
(50 – 13 SEER States)

29 USA NAACCR States
(Reporting – Non-Reporting States)

14 USA States
(Meet Certification Guidelines)

8 USA States
(Randomly Selected)
Figure 10: State Selection Process
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This goal of this research ―selection criteria‖ protocol was designed to minimize
bias. If one state is selected over another state it must be purely by chance thereby
eliminating any possible influences or bias. In other words, each state cancer registry
must have an equally likelihood of being selected; one state may be inherently different
and this difference would tend to diminish with the having all the states randomly
selected. Another source of bias may be introduced by the investigator if that
investigator selected a particular state over another state due to personal or unscientific
reasons – the random process would be invalid.
. The first text box of Figure 10 represents individual lung cancer cases from the
fifty US states which serve as the population from which the final research data set
(Criterion 1) was drawn. The research protocol was developed as to include lung cancer
cases selected from population based cancer registries (Criterion 2). The fifty states are
sub-divided into geographic regions by the US Census Bureau (Criterion 3). The Bureau
identifies four major US regions (South, Midwest, West, and the Northeast) which
correspond to regional populations from which the lung cancer cases will be selected. As
discussed in the literature, population characteristics can differ with geographic location
155, 260-262

and it is critical that the individuals selected are randomly selected lung cancer

cases as not to introduce bias (Criterion 4).
Of the 50 states, 13 states were excluded (text box 2 of Figure 6), leaving 37
NAACCR states. The states excluded were members of SEER and those SEER states
were: 1 - Connecticut, 2 - Hawaii, 3 - Iowa, 4 - Louisiana, 5 - New Jersey, 6 - New
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Mexico, 7 - Utah, 8 - Georgia (multi-country areas of Atlanta & rural Georgia), 9 Michigan (Detroit), 10 - California (San Francisco-Oakland, San Jose-Monterey, Los
Angeles county, remaining counties of California), 11 - Washington (Seattle-Puget
Sound), 12 - Arizona (American Indians), and 13 - Alaska (Alaskan Natives). SEER is
an active registry system and those states under SEER do not meet selection criterion 5.
This is important as there are two main types of cancer registries, passive and active, that
differ in the method data are collected. An active cancer registry collects the data from
the medical facilities whereas a passive registry has the data sent to the registry from the
medical facilities (reporting facilities) that are part of the state wide system. An example
of an active state cancer registry would be a member of SEER such as the Kansas Cancer
Registry. NAACCR cancer registries are passive; some of the state cancer registries are
listed in. In this research, passive registries were only selected (Criterion 5). Having only
passive registries served the following purpose: the ―passive‖ classification aided in the
standardization of the states selected; this helped to minimize selection bias by only
selecting states that have a similar reporting mechanism and reporting criteria.
The thirty-seven states were evaluated (text box 3 Figure 10.) for their NAACCR
status. Eight of the thirty-seven states were not members of NAACCR for a portion of
the years under study (2000-2004), thereby excluding them from participation in this
research; 29 US NAACCR states remained (Criteria 6 and 7). Selection Criterion 6,
restricting the time period under study (a 5 year range), will help to reduce any temporal
differences associated with lung cancer treatments. A temporal bias may be introduced
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when studying extended time periods or ranges. Treatment modalities have drastically
changed over the past 20 years, and trying to determine treatment effects over that 20
year time period would be more difficult to ascertain. Survival differences during this 5
year range are of particular concern; the treatment modality utilized to treat the lung
cancer case should be more consistent and this could impact survivorship. Therefore, the
date/time range established for lung cancer case data inclusion starts January 1, 2000 and
ends December 31, 2004.
The reporting system used for the cancer registries of interest for this research is
based on the ―Criteria and Standards for Eligibility of NAACCR Registry Certification
and CINA Combined Rates‖ (Criterion 8). The criteria and the standards are displayed
below in Table 7. Using this criterion, fifteen (15) states, as shown in Table 8., were
excluded and fourteen (14) NAACCR states remained from the 29 states (text box 4 of
Figure 10.). The selection criteria for state inclusion were based on the grading scales
established by the central cancer registry as outlined in Table 7 below (NAACCR Criteria
and Standards for Gold/Silver Certification). NAACCR certifies for ―High Quality
Incidence Data‖ and the exact protocol followed by the central cancer registry is
contained in the North American Association of Central Cancer Registries, Inc. Standards
for Cancer Registries Volume III, ―Standards for Completeness, Quality, Analysis, and
Management of Data‖. For example, the criteria and standards are used to evaluate
characteristic variables of the tumor such as tumor morphology (histology and behavior),
stage, grade, and the method of diagnostic confirmation. The standards are used to assess
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the quality of the information in the individual state cancer registry, completeness of the
data reported, and timeliness of reporting 258. In summary, a total of fifteen (15) of the
twenty-nine (29) states did not meet the selection criteria as outlined in Criterion 9;
thereby excluding those states from participation (see Table 7).

Table 7: NAACCR Criteria and Standards for Gold/Silver Certification

Source: Standards for NAACCR Cancer Registries: Standards for Completeness,
Quality, Analysis, and Management of Data
Note: DCO = Death Certificate Only

Table 8 lists the twenty nine NAACCR states from the four US Census Bureau
defined regions and their certification status over the study 5 year time period (2000 –
2004).
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Table 8: Annual NAACCR Certification Designation
Five Years of Certification - States (29) by Region (4)
REGION

WEST

STATE

2000

2001

2002

2003

2004

Annual
Incidence

Average
Annual
Cases

COLORADO

gold

silver

gold

gold

gold

54.9

2011

IDAHO

gold

gold

gold

gold

gold

55.2

683

MONTANA

silver

silver

silver

gold

gold

66.5

663

NEVADA

gold

gold

gold

gold

gold

76.9

1622

OREGON

gold

gold

gold

gold

gold

69

2489

ALABAMA

silver

silver

gold

silver

gold

75.2

3569

silver

silver

81.1

2404

silver

gold

gold

76.6

649

ARKANSAS

silver

DELAWARE

SOUTH

FLORIDA
NORTH
CAROLINA
OKLAHOMA
SOUTH
CAROLINA

gold

gold

gold

gold

gold

74.6

15838

gold

silver

silver

silver

gold

68.5

5611

gold

gold

gold

83.9

3068

gold

gold

gold

74.7

3111

gold

gold

68

12162

silver

silver

TEXAS

MIDWEST

WEST VIRGINIA

gold

gold

gold

gold

gold

87.7

1915

ILLINOIS

gold

gold

gold

gold

gold

72.8

8836

INDIANA

silver

gold

gold

silver

gold

80.6

4931

KANSAS

gold

gold

gold

gold

66.5

1841

MINNESOTA

gold

gold

gold

gold

58.8

2843

MISSOURI

gold

silver

gold

gold

gold

78.6

4731

NEBRASKA

gold

gold

gold

gold

gold

62.4

1118

OHIO

silver

silver

silver

silver

74.6

8993

silver

58.7

486

65.9

3700

SOUTH DAKOTA
WISCONSIN

gold
gold

MAINE

NORTHEAST

gold

gold

gold

gold

gold

gold

gold

79.1

1183

MASSACHUSETTS

gold

gold

gold

gold

gold

70.5

4764

NEW HAMPSHIRE

gold

gold

gold

silver

gold

67.7

860

PENNSYLVANIA

gold

gold

gold

gold

70.4

10292

RHODE ISLAND

gold

gold

gold

gold

73.8

860

silver

gold

63.9

418

gold

VERMONT
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Of the 29 states, 15 states were excluded as the state had to meet at a minimum
three years of gold certification and a maximum of 2 years of the silver certification as
defined the NAACCR criteria (see Table 7.) for the five year time frame under study
(Criterion 9). Table 9 lists the final 14 states; the minimum number of states in a region
(the South and the Northeast) was three with a maximum number of states of four in the
West and Midwest.
Table 9: Annual NAACCR Certification Designation by Region and State (14)
REGION

WEST

SOUTH

MIDWEST

NORTHEAST

STATE

2000

2001

2002

2003

2004

Annual
Incidence

Average
Annual
Cases

COLORADO

gold

silver

gold

gold

gold

54.9

2011

IDAHO

gold

gold

gold

gold

gold

55.2

683

NEVADA

gold

gold

gold

gold

gold

76.9

1622

OREGON

gold

gold

gold

gold

gold

69

2489

FLORIDA

gold

gold

gold

gold

gold

74.6

15838

SOUTH CAROLINA

silver

silver

gold

gold

gold

74.7

3111

WEST VIRGINIA

gold

gold

gold

gold

gold

87.7

1915

ILLINOIS

gold

gold

gold

gold

gold

72.8

8836

INDIANA

silver

gold

gold

silver

gold

80.6

4931

MISSOURI

gold

silver

gold

gold

gold

78.6

4731

NEBRASKA

gold

gold

gold

gold

gold

62.4

1118

MASSACHUSETTS

gold

gold

gold

gold

gold

70.5

4764

NEW HAMPSHIRE

gold

gold

gold

silver

gold

67.7

860

RHODE ISLAND

gold

gold

gold

gold

gold

73.8

860

The fourteen states were distributed from the four US geographic regions – from
each region the intent was to randomly select two states (Criterion 10). As stated
previously, the states were selected at random as not to introduce bias. The reasons for
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selecting two states from each region were:
1. At least two states were needed from each region to measure or account for variability
within the regions.
2. Including all fourteen states was not feasible due to limited resources, e.g. cost
considerations, manpower, and time constraints.
In the selection of the states from the four US geographic regions, a random
sample selection was made utilizing a SAS program; these samples represent the
population from which they were drawn (all US primary lung cancer cases). To account
for any variability of the population within each region, more than one state for the region
had to be selected. At a minimum, at least two states from each region must be selected
in order to account for any variability within the region.
As part of the selection criteria the data must be accessible (Criterion 11); not all
states consented to having the data distributed to an outside individual. Logistical issues,
such as data unavailability would prevent the selection of a state registry. An additional
logistical issue that could be encountered could be - although a particular state registry
may meet NAACCR requirement for certification, the state reporting system may not
report a variable needed for the research under study. The final step was to call each of
the state registries and request the procedure the particular state registry utilized for a data
request (Criterion 11). West Virginia was hesitant to participate due to concerns for the
protection of patient privacy and was requiring the author to send the author’s
Curriculum Vitae (CV), the committee members CV’s, and the complete IRB application
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that was submitted to the University of South Florida (the application contained
confidential information about the author and committee members); the registry would
not accept the official IRB approval letter. Also, West Virginia does not/did not report
the complete date listed for ―date of last contact‖ a variable of interest in this research;
the date is reported by year and does not include the day and month. As West Virginia
did not meet selection Criterion 11, South Carolina was selected to participate; the
resultant 8 states selected are given in Table 10. Additionally, after fourteen months of
requesting data from the Missouri Cancer Registry with no data forthcoming and in the
interest of completing this research, a decision was made to randomly select a different
state from the Midwest region, Nebraska was selected.
Table 10: Final NAACCR Eight State Cancer Registries
REGION

WEST
SOUTH

MIDWEST
NORTHEAST

STATE

2000

2001

2002

2003

2004

Annual
Incidence

Average
Annual
Cases

OREGON

gold

gold

gold

gold

gold

69

2489

IDAHO

gold

gold

gold

gold

gold

55.2

683

FLORIDA
SOUTH
CAROLINA

gold

gold

gold

gold

gold

74.6

15838

silver

silver

gold

gold

gold

74.7

3111

INDIANA

silver

gold

gold

silver

gold

80.6

4931

NEBRASKA

gold

silver

gold

gold

gold

78.6

4731

MASSACHUSETTS

gold

gold

gold

gold

gold

70.5

4764

RHODE ISLAND

gold

gold

gold

gold

gold

73.8

860

In summary, the selection criterion for this research utilized a process to minimize
selection bias. For example, Criterion 4, the state registry must use passive reporting

101

methods as outlined by NAACCR and not use other methods for reporting as in SEER
State registries. Possible geographic differences in the population under study are
addressed with selection criterion 3. It is critical to get a fair comparison of lung cancer
cases; selecting cases just from the Northeast could introduce bias possibly invalidating
several study results. The 10th item for selecting a state (registry) is the selection cannot
be done by the researcher in a biased manner; the selection must be made by a random
assignment. The last criterion, Item 11, (selection of the state based cancer registry) is
that the data must be available for acquisition. If the data cannot be acquired from a state
registry by the author that state cancer registry will be excluded from selection. The
seventh criterion is that the state registry must be a member of NAACCR. The
NAACCR has standardized guidelines for abstracting data. Data can only be compared if
the methods and information collected are consistent and complete. Deviations from a
standardized format can introduce error into the study results affecting internal validity
and external validity.

Variables of Interest (Inclusion and Exclusion Criteria)
Inclusion Criteria
Primary lung cancer cases from state population based cancer registries that are a
member of the North American Association of Central Cancer Registries were identified.
A primary site classification (NAACCR Code 400) is made by the state cancer registry
based on site of tumor origin and specified in the medical record. In this research the
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primary site code is specified by ―Code 36‖ for lung. This classification is made in
accordance with ICD-O coding schemes. Cases that were diagnosed between January 1,
2000 and December 31, 2004 were selected. An extensive inclusion criteria are listed in
this Chapter (Three) under the section ―Variables of Interest‖; some of the inclusion
criteria include a known date of diagnosis, that the case must be confirmed from a tissue
or cell sample and in terms of the case assessment: the primary lung cancer case was
classified as analytic 1, 258. In order to perform survival analysis, it is critical to have an
origin or beginning (date of diagnosis will serve as the origin), an observed time range,
and an endpoint/conclusion for the study or a valid analysis cannot be completed. Also,
for this research, a lung cancer case must be diagnostically confirmed by means of a
positive histology from the tumor tissue or a positive cytology (cells examined
microscopically) as not to bias any subsequent results with the addition of histologically
unconfirmed primary lung cancer cases in the data set. The descriptions of ―Diagnostic
Confirmation‖ codes are listed in Table 3.10.; those codes include 1, 2, 4, 5 - the codes
describe the methods of a diagnostic technique with a lung tissue/cell sample of the
tumor. An analytic lung cancer case classification code denotes that part of the diagnosis
and/or treatment of the lung cancer case was performed at the reporting (cancer registry)
facility. An analytic case can further be defined under the NAACCR classification
variable known as the ―Class of Case‖. Class of Case (NAACCR Code 610) describes
the criterion for inclusion as an analytic case with the codes 0-2 as shown in Table 3.12.
Non-analytic cases (codes 3 through 9) are cases that can have a greater chance of error
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as the information is abstracted from case information not directly associated with the
reporting facility. The data from non-analytic lung cancer cases can be subject to bias
when the information is provided by a patient (recall bias) that had the diagnosis and
treatment at a facility different from the reporting facility. The decision was made to
include only analytic cases for this research.

Exclusion Criteria
As only primary lung cancer cases are included in this study, secondary or
recurrent lung cancer case will be excluded. The variables of interest such as gender
include codes or categories that are not of interest in this research; those data are
excluded. These gender codes include 3= hermaphrodite, 4 = transsexual, or 9 =
unknown/not stated 258, 263. Other variable codes of interest that have a code category not
known or not stated (code = 9) must be identified during exploratory analysis. The
number of missing values (codes for the sex of an individual cancer case) can possibly
impact the research results. These values can provide information and knowing the exact
number of individuals not represented in the final data set is important as it can decrease
the validity of the results (increases the uncertainty) if the number of missing values is
large. Some of the other variables that include the not know or not stated category (code
= 9) are primary site, histology, stage, grade, treatment type (chemotherapy, surgery,
radiation therapy), tobacco use, marital status, and vital status. It was important to
address the missing values and record the number for each category as to assess the
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impact those missing values on the study results.
In the next section ―Variable Identification and Coding‖ (Chapter Three), each of
the research patient parameters or variables of interest will be described. The central
cancer registry information/data variables that were requested by the investigator for each
state cancer registry are listed in Table 11.
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Table 11: NAACCR Variable Code and Description
NAACCR
Code

NAACCR
Code

Description of Variable

Description of Variable

1

20

Patient ID Number

24

480

Morphology Coding
System - Original

2

150

Marital Status at DX

25

490

Diagnostic Confirmation

3

160

Race 1

26

500

Type of Reporting Source

4

161

Race 2

27

560

Sequence Number - Hospital

5

162

Race 3

28

580

Date of 1st Contact

6

163

Race 4

29

610

Class of Case

7

164

Race 5

30

630

Primary Payor at DX

8

190

Spanish/Hispanic Origin

31

759

SEER Summary Stage 2000

9

220

Sex

32

760

10

230

Age at Diagnosis

33

1200

11

240

Birth Date

34

1210

12

250

Birthplace

35

1220

13

340

Tobacco History

36

1290

14

390

Date of Diagnosis

37

1360

15

400

Primary Site

38

1390

SEER Summary Stage 1977
Record Date of
First Surgery
Record Date of
First Radiation
Record Date of
First Chemotherapy
Record Summary
Surgical Primary Site
Record Summary
Radiation
Record Summary
Chemotherapy

16

410

39

1750

Date of Last Contact

17

419

Laterality
Morphology Type and
Behavior ICD-O-2

40

1760

Vital Status

18

420

Histology (92-00) ICD-O-2

41

1910

Cause of Death

19

430

42

1930

Autopsy

20

521

Behavior (92-00) ICD-O-2
Morphology Type and
Behavior ICD-O-3

43

1940

Place of Death

21

522

Histology (92-00) ICD-O-3

44

2090

Date Case Completed

22

523

Behavior (92-00) ICD-O-3

45

2110

23

440

Grade

46

3000

Date Case Exported
Derived AJCC Stage
Summary

Some of the research variables (independent or explanatory and dependent or
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outcome) include the individual lung cancer case identifier assigned by the cancer
registry (this number was de-identified to the researcher of this study), the cancer registry
identification number, the date of first contact (the date may be representative of a
physician’s visit, biopsy, x-ray, or laboratory test), the treatment modality received
(radiation, surgery, chemotherapy), and the type of reporting source, e.g. hospital,
outpatient facility. It should be noted that the date of lung cancer diagnosis, NAACCR
recommends that the best approximation for the date of diagnosis should be used versus
coding the date as unknown (9) 258. Therefore in the situation of the year of diagnosis
being known but no other information on the month or day is given, the general
abstracting instruction is to use June 15 for the year indicated. If the year and month are
available but not the day, the 15th of the month is entered. The other patient demographic
variables of interest include gender, race, marital status at time of diagnosis, primary
insurance payer at diagnosis, a birthplace Geocode, and birth date. Table 11 includes
NAACCR variable names and the associated NAACCR item number to that variable.
Table 11 provides the complete list of patient or individual lung cancer case information
that was intended to be utilized in this study. Tumor information or data are collected to
describe the cancer case; this descriptive information includes the tumor histology, tumor
type and stage, date of diagnosis, and how the diagnosis was made. The individual lung
cancer case data that identifies dates that can be used for an origin or beginning of the
study time period and stop or end date are required for survival analysis. All variables
such as the date of diagnosis, vital status (alive or dead), date of last contact or date of
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death, were used to answer the research questions as it pertains to survival in conjunction
with gender, treatment type, and/or tumor descriptor variables.

Variable Identification and Coding
Patient Identification (ID) Number
NAACCR Designated Item Number = 20
The identification number is a unique NAACCR number assigned to a particular
individual (patient). The ID number serves several functions and purposes as a unique
identifier for a particular individual. It is the recommendation of NAACCR, that a
previously assigned patient ID number is never reused or reissued if a patient file is
deleted. This number will follow the patient assigned a unique Patient Identification (ID)
Number. Different state cancer registries may report tumor information on the same
patient to NAACCR or commonly referred to as the central registry. In this instance, the
central registry will identify that individual, verify any duplicate records, and then assign
a unique patient ID number, exclusive to that patient. This number assignment serves to
follow the individual patient throughout his/her cancer history regardless of any
subsequent tumors that are reported for the patient.
Marital Status at Diagnosis (DX)
NAACCR Designated Item Number = 150
When the tumor information is reported, the patient’s marital status on the
diagnosis date is recorded. The martial status can be different depending upon the tumor
being reported, as an individual may have different tumor sites. This variable is
important as the incidence and survival has been shown to vary by marital status with
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particular cancer types 264, 265 . The codes used by the central registry for marital status
are 1) Single (never married), 2) Married (including common law), 3) Separated, 4)
Divorced, 5) Widowed, 9) Unknown.
Race 1
NAACCR Designated Item Number = 160
The Race coding used by NAACCR is taken from the 2000 US Census Bureau
definitions for race, see Table 12 below.
Table 12: NAACCR Code and Description of Race
Code
01
02
03

Code
20
21

NAACCR Designation
Micronesian, NOS
Chamorran

22

Guamanian, NOS

04
05
06
07
08
09
10
11

NAACCR Designation
White
Black
American Indian, Aleutian, or
Eskimo (includes all indigenous
populations of the Western
hemisphere)
Chinese
Japanese
Filipino
Hawaiian
Korean
Asian Indian, Pakistani
Vietnamese
Laotian

25
26
27
28
30
31
32
96

12
13
14
15

Hmong
Kampuchean
Thai
Micronesian, NOS

97
98
99

Polynesian, NOS
Tahitian
Samoan
Tongan
Melanesian, NOS
Fiji Islander
New Guinean
Other Asian, including Asian,
NOS and Oriental, NOS
Pacific Islander, NOS
Other
Unknown

Source: The North American Association of Central Cancer Registries Standards for Cancer Registries
Volume II Data Standards and Data Dictionary 2007

Race 2
NAACCR Designated Item Number = 161
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When an individual is multiracial, Race 2 through Race 5 is coded and prior to
2000 Race 2 through 5 was blank. The acceptable coding for each race designation is
shown in Table 12 under Race 1.
Race 3
NAACCR Designated Item Number = 162
Race 4
NAACCR Designated Item Number = 163
Race 5
NAACCR Designated Item Number = 164
Spanish/Hispanic Origin
NAACCR Designated Item Number = 190
Spanish or Hispanic origin does not use the same code as Race 1 through Race 5.
Origin as defined by the Census Bureau is the ―heritage, national group, lineage, or
country of birth of the person or the person’s parents or ancestors before their arrival in
the United States. The NAACCR Coding Manual states that people who identify their
origin as Spanish, Hispanic, or Latino, may be of any race 266. This particular item
variable was used in an attempt by the US Census Bureau to increase the reporting
accuracy of the data.
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Table 13: NAACCR Code and Description of Spanish/Hispanic Origin
Code
0
1
2
3
4
5
6
7
8
9

Description of Spanish/Hispanic Origin
Non-Spanish; non-Hispanic
Mexican (includes Chicano)
Puerto Rican
Cuban
South or Central American (except Brazil)
Other specified Spanish/Hispanic origin (includes European; excludes
Dominican Republic)
Spanish, NOS
Hispanic, NOS
Latino, NOS
'unknown whether Spanish or not' should be used

Source: The North American Association of Central Cancer Registries Standards for Cancer Registries
Volume II Data Standards and Data Dictionary 2007

Sex
NAACCR Designated Item Number = 220
This variable is one of the key variables under study for gender differences
research. Under the coding scheme of NAACCR, there are 5 codes for this classification:
1) 1 = Male, 2) 2 = Female 3) 3 = Other (Hermaphrodite), 4) 4 = Transsexual and 5) 9 =
Not Stated or Unknown.
Age at Diagnosis
NAACCR Designated Item Number = 230
The patient’s age at the time of tumor diagnosis is recorded in years. The coding
scheme is shown in actual years of age, e.g. a 57 year old would be coded as 057. Other
examples of age coding are given as 000 for less than 1 year old, 001 for 1 year old, but
less than 2 years, 002 represents 2 years of age, 101 for 101 years, 120 for 120 years old,
and 999 for an unknown age.
Birth Date
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NAACCR Designated Item Number = 240
The NAACCR format is given as MMDDCCYY, where MM is the month (01 12), DD the day (01 – 31) and CCYY, the year. The birth date is coded in an 8 character
format as either a valid date in the NAACCR format or 99999999 (8 characters) if
unknown. The North American Association of Central Cancer Registries Standards for
Cancer Registries Volume II Data Standards and Data Dictionary recommends that if the
birth year is unknown, the birth date can be calculated from the age of diagnosis and the
year of diagnosis. The coding for the month and the day would be 9999 as unknown but
the calculated year would be used. The NAACCR Standards further state an estimated
birth date is better than an unknown value.
Birthplace
NAACCR Designated Item Number = 250
The coding of the birthplace of an individual is found in the SEER Program Code
Manual Appendix B. This variable is of interest as variations in disease patterns, genetic
and socioeconomic characteristics have been demonstrated in the literature varying on
place of birth 82, 261, 267.
Tobacco History
NAACCR Designated Item Number =340
NAACCR does not have a designated code for tobacco use or tobacco history.
Coding schemes for tobacco use varies across state cancer registries.
Date of Diagnosis
NAACCR Designated Item Number = 390
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The date of diagnosis is the initial date the primary lung tumor was identified. The
coding of the date is done with the same ―date‖ format as the variable, Birth Date (240).
Primary Site
NAACCR Designated Item Number = 400
The primary tumor site for this particular research is 36, lung. The coding used by
NAACCR is designated by the International Classification of Disease – Oncology.
Laterality
NAACCR Designated Item Number = 410
Laterality is used for paired organs and describes which lung (left or right) has
been diagnosed with the primary tumor (Table 14).
Table 14: NAACCR Code and Description of Laterality
Code
0
1
2
3
4
9

Description of Laterality
Not a paired site
Right: origin of primary
Left: origin of primary
Only one side involved, right or left origin unspecified
Bilateral involvement, lateral origin unknown; stated to be single
primary; including both ovaries
Paired site, but no information concerning laterality, midline tumor

Source: The North American Association of Central Cancer Registries Standards for Cancer Registries
Volume II Data Standards and Data Dictionary 2007

Morphology Type and Behavior ICD-O-2
NAACCR Designated Item Number = 420
The morphology code is representative of the cell type and the biological activity
the tumor presents. The ICD-O coding system uses a morphology code based on the
histology (cell type), behavior code, and grade; the codes are given in Table 15. The first
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four digits of the morphology code denote the cell histology, the fifth digit is the behavior
and the last digit is the grade. The ICD-O-2/3 terms include 1) C34.0 for the main
bronchus, 2) C34.1 for the upper lobe of the lung, 3) C34.2 for the middle lung lobe (this
can be for the right lung only), 4) C34.3 lower lobe, lung, 5) C34.8 an overlapping lesion
of lung, and 6) C34.9 Lung, NOS. The histologic and behavior codes vary as a function
of the lung cancer type.
Table 15: NAACCR Code and Description of LC Morphology

Lung Cancer Type
Small Cell
Lung Cancers

Squamous or
Epidermoid
Adenocarcinoma
Bronchi alveolar

ICD-O
Morphology Codes
80413
80423
80433
80443,
80453
807_3

Lung Cancer Type
Large Cell
Carcinoma

Adenosquamous
Carcinoma
Non-Small Cell
Carcinoma

814_3

ICD-O
Morphology Codes
80123

85603
80463

82503

Source: Florida Cancer Data System November 2003 Monthly Memo

Histology (92-00) ICD-O-2
NAACCR Designated Item Number = 420
There are three parts of the coding scheme for the morphology code and the tumor
type is classified under ―histology‖ which is the first part (first 4 digits) of the
morphology code. A complete explanation of the history classification scheme was given
in Chapter Two under the Pathology/Histology section. As shown in Table 15, the first
four digits are representative of the coding used for lung cancer cases. Each lung cancer
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type is classified and coded by standardized methods, as discussed in Chapter Two.
Behavior (92-00) ICD-O-2
NAACCR Designated Item Number = 430
The behavior of a tumor is the way or the mode of tumor growth or progression
within the human body. The physician, normally a pathologist, observes the tumor
behavior and classifies the growth pattern. It would be important to select or include
cases with the behavior code of ―3‖ (see Table 16.)
Table 16: NAACCR Code and Description of LC Behavior
Code
/0
/1
/2
/3
/6
/9

Description of Behavior
Benign
Uncertain whether benign or malignant, borderline malignancy, low
malignant potential, uncertain malignant potential
Carcinoma in situ, intraepithelial, non-infiltrating, non-invasive
Malignant, primary site
Malignant, metastatic or secondary site
Uncertain whether primary or metastatic site

Source: The North American Association of Central Cancer Registries Standards for Cancer Registries
Volume II Data Standards and Data Dictionary 2007

Morphology Type and Behavior ICD-O-3
NAACCR Designated Item Number = 521
Coding for the lung cancer type or morphology essentially did not change from
ICD-O-2 to ICD-O-3; for other tumor types and disease classifications, the ICD-O coding
did change. As part of the quality assurance procedure, ICD-O-2 lung cancer cases will
be compared to the ICD-O-3 cases, to ensure that the data are consistent. Another
method to identify any errors or errors in duplication will be to utilize the NAACCR
variable (code 480) ―Morphology Coding System – Original‖. There should be
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consistency between Morphology Type and Behavior ICD-O-2, Morphology Type and
Behavior ICD-O-, and Morphology Coding System – Original.
Histology (92-00) ICD-O-3
NAACCR Designated Item Number = 522
ICD-O-3 Histology or cell/tumor type designation is the same coding scheme as
Histology ICD-O-2.
Behavior (92-00) ICD-O-3
NAACCR Designated Item Number = 522
The ICD-O-3 Behavior or cell growth pattern designation is the same
coding scheme as described in Behavior IDC-O-2.
Grade
NAACCR Designated Item Number = 440
The code for grade describes the cells of the tumor. Grades I through IV (codes 1
– 4 as shown in Table 17) are utilized and the other grades listed in that table below are
not applicable to this research.

116

Table 17: NAACCR Code and Description for Grade
Code

Description of Grade

1

Grade I

2

Grade II

3

Grade III

4

Grade IV

Equivalent Term*
Grade I; grade 1; Well differentiated; Differentiated,
NOS
Grade II; grade 2; Moderately differentiated;
Moderately well differentiated; Intermediate
differentiation; Low grade;
Partially well differentiated;
Relatively well differentiated;
Generally well differentiated;
Fairly well differentiated;
Intermediate differentiation;
Grade I of 3 category system;
Grade I-II; Trabecular
Grade III, grade 3; Poorly differentiated;
Dedifferentiated; Medium grade; Moderately
undifferentiated; Relatively undifferentiated;
Relatively poorly differentiated; Grade II of 3
category system; Grade II-III
Grade IV; grade 4; Undifferentiated;
Anaplastic; High grade; Grade III of 3 category
system; Grade III-III

5
6
7
8
9

T-cell
B-cell
Null cell
NK (natural killer) cell
Grade/differentiation Cell type not determined, not stated or not applicable;
unknown, not stated, or No grade/differentiation in the primary site even if a
not applicable
grade is given for a metastatic site.
Source: The North American Association of Central Cancer Registries Standards for
Cancer Registries Volume II Data Standards and Data Dictionary 2007
*Source: Florida Cancer Data System Data Acquisition Manual 2006

Morphology Coding System – Original
NAACCR Designated Item Number = 480
The morphology coding system originally used will be utilized as a second check
to ensure data quality in the reporting and data received from the cancer registries.
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Diagnostic Confirmation
NAACCR Designated Item Number = 490
Diagnostic confirmation is essential for verification of a particular tumor type.
This confirmation can be made utilizing various methods such as an examination by a
pathologist or cytologist of tissues or cells via the microscope. For this research, certain
criteria for the variables of interest must be used when evaluating a particular tumor type,
in particular, in the study of lung cancer. One criterion to know is the specific scientific
method used to diagnosis the tumor type. Biological confirmation of the cancer type is
the gold standard in the medical community. In the NAACCR coding scheme, other
diagnostic confirmation methods other than biologic confirmation such as direct
visualization of the tumor are included and are shown in Table 18. The codes for the
reporting method for confirming a particular tumor type in this research will only include
biologically confirmed methods: 1) positive histology, 2) positive cytology, no positive
histology, 4) positive microscopic confirmation, method not specified, and 5) Positive
laboratory test/marker study as shown in Table 18.
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Table 18: NAACCR Code and Description Diagnostic Confirmation
Code

Description of Diagnostic Confirmation

1
2
4
5
6

Positive histology
Positive cytology, no positive histology
Positive microscopic confirmation, method not specified
Positive laboratory test/marker study
Direct visualization without microscopic confirmation
Radiography and other imaging techniques without microscopic
confirmation
Clinical diagnosis only (other than 5, 6, or 7)
Unknown whether or not microscopically confirmed

7
8
9

Source: The North American Association of Central Cancer Registries Standards for Cancer Registries
Volume II Data Standards and Data Dictionary 2007

Type of Reporting Source
NAACCR Designated Item Number = 500
The tumor information is contained in many different records at different
facilities. As the data are abstracted or collected in a standardized manner, it is necessary
to identify where the information was obtained from. As an example, information from
laboratory reports identified from the medical record in a medical oncology center would
have the reporting center coded as 2 – see Table 19. It is well documented in the
literature 57, 229 that death certificates many have incomplete information and may not
represent a complete picture of the patient’s medical history. It would be important to the
investigator to be aware that reporting source with a code of 7 as to address any
discrepancies during the analysis.
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Table 19: NAACCR Code and Description for Reporting Source Type
Code
1
2
3
4
5
6
7
8

Description of Type of Reporting Source
Hospital inpatient; Managed health plans with comprehensive, unified
medical records
Radiation Treatment Centers or Medical Oncology Centers
(hospital-affiliated or independent)
Laboratory only (hospital-affiliated or independent)
Physician's office/private medical practitioner (LMD)
Nursing/convalescent home/hospice
Autopsy only
Death certificate only
Other hospital outpatient units/surgery centers

Source: The North American Association of Central Cancer Registries Standards for Cancer Registries
Volume II Data Standards and Data Dictionary 2007

Sequence Number
NAACCR Designated Item Number = 560
This code is used by the cancer registry to identify primary, secondary, or
multiple lung tumors. As this research is focused on primary lung cancer cases, this
designation is 00 and codes other than the 00 will be identified.
Date of Admission or First (Adm/1st) Contact
NAACCR Designated Item Number = 580
This variable designates the date the first time a case was contacted either as an
outpatient or inpatient. The coding of the date is done with the same ―date‖ format as the
variable, Birth Date (240). The date may be representative of an outpatient procedure, an
x-ray, or pathology report associated with the diagnosis of the tumor.
Class of Case
NAACCR Designated Item Number = 610
Class of case describes the location of the reporting facility where the diagnosis
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was made and the codes for Class of Case are described in Table 20. Analytic cases are
those that are diagnosed at the reporting facility and include the codes 0 through 2. The
other codes include nonanalytic cases that are identified at the reporting facility but were
diagnosed and treated at a different facility. These cases also include those diagnosed at
autopsy.
Table 20: NAACCR Code and Description for Class of Case
Codes

Description of Class of Case

Analytic Cases
0
Diagnosis at the reporting facility and the entire first course of treatment
was performed elsewhere or the decision not to treat was made at another
facility.
1
Diagnosis at the reporting facility, and all or part of the first course of
treatment was performed at the reporting facility.
2
Diagnosis elsewhere, and all or part of the first course of treatment was
performed at the reporting facility.
Non-analytic Cases
3
Diagnosis and the entire first course of treatment were performed
elsewhere. Presents at your facility with recurrence or persistent disease.
4
Diagnosis and/or first course of treatment were performed at the reporting
facility prior to the reference date of the registry.
5
Diagnosed at autopsy
6
Diagnosis and the entire first course of treatment were completed by the
same staff physician in an office setting. ―Staff physician‖ is any medical
staff with admitting privileges at the reporting facility.
7
Pathology report only. Patient does not enter the reporting facility at any
time for diagnosis or treatment. This category excludes tumors diagnosed at
autopsy.
8
Diagnosis was established by death certificate only. Used by central
registries only.
9
Unknown. Sufficient detail for determining Class of Case is not stated in
patient record. Used by central registries only.
Source: The North American Association of Central Cancer Registries Standards for Cancer Registries
Volume II Data Standards and Data Dictionary 2007
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Primary Payor at Diagnosis
NAACCR Designated Item Number = 630
Information about the insurance carrier at the time of diagnosis can be an
important variable. Possible treatment disparities between minority groups with lung
cancer and the association between the types of insurance coverage could be of interest.
Table 21 lists the codes that are associated with the particular payor at the time of lung
cancer diagnosis.

Table 21: NAACCR Code and Description for Payor at Diagnosis
Code
01
02
10
20
21
31
35
60
61
62
63
64
65
66
67
68
99

Description of Primary Payor at Diagnosis
Not insured
Not insured, self-pay
Insurance, NOS
Private Insurance: Managed care, HMO, or PPO
Private Insurance: Fee-for-Service
Medicaid
Medicaid -Administered through a Managed Care plan
Medicare/Medicare, NOS
Medicare with supplement, NOS
Medicare - Administered through a Managed Care plan
Medicare with private supplement
Medicare with Medicaid eligibility
TRICARE
Military
Veterans Affairs
Indian/Public Health Service
Insurance status unknown

Source: The North American Association of Central Cancer Registries Standards for Cancer Registries
Volume II Data Standards and Data Dictionary 2007
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SEER Summary Stage 1977
NAACCR Designated Item Number = 760
The coding scheme for SEER Summary Stage 1977 (Table 22) is used at the time
of initial primary tumor diagnosis. Stage was a variable that was historically monitored
for time trends.
Table 22: NAACCR Code and Description SEER Summary Stage 1977
Codes
0
1
2
3
4
5
7
8
9

Description of SEER Summary Stage 1977
In situ
Localized
Regional, direct extension only
Regional, regional lymph nodes only
Regional, direct extension and regional lymph nodes
Regional, NOS
Distant
Not applicable
Unstaged

Source: The North American Association of Central Cancer Registries Standards for
Cancer Registries Volume II Data Standards and Data Dictionary 2007

SEER Summary Stage 2000
NAACCR Designated Item Number = 2000
SEER Summary Stage 2000 at initial diagnosis is a variable that includes the
description of the reportable tumor. Table 23 exhibits the site-specific single-digit coding
scheme explicit to the tumor location.
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Table 23: NAACCR Code and Description SEER Summary Stage 2000
Codes
0
1
2
3
4
5
7
8
9

Description of SEER Summary Stage 2000
In situ
Localized
Regional, direct extension only
Regional, regional lymph nodes only
Regional, direct extension and regional lymph nodes
Regional, NOS
Distant
Not applicable
Unstaged

Source: The North American Association of Central Cancer Registries Standards for Cancer
Registries Volume II Data Standards and Data Dictionary 2007

Record (RX) Date of First Surgery
NAACCR Designated Item Number = 1200
The date of the first surgery for the primary tumor is coded with the NAACCR
format given as MMDDCCYY, where MM is the month (01 - 12), DD the day (01 – 31)
and CCYY, the year. The surgical date is coded in an 8 character format as either a valid
date in the NAACCR format or 99999999 (8 characters) if it is unknown if any surgical
procedure was performed. If there was no surgical procedure performed or if the
individual was an autopsy-only case, the code would be 00000000.
Record (RX) Date of First Radiation
NAACCR Designated Item Number = 1210
This is the date that the treatment modality, radiation therapy began at any
radiation therapy facility, e.g. hospital, outpatient center, for the patient’s first course of
their treatment. The coding for this variable is the NAACCR format MMDDCCYY,
where MM is the month (01 - 12), DD the day (01 – 31) and CCYY is the year. Other
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variations include 00000000 when radiation therapy is not administered; autopsy-only
case, 88888888 if radiation therapy was scheduled as part of the first course of therapy,
but was not started at the time and 99999999 if the date was unknown, it was unknown
whether any radiation therapy was administered; or if the case was only identified by
death certificate.
Record (RX) Date of First Chemotherapy
NAACCR Designated Item Number = 1220
This designation is the date that chemotherapy was first started. The format used
by NAACCR is the same as in ―Birth Date‖. The other codes admissible include
00000000 when chemotherapy is not administered or in the case of an autopsy.
Record (RX) Summary of Surgery for Primary Site
NAACCR Designated Item Number = 1290
The summary of the surgery performed for the primary tumor site is given below
in Table 24. As the disease of interest for this research is lung cancer, all surgical sites
will be specific to regions of the lung.

Table 24: NAACCR Code and Description of Surgical Primary Site
Code
00
10-19
20-80
90
98
99

Description of Record (RX) Summary of Surgery for Primary Site
None
Site-specific code; tumor destruction
Site-specific codes; resection
Surgery, NOS
Site specific codes; special
Unknown

Source: The North American Association of Central Cancer Registries Standards for Cancer
Registries Volume II Data Standards and Data Dictionary 2007
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Record (RX) Summary of Radiation
NAACCR Designated Item Number = 1360
The coding for ―Record Summary of Radiation‖ described in Table 25 with an
explanation the type of radiation treatment the lung cancer case received.

Table 25: NAACCR Code and Description of Radiation Treatment
Code
0
1
2
3
4
5
6
7
8
9

Description of Radiation Treatment
None
Beam radiation
Radioactive implants
Radioisotopes
Combination of 1 with 2 or 3
Radiation, NOS—method or source not specified
Currently allowable for historic cases only; see Note
below
Patient or patient’s guardian refused*
Radiation recommended, unknown if administered*
Unknown if radiation administered

Source: The North American Association of Central Cancer Registries Standards for Cancer
Registries Volume II Data Standards and Data Dictionary 2007
“Note: In the SEER program, a code 2 for other radiation was used between 1973 and 1987.
When the radiation codes were expanded to add codes '2' radioactive implants
and '3' radioisotopes, all cases with a code '2' and diagnosed in 1973-1987 were converted to a
code '6' radiation other than beam radiation.‖

Record (RX) Summary of Chemotherapy
NAACCR Designated Item Number = 1390
The chemotherapy codes used for the NAACCR Designated (Item Number =
1390) Record Summary of Chemotherapy are listed in Table 26. The code is specified
when a chemotherapy agent/drug is received or not administered to an individual case as
part of the first treatment for lung cancer. Also a code is given to identify when it is
unknown if the lung cancer case received chemotherapy, i.e. codes 88 and 99.
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Table 26: NAACCR Code and Description for Chemotherapy
Code
00
01
02
03
82

85
86

87

88
99

Description of Chemotherapy Treatment
None, chemotherapy was not part of the planned first course of therapy.
Chemotherapy, NOS
Chemotherapy, single agent.
Chemotherapy, multiple agents.
Chemotherapy was not recommended nor administered because it was
contraindicated due to patient risk factors, i.e., comorbid conditions, advanced
age.
Chemotherapy was not administered because the patient died prior to planned
or recommended therapy.
Chemotherapy was not administered. It was recommended by the patient’s
physician, but was not administered as part of first-course therapy. No reason
was stated in the patient record.
Chemotherapy was not administered; it was recommended by the patient’s
physician, but this treatment was refused by the patient, the patient’s family
member, or the patient’s guardian. The refusal was noted in the patient record.
Chemotherapy was recommended, but it is unknown if it was administered.
It is unknown whether a chemotherapeutic agent(s) was recommended or
administered because it is not stated in patient record; death certificate-only
cases.

Source: The North American Association of Central Cancer Registries Standards for Cancer Registries
Volume II Data Standards and Data Dictionary 2007

Derived AJCC Stage Group
NAACCR Designated Item Number =3000
This variable, Derived AJCC Stage Group, encompasses all stage designations
from the AJCC Sixth Edition TNM stage, SEER Summary Stage 1977, and SEER
Summary Stage 2000 and complies the different coding into this one item number, 3000.
The coding designation, shown in Table 27 came into effect as a result of a joint task
force so a common, uniform set of rules and coding will be available. Representatives
from SEER, ACoS, CDC, NAACCR, NCRA, and AJCC collaborated on the coding
designation to standardize the grouping of disease stage.
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Table 27: Derived AJCC Stage Group
AJCC
Code
00
01
02
10
11
12
13
14
15
16
17
18
19
23
24
20
21
22
30
31
32
33
34
35
36
37
38
39
40
41
42
43
50
51
52
53
54
55

Display
String
0
0a
0is
I
INOS
IA
IA1
IA2
IB
IB1
IB2
IC
IS
ISA
ISB
IEA
IEB
IE
II
IINOS
IIA
IIB
IIC
IIEA
IIEB
IIE
IISA
IISB
IIS
IIESA
IIESB
IIES
III
IIINOS
IIIA
IIIB
IIIC
IIIEA

Comments
Stage 0
Stage 0a
Stage 0is
Stage I
Stage I NOS
Stage IA
Stage IA1
Stage IA2
Stage IB
Stage IB1
Stage IB2
Stage IC
Stage IS
Stage ISA (lymphoma only)
Stage ISB (lymphoma only)
Stage IEA (lymphoma only)
Stage IEB (lymphoma only)
Stage IE (lymphoma only)
Stage II
Stage II NOS
Stage IIA
Stage IIB
Stage IIC
Stage IIEA (lymphoma only)
Stage IIEB (lymphoma only)
Stage IIE (lymphoma only)
Stage IISA (lymphoma only)
Stage IISB (lymphoma only)
Stage IIS (lymphoma only)
Stage IIESA (lymphoma only)
Stage IIESB (lymphoma only)
Stage IIES (lymphoma only)
Stage III
Stage III NOS
Stage IIIA
Stage IIIB
Stage IIIC
Stage IIIEA (lymphoma only)
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56
57
AJCC
Code
58
59
60
61
62
63
70
71
72
73
74
88
90
99

IIIEB
IIIE
Display
String
IIISA
IIISB
IIIS
IIIESA
IIIESB
IIIES
IV
IVNOS
IVA
IVB
IVC
NA
OCCULT
UNK

Stage IIIEB (lymphoma only)
Stage IIIE (lymphoma only)
Comments
Stage IIISA (lymphoma only)
Stage IIISB (lymphoma only)
Stage IIIS (lymphoma only)
Stage IIIESA (lymphoma only)
Stage IIIESB (lymphoma only)
Stage IIIES (lymphoma only)
Stage IV
Stage IV NOS
Stage IVA
Stage IVB
Stage IVC
Not applicable
Stage Occult
Stage Unknown

Source: The North American Association of Central Cancer Registries
Standards for Cancer Registries Volume II Data Standards and Data Dictionary
2007

Date Case Report Received
NAACCR Designated Item Number = 2111
The ―Date Case Report Received‖ is the date that the source record is submitted
and received by the central cancer registry 258. In the event of multiple reports on the
same individual and one date is needed, the protocol is to use the first date the record was
received. This variable can be used to evaluate the reporting timeliness of the cancer
registries. This variable may also be used to measure how long the individual cancer
registry takes to submit the data when the date the report (2111) is received is compared
to the date of first contact (580).
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Date of Last Contact
NAACCR Designated Item Number =1750
The Date of Last Contact is the last date of known contact but also can represent
the date of death. The date is obtained from either an active or a passive follow-up. The
sources include the state registries date of last contact or death (passive) or from an active
state SEER registry or the National Death Index. The date coding follows the NAACCR
format of MMDDCCYY, where MM is the month (01 - 12), DD the day (01 – 31) and
CCYY is the year. The main purpose of this variable is to record the date of last contact
or date of death.
Vital Status
NAACCR Designated Item Number =1760
The vital status of the individual as given by the NAACCR is 0 for dead, 1 for
alive, 4 for dead. A code of 0 is obtained from states that report based on the guidelines
of the Commission on Cancer (passive registry) and a code of 4 is based on information
obtained from a SEER state (active registry).
Follow-Up Source
NAACCR Designated Item Number =1790
The source is given for the most currently recorded information for an individual.
Any discrepancies in the record can be reviewed and cross-checked with other variable
coding. Table 28 lists the sources or the contributors to the follow-up data. It includes
information reported from the Department of Motor Vehicles, death certificate
information, patient or physician reporting, Medicare/Medicaid files, and if the data is
unknown, not stated in the patient record.
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Table 28: NAACCR Code and Description of Follow-Up Sources
Code
0
1
2
3
4
5
7
8
9

Description of Follow-Up Source
Reported hospitalization
Readmission
Physician
Patient
Department of Motor Vehicles
Medicare/Medicaid file
Death certificate
Other
Unknown, not stated in patient record

Source: The North American Association of Central Cancer Registries Standards for Cancer Registries
Volume II Data Standards and Data Dictionary 2007

Autopsy
NAACCR Designated Item Number =1930
This designation is the indicator if an autopsy was performed or not. This
information could be use to verify the correctness of the coding for other variables. For
example, the coding for this NAACCR designated item number, 1930, could be
compared to a patient status code for a particular individual to check for agreement. A
case could not be alive if an autopsy was performed.

Table 29: NAACCR Code and Description of Autopsy
Code
0
1
2
9

Description of Autopsy
Not applicable; patient alive
Autopsy performed
No autopsy performed
Patient expired, unknown if autopsy performed

Source: The North American Association of Central Cancer Registries Standards
for Cancer Registries Volume II Data Standards and Data Dictionary 2007

Place of Death
NAACCR Designated Item Number = 1940
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This variable is useful to correlate to the date of last contact. If the patient is
coded as alive and a place of death is documented, further investigation is warranted.
Date Case Completed
NAACCR Designated Item Number = 2090
The date can be used to assess the quality and timeliness of reporting for the data.
Date Case Exported
NAACCR Designated Item Number = 2110
The date can be used to assess the quality and timeliness of reporting for the data.
Derived AJCC Stage Summary
NAACCR Designated Item Number = 3000
This variable is used to compare stage information.

Epidemiologic Research Design
The epidemiologic study design for this research was based on a historical cohort
of primary lung cancer case. Female lung cancer cases were compared to male lung
cancer cases and this comparison between genders included the histological type, stage,
and grade of lung cancer and the treatment received (chemotherapy, radiation therapy,
surgery, or combination) as variables of interest. Some of the strengths of this study
design are multiple effects of the exposure were assessed simultaneously. Historically, a
weakness of a retrospective or historical study design is it can be prone to bias due to
recall or information bias. This particular limitation or weakness was minimized as the
data were collected by a standardized, controlled method utilizing trained cancer registry
abstractors; information was provided by medical records and non-analytic cases were
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excluded, e.g. information provided by the patient or members of the family. As the
majority of the states are mandated by law to report cancer case information; noncompliance is minimal and monitored by the NAACCR; therefore the case information is
assumed to be complete.

Data Collection Methods
Prior to the collection of any lung cancer case information, approval from the
University of South Florida Internal Review Board Data (IRB) was sought by the
principle investigator, PI. The chief concern of the IRB was that the case information
could not be used to identify any one particular individual. The research data acquired
for primary lung cancer cases for this study are cases from state cancer registries that are
members of NAACCR. Initially, there were two main approaches to collecting the lung
cancer case information. The first method was to contact the eight states selected (Table
10). As stated previously, West Virginia was randomly selected but the cancer registry
was unable to comply with the data research request. Table 30 outlines the contact
process followed for the cancer registries and the contact information. The data set
acquisitions was done in accordance to protocol and procedures outlined by each state
based cancer registry.
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Table 30: State Cancer Registry Contact Information

State
Oregon

Idaho

Florida

South Carolina

Indiana

Massachusetts

Nebraska

Rhode Island

Contact Information

Requirements for the Release of Data
Requested Lung Cancer Data and sent the following three
files:
1. The PDF file of the approval letter from the IRB at the
University of South Florida concerning my dissertation
research.
2. The variables of interests are outlined in "NAACCR
VARIABLE" (the data will be utilized as part of my
dissertation/research project).
3. The eight state cancer registries selected to participate in
my dissertation research project that includes Oregon.

Catherine Riddell (great resource)
Research Analyst
Oregon State Cancer Registry
Phone: (971) 673-1113
FAX: (971) 673-0996
catherine.a.riddell@state.or.us

Cancer Data Registry of Idaho
615 N. 7th Street
P.O. Box 1278
Boise, Idaho 83701
http://www.idcancer.org/generalinfo.html

The Cancer Data Registry of Idaho has a release requirement
and form that must be submitted prior to the release of any
data.

Florida Cancer Data System
http://fcds.med.miami.edu/

The FCDS has a release requirement and form that must be
submitted prior to the release of any data. The data request
forms are located on the FCDS website at:
http://fcds.med.miami.edu/inc/datarequest.shtml

S.C. Department of Health & Environmental
Control
S.C. Central Cancer Registry
810 Dutch Square Blvd., Ste. 220
Columbia, SC 29210

The South Carolina Central Cancer Registry has a release
requirement and form that must be submitted prior to the
release of any data.
Telephone # (803) 731-1419
Fax # (803) 731-1455

Indiana State Department of Health
Epidemiology Resource Center
2 North Meridian, 5K
Indianapolis, IN 46204
317-233-7807
317-234-2812 FAX

The Indiana State Department of Health has a release
requirement and form that must be submitted prior to the
release of any data.

Massachusetts Cancer Registry
250 Washington Street, 6th Floor
Boston, MA 02108
Phone: (617) 624-5642
Fax: (617) 624-5695
Annie McMillan (great resource and
extremely helpful)
Nebraska Cancer Registry
Nebraska Comprehensive Cancer Control
Program
Janis Singleton (very nice)
3 Capitol Hill
Providence, RI 02908
(401)222-1172
Fax: 222-3551
http://www.health.ri.gov/disease/cancer/regis
try.php
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The Massachusetts Cancer Registry has a release requirement
and form that must be submitted prior to the release of any
data.
Confidential Data Officer Privacy and Data Access Office
Massachusetts Department of Public Health
250 Washington Street, 2nd Floor
Boston, MA 02108-4619
TEL: (617) 624-5229
FAX: (617) 624-5234
IRB approval process
DHHS, Division of Public Health
301 Centennial Mall South
Lincoln NE 68509
The Rhode Island Cancer Registry has a release requirement
and form that must be submitted prior to the release of any
data.
Main Contact (extremely helpful): John P. Fulton, PhD, RI
Department of Health: 401-277-1394 x115

The other or second method of data case acquisition was attempted through the
central cancer registry, NAACCR, for the states of interest (Table 9). To answer the
research questions, data from the eight states was required. It was considered a viable
option that collecting the data from a centralized data bank, like NAACCR, would
streamline the data collection process. The second option was pursued via multiple data
requests made directly to NAACCR. The complete approval/disapproval process for data
release took over a year and after multiple requests and multiple re-submissions for the
lung cancer data, NAACCR determined they would provide the information to the
researcher. Within 1 month of receiving the NAACCR approval letter, the investigator
was again contacted by NAACCR and was told more approvals by another NAACCR
committee were required and the approval was withdrawn. Ultimately, after several more
months, a letter was received by the investigator and was told by NAACCR the data
would not be provided to the researcher; multiple reasons were given. During this
process of awaiting the second NAACCR approval, the investigator was contacted by
telephone by one of the NAACCR committee members; that particular committee
member said that the dissertation research did not serve any scientific merit. NAACCR
can be contacted via the URL http://www.naaccr.org/ . Any other future attempts to use
the NAACCR data base were deemed unproductive therefore method one of contacting
the states directly was utilized for the primary lung cancer case data collection.
When the data sets were acquired from each state cancer registry, the data set was
assessed for completeness of information, i.e. that the variables of interest were included.
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Also the categories for the variables of interest were evaluated for coding as the format
would have to be similar as outlined by the standard NAACCR protocols. The
comparison of results from state based registries for lung cancer cases would not be
possible without this standardization. When each state cancer registry was contacted,
each state representative was particularly interested in how the data are used for the
specified or requested research project and that patient confidentiality would not be
compromised. Additionally, it was requested that the database not shared with anyone
other than the researchers identified on the data request form (the researchers must attest
to this; in some instances the state data request form had to be notarized), and any
confidential patient information inadvertently discovered must be kept confidential.

Statistical Procedures
Prior to any statistical procedures, complete assessment of the study design
methods was completed. The methods outlined in the selection criteria for cases
identification and state cancer registry selections were based on epidemiological
principles so ultimately valid assessments could be made after utilizing the most
appropriate statistical procedures. In other words, data sets that contain inherent flaws
due to bias would never result in invalid conclusions regardless of the statistical methods
applied. For example, randomization during the selection of the regional state based
cancer registry was part of the initial selection process. Any bias that may have been
introduced by the selection of a state in theory was minimized by that randomization
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process. In the previous sections, the importance of the data selection or variables of
interest (inclusion and exclusion criteria) was discussed. Collecting data from cancer
registries that utilize a standardized format 258 was critical. Data not collected in such a
manner could be subject to bias resulting in erroneous results. Each lung cancer case
acquired from each state cancer registry was assessed for completeness of the data. In
other words, all the variables of interest should be included in the case information and
the categories for the variables of interest should be coded in a similar manner as outlined
by the standard NAACCR protocols. The comparison of results from state based
registries for lung cancer cases would not be possible without the standardization of the
variables of interest.
The selection of the most appropriate statistical model that best represented and
accounted for the behavior of the data was critical in the evaluation of the three research
questions. The statistical procedures applicable to each research question are discussed
and reviewed in the following section; these procedures are utilized so that the research
questions were answered appropriately. Each of the eight state based primary lung
cancer case data was concatenated into one data set; this data set was used to answer the
research questions. The lung cancer case information from each state is representative of
the lung cancer cases that state (Idaho, Oregon, Florida, South Carolina, Indiana,
Massachusetts, Nebraska, and Rhode Island) as each case within the state cancer registry
has as likely a chance to be included in the state registry as another. The ability to
identify which state the individual lung cancer case originated from in the merged data
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set will be done by means of a generated variable (code). This coding enabled the
researcher to not only look at the aggregate population statistics but also by state and
region.
One of the first statistical procedures performed on the data sets was exploratory
analysis. These descriptive procedures enabled the investigator to identify any
differences, as well as the similarities of the patient population under study. This was
accomplished by the PROC FREQ statistical procedure in SAS and univariate analysis by
investigating the resultant means of the continuous variable age; results of the testing are
given in Chapter Four. For example, it was useful to examine the difference between
men and women, age of diagnosis, and state/region. Several studies recently published,
suggest that the age at diagnosis of lung cancer is less for women versus men 40, 15 and the
opportunity to compare the results of this data set analysis served to increase the validity
of this research. Any differences in the lung cancer case population were determined for
the number of men and women in each particular variable category such as morphology
(histology and behavior) group, treatment group, or the age at tumor diagnosis categories.
The results of the SAS PROC FREQ statistical procedure were examined for the other
research variables of stage, grade, marital status at the time of diagnosis, race, vital status
and state. The statistical procedures were used to count the frequencies of the data
variables and calculated percentages. In summary, all categorical variables are displayed
in Chapter Four tables and were also classified according to gender (male and female).
The continuous variable of age at diagnosis was evaluated by the SAS PROC
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UNIVARIATE procedure and described in terms of the mean, medians and ranges
comparing to males and females. Age was categorized into five age groups and those
categorical classifications were used in the subsequent analysis to answer the three
research questions.

Study Question One
Null Hypothesis: Females receive the same treatment as men regardless of the
histological type, stage and grade of lung cancer. The outcome variable is treatment, the
exposure is gender (a main effect), and the variables classified as other main effect
variables include stage, grade, and histological type; the demographic independent
variables included age group at diagnosis, marital status at diagnosis and race. The
statistical model used to examine the relationship between the dependent and independent
variable, gender, will be the multinomial logistic regression model (MLRM). The
multinomial logistic regression model facilitates the examination of the categorical
outcome variable (Treatment Group) and the relationship between the independent
variables. In this research, the outcome variable is multinomial or polychotomous and is
coded on a nominal level. Each treatment type or treatment group (txgrp) or
combination of treatments is categorized on a nominal scale meaning the levels (scale) do
not represent a better or worse category. These nominal outcome levels and the
independent variables were modeled or ―fitted‖ to a multinomial logistic regression
model. There are eight treatment types (outcome variable levels) 1) radiation, 2) surgery,
3) chemotherapy, 4) radiation combined with surgery, 5) radiation combined with
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chemotherapy, 6) surgery combined with chemotherapy, 7) radiation combined with
chemotherapy and surgery, and 8) no treatment received that were analyzed to answer
question one.

A representative equation for the full model is listed below and is defined as:
Pr (yi=1) = G (0 + 1xi1 + 2xi2 +…+ kxik)
G ( w) 

Where

ew
1  e w is the cumulative distribution function for a logistic variable and

upon transformation is referred to as the logit model. This model makes the assumption the
chance (odds) of an outcome given a response level (in this case, a particular treatment
modality received) are constant regardless of which level (treatment type) selected. For
nominal outcome logistic models with k + 1 possible levels for the outcome variable, the
logistic model can be extended to a multinomial model called a generalized or baselinecategory logit model, and is shown below:
ln

/

(Pr(Y = i| x)) (Pr(Y = k+1| x))

= i + ’ixi, where i= 1,……,k

Where the 1, …, k are the k intercept parameters and the 1, …., k are the k vectors of
the slope parameters; these models are designated as a special case of the discrete choice
or conditional logit model. The coefficients resulting from multinomial logistic
regression upon exponentiation are commonly referred to as an Odds Ratio.
As gender was one of the main interests of this research, the effect that gender had
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on the selection of the treatment received classified gender as the primary ―main effect‖
variable for this particular research question (Question I). Each covariate, gender, stage,
grade, morphology, age group, race, and marital status had different coding or levels
within the particular variable and was discussed in the ―Variable of Interest‖ section of
this chapter. The statistical results including the Odds Ratios and 95% Confidence
Intervals generated by the MLRM included the main effects, interaction effects, and the
overall gender effect on the outcome, i.e. treatment type received, are included in the
overall assessment to answer Question One. In summary, the multinomial logistic
regression model utilizing categorical variables was used as the statistical model to test
Hypothesis I in order to answer question one.
Additionally, a random effect model utilizing the SAS PROC GLIMMIX
procedure with a link function to the generalized logit model was included to evaluate
any effect state had the outcome as compared to another state. The identification of each
state in the data set was important with respect to the study of any random effects
introduced by a state on the relationship between the outcome (lung cancer treatment)
and the independent variables. A random effect model was useful in the identification of
one state that behaved differently (in the statistical sense) or having variability as
compared to another state. As an example, a possible contributor to the ―random effect
of state‖ would be that Florida is known as a retirement state. Florida’s population has an
overrepresentation of individuals with a greater probability of cancer incidence. Statistics
based on the treatment of Florida lung cancer female and male cases when compared to
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another state such as Nebraska (different population base) may lead to variability in the
relationship of lung cancer treatment and the independent variables dependent upon state.

Study Question Two
The statistical procedures to address the second study question (Is there a
statistically significant difference in survival in women with lung cancer as compared to
men with lung cancer regardless of the treatment modality received?) included the
Kaplan-Meier and the Life Table methods for overall lung cancer survival analysis between
men and women. The log-rank statistical test was utilized to test for survival differences
between women and men by examining for any statistical significance. Survival was defined
in this study as the time (in months) from the diagnosis of lung cancer to death or to the date
of last contact when the individual was reported as alive – a cutoff date of 12-31-2004 was
used to censor individuals that had a date of last contact greater than 12-31-2004.

Study Question Three
The third research question, ―Do women with the same histological type,
stage/grade of lung cancer, and the same treatment modality differ significantly in
survival as compared to men with the same histological type, stage/grade of lung cancer,
and the same treatment modality‖ utilized the Cox Proportional Hazards model. The Cox
Proportional Hazards model estimated the relative risk or hazard ratio for death for women as
compared to men. This model was used to address gender differences in overall survival
while adjusting for the primary main effects, demographic main effects and interaction term
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moderation. The effect of gender on survival was examined by determining the estimated
relative risk (hazards ratio) of death for women as compared to men by adjusting by stage,
histology, grade, treatment type, race, marital status, and age group as well as interaction
terms with the adjusted Cox Proportional Hazards model. The proportionality assumption of
the Cox’s Proportional Hazard model for each variable was tested by evaluating the graphs of
the survival function and noting that the distance between the levels or strata of a variable did
not change (increase or decrease) over time or cross. In each case, the proportionality
assumption held with the exception of the variable, treatment groups. In this case there was
crossover between two of the treatment groups suggestive of limitations in the analysis.
Residual analysis was completed for the final model, there were some trends demonstrated in
the Martingale Residuals over time but the majority of the residuals were varying about zero
as expected - demonstrating no trends.

Preliminary Statistical Analysis
Initially, a study was conducted by the investigator to determine if there were
statistically significant differences between females versus males and the treatment
received prior to the development of this dissertation. The data set was drawn from the
Florida Cancer Data System 1 in which Commercial File 4505 had 2,393,853 cancer
cases from the years 1981 through 2003. The lung cancer cases (n = 139,926) were
categorized by the International Classification of Diseases – Oncology (ICD-O) and
included the four major histological lung cancer types: adenocarcinoma, squamous cell
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carcinoma, large-cell carcinoma, and small-cell carcinoma. Other FCDS gender
categories: 3 = Other (Hermaphrodite), 4) 4 = Transsexual and 5) 9 = Not Stated or
Unknown, were excluded from the analysis as those particular gender categories did not
contribute to the research question. The major treatment modalities (chemotherapy,
surgery, hormone use, and radiation therapy) for FCDS lung cancer cases were included;
other treatment modalities were excluded as this research focused on the major treatment
modalities used to treat cancer. The major races/ethnic groups were selected based on
the overall FCDS statistics; white and African-American were selected as the two
racial/ethnic groups. Inclusion criteria for smoking status consisted of never smoking,
past history of smoking, and presently smoking as referenced to the date of lung cancer
diagnosis. The mean age for FCDS males (n = 88,248) was 68.96 years of age and for
FCDS females (n = 51,678) 68.66 years of age was calculated with the SAS PROC
UNIVARIATE program. Variable frequencies classified by gender were determined
with the SAS PROC FREQ procedure. The majority of the FCDS women were married
(14.2%), had a history of smoking (90.43%), and were white (n = 49,227 (95.26%)).
Adjusted Odds Ratios were derived from the logistic regression model utilizing
SAS Institute Inc., Cary, NC, USA Version 9.1 software. Based on a the statistics
generated by a logistic regression model, there were statistically significant differences
between gender and the treatment modality after adjusting for race, age and tobacco use.
FCDS females had a decrease odds of receiving radiation therapy (OR = 0.939 (95%CI =
0.919, 0.961)) and surgery (OR = 0.940 (95%CI = 0.915, 0.966)) as compared to FCDS
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men. Additionally, there was decrease in the odds of having radiation therapy as a
treatment modality for lung cancer for white FCDS females as compared to AfricanAmerican females (OR = 0.806 (95%CI = 0.771, 0.841)). FCDS African-American
females had a decrease odds of receiving surgery as a treatment modality (OR = 0.605
(95%CI = 0.569, 0.643)) and chemotherapy (OR = 0.790 (95%CI = 0.751, 0.831)) for
lung cancer as compared FCDS white women. FCDS females had a greater probability
or risk of adenocarcinoma and small cell carcinoma as compared to FCDS males. Some
of the limitations of investigator’s initial FCDS study were that the treatment groups were
not stratified to examine a combination of receiving more than one treatment type nor
were interaction terms considered in the relationship between treatment and gender.

Summary
Initially, this research was based on a preliminary investigation of primary lung
cancer cases for the Florida Cancer Data System 1 that studied if the treatment modality
selected to treat a lung cancer case was based on gender. This research expanded the
concept of lung cancer treatment differences based on gender to include the
determination of survival differences in women as compared to men dependent upon the
treatment modality received. The initial study objective was to investigate differences in
major treatment modalities by gender, all four major histological lung cancer types
combined by gender, and the major histological lung cancer types by gender. The
relationship between treatment modalities and other variables (race, smoking status, vital
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status, and marital status) was evaluated. In particular, race was investigated to
determine if any disparities between race and treatment type existed for FCDS women.
This research expands on the preliminary findings and the patient population by
including other NAACCR associated cancer registry lung cancer data in an attempt to
determine if the particular treatment modality used to treat a woman with lung cancer
affects her survival as compared to a man. As statistically significant differences in the
association between gender and treatment have been demonstrated previously in the
preliminary findings of this research, it was important to address these findings during the
next phase of gender differences in lung cancer survival research. This study is a first
step in the determination of survival in women with lung cancer and differences in
treatment patterns as compared to men utilizing the data from state registries that are
members of NAACCR. Results from this newly combined database will be in an attempt
to quantify the extent of a gender specific treatment effect and the impact of this effect on
survival. Another novel statistical approach in the study of gender differences in
treatment selection and gender specific survival is the addition of interaction terms in the
analysis. Also with the inclusion of interaction terms, the calculation of an overall gender
effect of the treatment outcome and on survival could be possible. In the literature
reviewed and cited throughout this dissertation, this approach has not been demonstrated.
This approach adds another dimension in the study of gender differences for lung cancer
treatments and survival as statistically significant results were demonstrated.
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CHAPTER IV: PRESENTATION AND ANALYSIS OF DATA
Introduction
This chapter presents the study findings. The study population consisted of
lung cancer cases drawn from state based passive cancer registries in the United States.
The lung cancer cases that were selected from each state cancer registry were intended to
be representative of all the lung cancer cases for that particular state. For each state, the
lung cancer case had equally as likely a chance of being included or excluded from the
cancer registry. The study individuals were selected from state cancer registry lung
cancer cases diagnosed during a five year time period, 1-1-2000 through 12-31-2004.
The time or date of diagnosis served a dual purpose as that date was also used to specify
the origin or start date for subsequent Survival Analysis. As previously stated in Chapter
Three, the eight state cancer registries with the lung cancer cases were randomly selected
from NAACCR US state cancer registries in four geographic regions. The reason for
selecting cancer registries from four different geographic regions in the United States was
reduce or eliminate any biases, e.g. selection, treatment, that may have been introduced
by selecting cases from only one geographic region. The overall intent was to account
for any differences in the population characteristics.
Forty-six variables for each lung cancer case were requested from the eight
NAACCR cancer registries. Each state reviewed the requested information and provided
data that was consistent with their Internal Review Board (IRB) protocol, policies, and
procedures. While some of the individual states did not provide information on all 46
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variables requested, the data provided by each state, did allow for a complete assessment
so that the three research questions proposed in this study could be answered. Many of
the study variables requested were intended to be utilized in a quality of data assessment.
For example, evaluating the number of autopsies reported and comparing that frequency
with Vital Status (alive versus dead) could be used to check the integrity of the data. As
some data were either incomplete or unavailable to the researcher, a quality assessment or
test could not be completed. Additionally, in the original request for specific variables, a
number of states would not provide the variable information that they (the state registry)
determined could possibly compromise the confidentially of a particular lung cancer case.
Some of the state cancer registries made the determination of the variables or variables
that were needed to answer the three research questions and provided only that
information. As an example, the variables, ―date of diagnosis‖ and the ―date of last
contact or date of death‖, were not provided in the South Carolina data set. Rather than
providing the date of death, the South Carolina Cancer Registry computed ―survival
time‖ for those lung cancer cases that were either died or alive. Survival time was
calculated as the number of months from date of diagnosis to date of death or censure
time (12/31/2004).
Of the original 46 variables requested from the cancer registries, eleven variables
were chosen to answer the three research questions. The list of variables in Table 31
include gender, stage of disease, grade of lung cancer, morphology (histology and
behavior), treatment group, age at diagnosis, age group at the time of diagnosis, race,
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marital status at diagnosis, state of the cancer registry, vital status, and survival time
(number of months from the date of diagnosis to date of death or censure time
(12/31/2004)). Four variables of the original forty-six variables were selected as primary
variables and are listed below in the Table 31. The primary independent variables are
gender, morphology, stage, and grade and all four are included in the analysis to answer
research questions one and three. When Hypothesis II for question two was tested,
gender was used as the primary independent variable.
Table 31 – Final Data Lung Cancer Set Variables
Description of Variables
Gender
Morphology (Type and Behavior)
Stage
Grade
Marital Status at Diagnosis
Race
Age at Diagnosis Group
Vital Status
Survival Time*
Treatment Group
State
*Survival time in months: from date of diagnosis
to date of death or censure time (12/31/2004)

From the originally requested 46 variables, several variables were intended to be
used as quality indicators, be evaluated as possible confounders and to test for interaction
effects. For the scope of this research, these are referred to as ―secondary‖ variables.
Table 31 secondary variables include race, marital status at the time of diagnosis, and age
group at the time of diagnosis. Treatment Group was used as a response variable for
testing Hypothesis I and as an independent variable for testing Hypothesis III. Table 32
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provides clarification and gives a description of the independent and outcome variables
used to answer each of the research questions via hypothesis testing.

Table 32: Classification of Variables for Hypothesis Testing
Independent Variables
(Predictor)

Dependent Variables
(Response)

Hypothesis I

Gender, Stage, Grade,
Morphology, Race, Marital
Status, Age Group, and State*

Treatment Group

Hypothesis II

Gender

Survival Time, Vital
Status

Hypothesis III

Gender, Stage, Grade,
Morphology, Race, Marital
Status, Age Group, Treatment
Group,

Survival Time, Vital
Status

*State was used in a separate model when testing for any random effect, i.e. any effect that state
could have on the relationship between the outcome and the independent variables.

In conclusion, eleven variables were utilized for the final analysis in order to
answer the three research questions via hypothesis testing. The list of variables include
gender, stage of disease, grade of lung cancer, morphology (histology and behavior),
treatment group, age at diagnosis, race, marital status at diagnosis, state of the cancer
registry, vital status, and survival time (number of months from date of diagnosis to date
of death or censure time (12/31/2004)).
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Population Characteristics
Demographics
The demographic characteristics of the population under study from each state are
given in Tables 33 through 36. There were a total of 44, 863 primary lung cancer cases
included in the analysis after the study selection criteria for inclusion and exclusion were
met and as outlined in Chapter Three. Briefly, the combined primary and secondary
variable data set consisted of lung cancer cases that excluded individuals that were not
diagnostically confirmed lung cancer, e.g. a diagnosis made by a cell/tissue sample or
that were not analytic. For a lung cancer case to be considered analytic, one of three
criterion must be met: (1) the diagnosis at the reporting facility and the entire first course
of treatment was performed elsewhere or the decision not to treat was made at another
facility, (2) the diagnosis at the reporting facility, and all or part of the first course of
treatment was performed at the reporting facility, and (3) the diagnosis was made
elsewhere, and all or part of the first course of treatment was performed at the reporting
facility. Also, for each individual lung cancer, any missing or NOS (not otherwise
specified) values for the primary and secondary variables were excluded.
As shown in Table 33 below, Florida provided the major contribution of lung
cancer cases at 24,602 (55.5% of all females, 54.9% of all males) with the overall data set
minimum for lung cancer cases from Idaho (2.0% of all females, 2.0% of all males). As
expected, for all states, there were a higher percentage of males with lung cancer as
compared to females with lung cancer. Overall, the data set has 19,994 females (44.6%
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of the total lung cancer cases) and 24,869 males (55.4% of the total lung cancer cases) –
shown in Table 36.
Table 33: State Cancer Registries versus Gender
Lung Cancer Distribution from the Eight State Cancer Registries
Females
Frequency
Percent
State Cancer Registry
Florida
Idaho
Indiana
Massachusetts
Nebraska
Oregon
Rhode Island
South Carolina
Total

11089
400
2333
2823
702
735
459
1453
19994

55.5
2.0
11.7
14.1
3.5
3.7
2.3
7.3
100.0

Males
Frequency Percentage

13513
496
3107
2992
1018
824
666
2253
24869

54.9
2.0
12.5
12.0
3.5
3.3
2.7
9.1
100.0

Total

24602
896
5440
5815
1720
1559
1125
3706
44863

The demographic characteristics for the lung cancer cases (gender, vital status,
race, age group, and marital status at diagnosis) are listed in Table 24. The ages for the
combined data set (primary lung cancer cases diagnosed between 1/1/2000 – 12/31/04)
ranged from 40 - 89 years old. The mean age for the data set (N = 44,863) was 67.9
years, SD+10.2; for females (Nfemale = 19,994) the mean age was 67.9 years, SD + 10.4
and for males (Nmale = 24,869), the mean equaled 68 years, SD+10.0. For hypothesis
testing, the continuous variable ―Age at Diagnosis‖ was classified into age groups
(categorical variables); five ―Age Group-at-Diagnosis‖ strata or intervals were generated
and are described in Table 24. The Age at Diagnosis (in years) Group 7 (> 70 - < 80) had
greatest frequency of lung cancer cases with 16,404 (36.6 %), followed by Group 6 (> 60
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- < 70) with 13,536 (30.2 %), Group 5 (> 50 - < 60) 7,179 (16.0 %), and the minimum
number in an age group was the > 40 - < 50 age interval, Group 4 with 2, 352 (5.2 %).
Table 34: Lung Cancer Distribution
Gender, Vital Status, Race, Age Group, and Marital Status at Diagnosis
Frequency

Percent

Total

19994
24869
44863

44.6
55.4
100

Total

31869
12994
44863

71.0
29.0
100

41458
3042
363
44863

92.4
6.8
0.8
100

2352
7179
13536
16404
5392
44863

5.2
16.0
30.2
36.6
12.0
100

4427
26759
367
4920
8390
44863

9.9
59.6
0.8
11.0
18.7
100

Variable
Gender
Female
Male
Vital Status
Dead
Alive
Race
White
Black
Other
Total
Age Group at Diagnosis
> 40 - < 50 yrs
> 50 - < 60 yrs
> 60 - < 70 yrs
> 70 - < 80 yrs
> 80 - < 90 yrs
Total
Marital Status at Diagnosis
Single
Married
Separated
Divorced
Widowed
Total

Originally, there were ten ―Age Group at Diagnosis‖ levels. Those age range
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groups not listed in Table 34 were > 0 - <10 years old, > 10 - <20 years old, > 20 - <30
years old, > 90 - <100 years old, and > 100 years old. The decision was made to limit the
number of age groups based on the following: first, there were limited numbers of lung
cancer cases that were younger than 40 and older than 90. The cumulative percent was
less than 1% for the lung cancer data set for those lung cancer cases less than forty years
of age and for those cases greater than 90 years old. An analysis and subsequent results
would be subject error due to the limited sample size (decreased power or lack of ability
to detect the ―effect‖ under study). Secondly, the population for the extremely young and
extremely old, as referenced to lung cancer, is different and would not contribute to the
relevance of the lung cancer cases selected for this research. In summary, the decision
was made to exclude these age range groups.
Seventy-one percent of the lung cancer cases (31,869) were classified under the
variable ―Vital Status‖ as dead and 12,994 cases (29.0 %) were coded as alive. The study
set, under Race, consisted mainly of ―White‖ lung cancer cases (41,458 (92.4 %)), with
3,042 (6.8 %) ―Black‖ and 363 (0.8%) cases were coded as ―Other‖. Table 34 also
displays marital status at the time of lung cancer diagnosis. Approximately 60 percent of
all the lung cancer cases (26,759, 59.6%) were classified as married at the time of
diagnosis. The next classification with the greatest frequency was windowed (8,390,
18.7%) followed by divorced (4,920, 11.0%) and single (4,427, 9.9%) with the minimum
number classified as separated of 367 (0.8%).
The primary research variables (main effect) listed in Table 35 includes stage,
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grade, and morphology. Morphology coding, as previously stated in Chapter Three,
includes coding for the histological type of lung cancer combined with the behavior code
of the disease. All the primary lung cancer cases in this data set have a behavior code of
3, meaning all lung cancer cases in this data set were classified as malignant.
Table 35: Lung Cancer Distribution
Stage, Grade, and Morphology
Frequency

Percent

Total

12028
4107
10359
18369
44863

26.8
9.2
23.1
40.9
100

Total

3153
12715
22417
6578
44863

7.0
28.3
50.0
14.7
100

Total

16139
13425
8473
6826
44863

36.0
29.9
18.9
15.2
100

Variable
Stage
I
II
III
IV
Grade
I
II
III
IV
Morphology
Adenocarcinoma
Squamous
Large Cell
Small Cell

Stage IV lung cancer accounts for 40.9 % of the total four stage classification
scheme with the minimum number of cases found with Stage II at 9.2 %.
Adenocarcinoma was the major morphological type with 16,139 cases (36.0 %),
squamous cell had the second highest frequency with 13, 425 (29.0 %), followed by large
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cell carcinoma with 8,473 (18.9 %) cases, and lastly, small cell carcinoma having 6,826
cases made up 15.2 % of the total four different stages of the lung cancer data base (N =
44,863). The grade of lung cancer (Table 35) consists of four classifications, most
commonly found was Grade III (22,417, 50.0%); the Grade II lung cancers consisted of
12,715 (28.3%) cases, Grade IV (6,578, 14.7%), and Grade I had the minimum number
of lung cancer cases of 3,153 (7.0%).
One of the last tables of demographic data, Table 36-a, consists of the frequency
and percent for state each cancer registry and the treatment groups. Of the eight states
listed, Florida was the major contributor of the lung cancer cases as expected due to a
greater number of residents – see Table 36-b for the 2000 – 2004 annual estimated
population. Additional demographics for each state are provided in Appendix I in Tables
70 through Table 77. There are eight treatment classifications in Table 36-a which
include a single treatment modality (Radiation Therapy (I), Chemotherapy (II), or
Surgery (III)) treatment group, combinations of treatment modalities received (Radiation
and Surgery (IV), Radiation and Chemotherapy (V), Surgery and Chemotherapy (VI), or
Radiation combined with Surgery and Chemotherapy (VII) and the last classification
consisted of lung cancer cases that received no treatment (Treatment Group VIII).
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Table 36-a: Lung Cancer Treatment Group and State
Lung Cancer Distribution (Frequency and Percent)
Frequency

Percent

Total

24602
896
5440
5815
1720
1559
1125
3706
44863

54.8
2.0
12.1
13.0
3.8
3.5
2.5
8.3
100

Treatment Group
Radiation
Chemotherapy
Surgery
Radiation + Surgery
Radiation + Chemotherapy
Surgery + Chemotherapy
Radiation + Surgery + Chemotherapy
No Treatment
Total

4351
6472
12728
1063
7955
1249
1348
9697
44863

9.7
14.4
28.4
2.4
17.7
2.8
3.0
21.6
100

Variable
State
Florida
Idaho
Indiana
Massachusetts
Nebraska
Oregon
Rhode Island
South Carolina
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Table 36-b: Total Population for the Eight States*
Males
State
Florida
Idaho
Indiana
Massachusetts
Nebraska
Oregon
Rhode Island
South Carolina
Total

Females

Total

N

%

n

%

N

%

7,797,715
648,660
2,982,474
3,058,816
843,351
1,696,550
503,635
1,948,929
19,480,130

48.8
50.1
49.0
48.2
49.3
49.6
48.0
48.6
100

8,184,663
645,293
3,098,011
3,290,281
867,912
1,724,849
544,684
2,063,083
20,418,776

51.2
49.9
51.0
51.8
50.7
50.4
52.0
51.4
100

15,982,378
1,293,953
6,080,485
6,349,097
1,711,263
3,421,399
1,048,319
4,012,012
39,898,906

40.00
3.24
15.24
15.91
4.29
8.58
2.63
10.06
100

*Source: U.S. Census Bureau, Census 2000, and used as most current source of population
statisitics for estimate purposes only

Although this research was focused primarily on specific treatment modalities, a
proportion of lung cancer cases received no treatment (no radiation, chemotherapy,
and/or surgery) were classified as Treatment Group VIII (Table 36-a). This classification
allowed for the investigation of lung cancer cases that received no treatment by
comparing the no treatment group to the other levels of the treatment groups. Treatment
Group VIII had the second largest number of lung cancer cases as shown in Table 36-a
with 9,697 (21.6%) subjects. One concern regarding the utilizing this treatment group
(VIII) would be a possible bias being introduced from utilization of the ―no treatment
received group‖ as the reference group during the statistical testing/analysis. For
example, utilizing Treatment Group VIII as the reference group could introduce a
differential classification bias. This bias would be resultant from using a set/group of
lung cancer cases (VIII) that were different from all the other lung cancer cases
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(Treatment Group I - VII) as they (VIII) never received any treatment, i.e. radiation,
chemotherapy, surgery, radiation + chemotherapy, radiation + surgery, chemotherapy +
surgery, or radiation + chemotherapy + surgery. This could bias the null in any direction
and any effect from the comparison of other treatment groups could be masked. Simply
stated, the category of no treatment group used as a reference group cannot be lung
cancer cases that are comprised from a different population. The population
characteristics of the eight treatment groups were compared; there were no observable
trends that suggested that Group VIII had any observable differences suggesting a
dissimilar population mix. The following tables, Table 37 through Table 40, contain the
assessment of the primary variable by the individual treatment groups. Each treatment
group was evaluated for any dissimilarity or variability in gender, morphological type,
stage, and grade of lung cancer. Table 37 displays the lung cancer distribution between
the Treatment Groups versus Gender. In Table 37 for all treatment groups, the frequency
of males with lung cancer is greater than females with lung cancer. When evaluating the
eight treatment groups versus gender, the greatest number of males with lung cancer is
found in Treatment Group III (Surgery only) with 6,718 cases. The minimum number of
male lung cancer cases (612) was documented for Treatment Group IV (Radiation and
Surgery). The maximum number of females (6010) was found in Treatment Group III
(Surgery only) with the minimum number of female lung cancer cases (451) in Table 37
receiving a combination of Radiation and Surgery (Treatment Group IV).
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Table 37: Lung Cancer Distribution – Treatment Group vs. Gender
Treatment Group
Radiation
I
Chemotherapy
II
Surgery
III
Radiation + Surgery
IV
Radiation + Chemotherapy
V
Surgery + Chemotherapy
VI
Radiation + Surgery +
Chemotherapy
VII
No Radiation, Surgery,
and/or Chemotherapy
VIII

Gender Frequency

Percent

Female
Male

1772
2579

40.7
59.3

Female
Male

2946
3526

45.5
54.5

Female
Male

6010
6718

47.2
52.8

Female
Male

451
612

42.4
57.6

Female
Male

3346
4609

42.1
57.9

Female
Male

585
664

46.8
53.2

Female
Male

608
740

45.1
54.9

Female
Male

4276
5421

44.1
55.9

Note: During statistical testing surgery was designated as the reference Treatment Group
(VIII), the No Radiation , Surgery, and/or Chemotherapy Group (No Treatment Group) was
designated as Treatment Group III

The next three tables compare the eight treatment groups with the primary
variables of stage (Table 38), grade (Table 39) and morphology (Table 40).
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Table 38: Lung Cancer Distribution – Treatment Group vs. Stage
Treatment Group
Radiation
I

Chemotherapy
II

Surgery
III

Radiation + Surgery
IV

Radiation + Chemotherapy
V

Surgery + Chemotherapy
VI

Radiation +Surgery+ Chemotherapy
VII

No Radiation, Surgery,
and/or Chemotherapy
VIII
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Stage
I
II
III
IV
I
II
III
IV
I
II
III
IV
I
II
III
IV
I
II
III
IV
I
II
III
IV
I
II
III
IV
I
II
III
IV

Frequency Percent
658
15.1
278
6.4
820
18.9
2595
59.6
337
5.2
277
4.3
1224
18.9
4634
71.6
8332
65.5
1847
14.5
1972
15.5
577
4.5
195
18.3
200
18.8
482
45.3
186
17.5
585
7.4
551
6.9
2677
33.7
4142
52.1
334
26.7
163
13.1
551
44.1
201
16.1
119
8.8
160
11.9
816
60.5
253
18.8
1468
15.1
631
6.5
1817
18.7
5781
59.6

The purpose of Table 38 was to compare the eight different treatment groups with the
four stages of lung cancer. There were four treatment groups having the greatest percent of Stage
IV lung cancer, Group I Radiation (59.6%), Group II Chemotherapy (71.6%), Group V Radiation
and Chemotherapy (52.1%), and Group VIII (59.6%). One treatment group, the surgical
treatment group, Group III, had the greatest percent (65.5%) for Stage I. Stage three lung cancers
had the highest percentage in Group IV (Radiation and Surgery) at 45.3%, Group VI Surgery and
Chemotherapy (44.1%) and Treatment Group VIII which combined all three treatment
modalities: Radiation, Surgery, and Chemotherapy.
Seven of the eight treatment groups (Table 39) had the highest percentage of lung
cancers considered Grade III as compared to the other three grades: Treatment Group I
(58.7%), Treatment Group II (47.5%), Group IV (52.5%), Group V (53.3%), Group VI
(49.6%), Group VII (59.4%), and Group VIII (55.5%). There was only one treatment group
(those receiving surgery only, Treatment Group III) in which the highest proportion (44.8%)
of lung cancer cases were Grade II. In Table 40, Adenocarcinoma was the most frequent
histological type of lung cancer for Treatment Groups III (46.2%), IV (45.6%), VI
(46.3%), and VIII (33.7%). Squamous cell lung cancer was most common in Groups I
(36.7%) and V (27.3%). Lastly, the most common histologic type of lung cancer for
Group II Chemotherapy (38.5%) was Small Cell Lung Cancer (SCLC).
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Table 39: Lung Cancer Distribution - Treatment Group vs. Grade
Treatment Group
Radiation
I

Chemotherapy
II

Surgery
III

Radiation + Surgery
IV

Radiation + Chemotherapy
V

Surgery + Chemotherapy
VI

Grade
I
II
III
IV
I
II
III
IV
I
II
III
IV
I
II
III
IV
I
II
III
IV
I
II
III
IV

Radiation +Surgery
+ Chemotherapy
VII

I
II
III
IV
I
II
III
IV

No Radiation, Surgery,
and/or Chemotherapy
VIII
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Frequency Percent
244
5.6
1171
26.9
2553
58.7
383
8.8
216
3.3
926
14.3
3072
47.5
2258
34.9
1627
12.8
5697
44.8
5194
40.8
210
1.7
63
5.9
418
39.3
558
52.5
24
2.3
280
3.5
1496
18.8
4239
53.3
1940
24.4
103
8.3
463
37.1
619
49.6
64
5.1
52
429
801
66
568
2115
5381
1633

3.9
31.8
59.4
4.9
5.9
21.8
55.5
16.8

Table 40: Lung Cancer Distribution – Treatment Group vs. Morphology
Treatment
Group
Radiation
I

Chemotherapy
II

Surgery
III

Radiation + Surgery
IV

Radiation + Chemotherapy
V

Surgery + Chemotherapy
VI

Radiation + Surgery +
Chemotherapy
VII
No Treatment
VIII

Morphology
Adenocarcinoma
Squamous
Large Cell
Small Cell
Adenocarcinoma
Squamous
Large Cell
Small Cell
Adenocarcinoma
Squamous
Large Cell
Small Cell
Adenocarcinoma
Squamous
Large Cell
Small Cell
Adenocarcinoma
Squamous
Large Cell
Small Cell
Adenocarcinoma
Squamous
Large Cell
Small Cell
Adenocarcinoma
Squamous
Large Cell
Small Cell
Adenocarcinoma
Squamous
Large Cell
Small Cell
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Frequency Percent
1430
32.9
1596
36.7
980
22.5
345
7.9
1747
27.0
1087
16.8
1145
17.7
2493
38.5
5880
46.2
4610
36.2
2142
16.8
96
0.8
485
45.6
426
40.1
144
13.6
8
0.8
2106
26.5
2171
27.3
1597
20.1
2081
26.2
602
48.2
350
28.0
238
19.1
59
4.7
624
46.3
419
31.1
241
17.9
64
4.8
3265
33.7
2766
28.5
1986
20.5
1680
17.3

The tables and results of the analysis by treatment group versus the secondary
variables are located in Appendix II - Tables 41 through 43. The tables display a
comparison of the treatment groups versus age race (Table 41), marital status group at
diagnosis (Table 42), and age group at the time of lung cancer diagnosis (Table 43).
There were no obvious differences in treatment groups versus and distribution of race,
Table 41 in Appendix II. The majority of lung cancer cases are White ranging from
91.3% of all lung cancer cases in Group V (Radiation and Chemotherapy) to 94% of all
lung cancer cases in Group III (Surgery). The classification of ―Other‖ for race contained
the least amount of lung cancer cases for each treatment group with each Treatment
Group having a minimum of approximately one percent within each treatment
classification (I – VIII). All treatment groups in Table 42 (Treatment Group vs. Marital
Status at Diagnosis) have the greatest percentage of the lung cancer cases classified as
married at the time of diagnosis ranging from 52.2 percent for Treatment Group VIII (no
treatment) to maximum percentage of 69.9 percent for surgical and chemotherapy, Group
VI. Lastly, each treatment group was evaluated for Age Group at Diagnosis. The
treatment groups, I - VII did not display that Treatment Group VIII was any different or
displayed any trends that would suggest that the patient population was not comparable to the
other seven treatment groups. It was determined that the lung cancer cases in Group VIII were
just as likely to receive a treatment modality or combination of treatment modalities when
comparing the treatment patterns for Groups I through VII. The decision was made to
include Group VIII for the analysis.
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Testing the Hypotheses
Hypothesis I
Women with the same histological type, stage and grade of lung cancer received the
same treatment modality as compared to men with the same histological type, stage and
grade of lung cancer.
Introduction
The first aim was to determine if men and women stratified by histologic type,
stage, and grade of lung cancer received the same treatment type. The relationship
between gender and the treatment modality received was evaluated including other
independent variables and interaction terms. Interaction terms were included in the
model to assess the role of moderating variables. A moderating variable can change the
association (Odds Ratios) between the independent variable and the outcome variable at
different levels of that moderator. It was important to establish if different treatments,
e.g. radiation therapy, chemotherapy, surgery, were received based on gender; this has
not been addressed specifically in the literature. Also after determining if the type of
lung cancer treatment received was gender dependent, further analysis or study of that
impact on gender specific survivorship could be addressed in Hypotheses II and III. As
stated in Chapter Three, the statistical model selected to examine the relationship
between the outcome variable (treatment group) and the independent variables was the
multinomial, polychotomous or polytomous logistic regression model. The multinomial
logistic regression or ―logit‖ models an outcome variable that has more than two
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outcomes; the research outcome variable, treatment group, was comprised of eight
categories or eight different treatment selections.
Table 44 lists the variables used during the testing of Hypothesis I; the variables
were coded as categorical variables and were classified on the nominal scale. Also
shown in Table 44 are the reference groups, for example Group VIII (Surgery) was
utilized as the reference group during statistical testing with the generalized logit model.

Table 44: Outcome Variable and Independent Variables
Variables for Testing Hypothesis I
Multinomial Logistic Regression Model (MLR1)

I.
II.
III.

IV.
V.
VI.
VII.
VIII.

Outcome Variable*
Treatment Group
Radiation Therapy
Chemotherapy
No Treatment Assignment (No
Radiation, Chemotherapy and/or
Surgery)
Radiation + Surgery
Radiation + Chemotherapy
Surgery + Chemotherapy
Radiation + Chemotherapy + Surgery
Surgery

Independent Variables**
Gender
Stage
Grade
Morphology
Race
Marital Status at Diagnosis
Age Group at Diagnosis

* Outcome Variable Reference Group: Treatment Group = Surgery
** Independent Variable Reference: Gender = 2 (Male), Stage = IV, Grade = IV, Morphology = 4 (SCLC),
Race = 3 (Other, Non-White), Marital Status = 5 (Widowed), and Age Group = 5 (> 80 - < 90 yrs)

The outcome variable profile given previously in Table 36 had a total frequency
of 44,863 lung cancer cases; there was one outcome variable, treatment group, with eight
treatment groups. The total frequency of each treatment group of lung cancer cases were
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also given in Table 36 with the minimum number of cases in treatment group IV
(Radiation and Surgery) with 1,063 cases and a maximum of 12,728 lung cancer cases in
treatment group VIII (Surgery).

Potential Confounders, Multicollinearity and Interactions
This next section reviews three topics of interest: potential confounders,
multicollinearity and interaction as each can impact the study by biasing the results due to
the design and in the analysis phase. First, a potential source of error affecting the
validity of study can be confounding variables. Confounding can cause a distortion in the
measure of association due to an unequal distribution of a determinant of the outcome 73,
224

. Confounding is a problem of comparison, a problem that arises when important

extraneous factors are differentially distributed across groups being compared. A
confounding variable is related to the outcome variable and the independent variable but
not on the direct causal pathway between the outcome and independent variable of
interest 73, 224. The following methods were utilized to control for confounding in the
design phase of the study. In the study design phase, two methods selected to reduce any
confounding were 1) randomization in the selection of the states and 2) restriction: some
of the restrictions included selecting only primary lung cancer cases and cases from
NAACCR cancer registries.
Smoking is a major confounding variable for lung cancer but smoking was not
addressed as a variable in this study due to several reasons. There was difficulty in
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studying the variable ―smoking‖ as cancer registry procedures and methods in the coding
and collection of smoking history can be dissimilar and are listed below:
I. Smoking was coded differently, e.g. the NAACCR standard code format
was not followed in each state cancer registry.
II. The data for smoking or smoking history were not collected in similar
manner across all states, e.g. different start/inception dates to begin the
collection of smoking information.
III. No smoking history was collected or the information was not available
from two state cancer registries under study, therefore a complete
assessment could not be made.
IV. Whether a person smokes or not is not a variable of interest in this
research. In the opinion of the researcher, smoking or not smoking is not
associated or rather will not determine if a lung cancer case receives a
particular treatment modality, e.g. radiation, surgery, and or any
combination of treatment modalities.

Next, a second possible source of error could be in the case of collinearity or
highly collinear values between two independent variables that could affect the
relationship of either or both variables on the research outcome, i. e. the lung cancer
treatment received. This is commonly referred to as ―multicollinearity‖. When there is a
high level of intercorrelation between the independent variables, the effects of the
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independent variables may not be separated resulting in statistical inferences made about
the data that could be unreliable. For the research data set, a similar method described by
Hosmer and Lemeshow1 for categorical variables was utilized to test for
multicollinearity. First, a logistic regression model was run or generated with all seven
independent variable: gender, stage, grade, morphology, marital status, age group, and
race. Then seven logistic regression models (variable subsets) were generated, i.e. each
model dropped one of the independent variables that were originally included in the full
model. The full model coefficients and standard errors were examined and then
compared to the coefficients and standard errors for the seven other logistic regression
models (Model I all variables, Model II stage excluded, Model III grade excluded, Model IV morphology
excluded,

Model V gender excluded, Model VI marital status excluded, Model VII race excluded, Model VIII

age group excluded).

There were no appreciable differences between the standard errors and

the coefficients. An appreciable difference as noted by Hosmer and Lemeshow could be a
change in the beta coefficients or standard errors by an order of magnitude. For example,
in Table 45 the data extracted from the full model, Model I and Model II (morphology
removed from the other independent variables) does not display such a change. From
this assessment in combination all other ―subset‖ model comparisons, multicollinearity
was deemed minimal; therefore the coefficients were assumed to be unbiased.

1

David W. Hosmer and Stanley Lemeshow ―Applied Logistic Regression‖ Second Edition Section 4.5
Pages 140 -141
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Table 45: Multicollinearity Assessment via Logistic Regression
Comparison of Coefficients and Standard Error
Extracted from the Logistic Regression Models
Parameter

MODEL I*
(Full Model)

Morphology
Morphology
Morphology
Grade
Grade
Grade
Stage
Stage
Stage
Gender
Race
Race
Marital Status
Marital Status
Marital Status
Marital Status
Age Group
Age Group
Age Group
Age Group

1
2
3
1
2
3
1
2
3
1
1
2
1
2
3
4
4
5
6
7

Coefficient

Standard Error

-0.285
0.007
-0.016
-0.221
-0.198
0.189
-1.364
-0.381
0.321
-0.037
-0.097
0.103
0.061
-0.162
0.071
-0.021
-0.212
-0.162
-0.127
0.013

0.017
0.018
0.019
0.029
0.020
0.016
0.018
0.023
0.016
0.009
0.035
0.039
0.030
0.023
0.077
0.029
0.032
0.020
0.017
0.016

Grade
1
-0.324
0.027
Grade
2
-0.301
0.017
Grade
3
0.121
0.014
Stage
1
-1.363
0.018
Stage
2
-0.379
0.023
MODEL II*
Stage
3
0.328
0.016
(Morphology Excluded)
Gender
1
-0.047
0.009
Race
1
-0.091
0.035
Race
2
0.110
0.039
Marital Status
1
0.063
0.030
Marital Status
2
-0.170
0.023
Marital Status
3
0.074
0.077
Marital Status
4
-0.022
0.029
Age Group
4
-0.232
0.032
Age Group
5
-0.166
0.020
Age Group
6
-0.121
0.017
Age Group
7
0.025
0.016
*Model I included the independent variables of gender, stage, grade, morphology, marital
status, race, and age group
** Model II included the independent variables of gender, stage, grade, morphology, marital
status, race, and age group
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Another area of importance in the testing of the hypothesis was the evaluation of
possible interaction or effect modification that might significantly affect the relationship
between the outcome and the independent variables. An effect modifier is a variable that
changes the relationship between the independent variable and the outcome variable. A
variable that acts as an effect modifier is contained in the interaction term and the
outcome/independent variable relationship changes at different levels or strata 73, 74, 226.
The interaction terms were evaluated for their impact on the outcome and any effect on
the overall fit of the model equation. In the statistical testing and analysis stage,
interaction or effect modification was addressed by evaluating the stratified multivariate
analyses. In summary, stratification based on the independent variables, such as stage,
grade and morphological lung cancer type was employed in the statistical methods and
interaction terms were included to evaluate the effects of any possible moderating
variable on the relationship between the independent variable and outcome variable at
different levels of that moderating variable.

Multinomial Logistic Regression
Stepwise multinomial logistic regression (MLR) testing was used to select the
variables (main effects and interaction terms) for the full model. The stepwise process
consisted of a forward selection of covariates with a backward elimination of variables
that did not meet a specified significance level. The stepwise procedure incorporated
(specified in the model statement) the four primary variables (gender, stage, grade, and
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morphology) throughout the process selection and included variables with second degree
interaction terms in the stepwise model selection process. The criterion for inclusion into
a model was a significance level of 0.05 and an elimination of variable/interaction terms
when the significance level was greater than 0.05. In the stepwise multinomial logistic
procedure, Type III Analysis of Effects showed the change in the model fit when an
independent variable was dropped while keeping the other variables in the model. In all,
there were eleven different models generated. The resultant multinomial logistic model
included seven main effects for the variables of gender, morphology, stage, grade, marital
status, race, age group and five interaction terms of gender*morphology, gender*stage,
stage*grade, gender*marital status and stage*age group. Table 46 gives the results for
the statistical test that was generated for the final model, i.e. Type III Analysis of Effects.
The Type III test statistic is associated with the estimated coefficients in the model and
represents an effect due to a particular variable, e.g. gender. The statistic for the Type III
test is the amount of variation in the response when a particular variable, e.g. gender, is
added to the model that already contains all the other variables. Also, the Type III test
statistic is not depended upon the order that the independent variables (to include
interaction terms) are specified in the model.
In the full model, gender was not significant (p-value >0.05) as a main effect but
was significant in the interaction terms of gender and stage (gender*stage) and gender
and marital status (gender*marital status). Other statistically significant interaction terms
included stage and grade (stage*grade) and stage and age group (stage*age group). The
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interpretation of the exponentiated parameter estimates are presented as Odds Ratios with
the associated 95% confidence intervals in the following paragraphs of this chapter. Also
as noted in Table 46, there are large Wald Chi Square values for several main effect
variables and interaction terms. Large Wald Chi-Square statistics are an indication of the
variability of the data contained in the model. For example, this result could be attributed
to the multinomial nature of the output variable, treatment group. The variability of the
parameter estimates in the model could be increased due to the fact there are eight
different levels of the outcome variable, treatment group.

Table 46: Type III Analysis of Effects
Main Effect and Interaction Terms*
Multinomial Logistic Regression Model (MLR1)

Effect
Gender
Morphology
Gender*Morphology
Grade
Stage
Gender*Stage
Stage*Grade
Marital Status
Gender*Marital Status
Age Group
Stage*Age Group
Race

DF
7
21
21
21
21
21
63
28
28
28
84
14

Wald
Chi-Square
10.63
879.88
29.43
132.55
260.73
45.31
178.92
325.40
52.94
948.87
222.51
88.36

Pr > ChiSq
0.156
<.0001
0.104
<.0001
<.0001
0.002
<.0001
<.0001
0.003
<.0001
<.0001
<.0001

Note: Age Group and Marital Status at defined on/at Date of Diagnosis
* indicates interaction term
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The Multinomial Logistic Regression (MLR) model (also known as the
generalized or baseline-category logit model) with treatment group as the outcome
variable is represented by the following equation (coefficients are not displayed):

=

Gender + Morphology + Gender*Morphology +
Grade + Stage + Gender*Stage + Stage*Grade +
Marital Status + Gender*Marital Status + Age
Group + Stage*Age Group + Race

There were seven categories of the response variable (treatment group) for the
multinomial logistic regression model. From the equation above, in the numerator Y
represents the treatment type; when i = 1, the treatment group is radiation alone, if i = 2
the treatment group is chemotherapy alone, i = 3 the treatment group is no treatment, i =
4, the treatment group is radiation + chemotherapy, i =5 the treatment group is surgery +
radiation, i = 6 the treatment group is surgery + chemotherapy, and when i = 7 the
treatment group is radiation + chemotherapy + surgery. Also in the equation above, in
the denominator Y is the reference treatment group for each of the treatment groups, 1
through 7. For the term Y (in the denominator), Y is the reference group and is the eighth
treatment group (surgery). In the equation above, k + 1 is a numerical expression that
specifies or is representative of the reference treatment group 8 (surgery); k = 7 therefore
k +1 = Y =8.
From Table 46, the following equation was derived from the full model (the
interaction term of Gender*Morphology was not included because it was not statistically
significant and therefore would not affect the outcome):
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Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI +
5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 9
stageI* age_groupI + 10 morphologyI + 11 raceI + others

The Wald statistic in Table 46 is a parameter/statistic that can be utilized to assess
the ―goodness of fit‖ of the data to the model. In other words, the ―goodness of fit‖ can
be interpreted as how well a mathematical equation estimates the behavior of the data. If
a large variability of Wald Chi-Square (a statistic derived from the parameter estimate
and standard error) existed, this could be interpreted that the wrong model was selected to
examine the data. A brief review will be presented concerning the issue of how the
assessment of the model fit was evaluated prior to reviewing the MLR model results.
Model fit or the assessment of the predicted results versus the truth (the actual
results from the data) for a statistical test can be performed after the analysis because the
researcher wishes to ensure that he/she are using the correct method to test or assess their
data and that the results are valid. Prior to inferences being made for the fitted model, an
assessment of the model fit via diagnostics for the multinomial logistic regression model
was made. Residual testing is a common statistical approach in the evaluation of the
error in the model equation comparing the predicted or estimated results with the data.
Because residual analysis was not available in the SAS software for a multinomial or
multiple outcome variable (treatment) levels; Hosmer and Lemeshow2 suggest assessing

2

David W. Hosmer and Stanley Lemeshow ―Applied Logistic Regression‖ Second Edition Section 4.5
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the fit via logistic regression models for each outcome (seven logistic regression models
in total). The results of the residual analysis were compared and examined for any trends
that would demonstrate a lack of model fit. This type of assessment was made for the
seven possible treatment outcomes of 1) radiation alone, 2) chemotherapy alone, 3) no
treatment, 4) radiation + chemotherapy, 5) radiation + surgery, 6) surgery +
chemotherapy, and 7) radiation + chemotherapy + surgery) with surgery as the reference
group for each treatment group. Examples of the residual analysis results for three of the
treatment outcome groups are given in Tables 52 through 54. No trends were
demonstrated for the seven models meaning the use of the multinomial logistic regression
model to the best of our knowledge was appropriate.
In the next five sections, the statistical results obtained from the logistic
regression models for the coefficient estimates, standard errors, the Odds Ratios and 95%
confidence interval are evaluated. The first section reviews the ORs/95% CIs for the
statistically significant main effect variables, morphology and race (Tables 47: a - b).
Note these main effects are reported because they are not included in any statistically
significant interaction terms. If morphology or race were in an interaction term that was
statistically significant, that result due to the interaction would be reported. As the
outcome could change due to the interaction; the outcome could be misinterpreted if the
main effect variables were the only variables considered. In the second section, the
MLRM ORs of the interaction terms (Tables 48 - 51) are evaluated. The third section
compares and contrasts the results of the assessment of the model fit. The fourth section
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presents the results of a random effect component for state in the multinomial logistic
regression model. The results given in the fifth section are the statistics and
interpretation of the overall variable effect on the treatment type received.

Section 1: Multinomial Logistic Regression Main Effects
When examining only main effect results from a statistical model, any type of
effect modification between an independent variable and the outcome based on a
moderating variable is not accounted for. When two variables interact in determining the
chance of a particular outcome, it is inappropriate to just report the main effect as it will
give misleading results. In this research the relationship between some of the main effect
variables and the outcome variable changed when a moderating variable was present, as
in the interaction term. The only time it is appropriate to report the main effect results is
when that main effect variable gives statistically significant results and any interaction
term containing that main effect variable is not statistically significant.
Table 47-a consists of non-significant and significant OR’s and 95% confidence
intervals generated in the full model, MLR1 for the main effect of morphology. The main
effect of morphology is reported because this variable is significant and the interaction
term of gender and morphology (gender*morphology) was not statistically significant
(the results for the interaction of gender and morphology term are not reported in the final
analysis). When evaluating morphology in Table 47-a, lung cancer cases with
adenocarcinoma versus other lung cancer morphological types were at a statistically
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significant decreased risk for all treatment types (OR’s ranged from 0.03 – 0.23) with the
exception of adenocarcinoma lung cancer cases receiving radiation therapy in
combination with surgery (OR = 1.55, 95% CI 0.52, 2.65) as compared to receiving
surgery after adjustment for gender, gender*morphology, grade, stage, gender*stage,
stage*grade, marital status, gender*marital status, age group, stage*age group, and race.
Comparing the Odds Ratios between adenocarcinoma and treatment type to lung cancer
cases with squamous cell and treatment type, the same relationship was exhibited. There
was an decreased risk that lung cancer cases with squamous cell carcinoma as compared
to other lung cancer morphological types would receive any treatments (OR’s ranging
from 0.04 to 0.28) with the exception of radiation in combination with surgery (OR =
1.92, 95% CI 0.64, 3.01) as compared to receiving surgery alone but this was not
statistically significant.
The last table for a main effect is Table 47-b, with race as the main effect with the
outcome of treatment type. There was one statistically significant association between
race and treatment type; no trends were exhibited for white and black lung cancer cases
receiving a particular treatment versus receiving surgery. A possible limitation to this
analysis of race was the reduced number of the reference group, other lung cancer cases
(n = 363, 0.8%). There was an increased number of white (n = 41,458, 92.4%) and black
lung (n = 3,042, 6.8%) cancer cases. This reduced number as the reference group could
have introduced some bias into results (artificial inflation of the ORs). As the ORs only
demonstrated one statistically significant result and as the variability of the confidence
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intervals was minimal, the decision was made to keep this group (other) as the referent
group.
Table 47-a: Main Effect for Morphology
Extracted From the Full Model (MLR1)
Odds Ratios and 95% Confidence Intervals by Treatment Group
Treatment Type (Outcome)

Main Effect

Odds Ratio

95% LCI

95% UCI

Morphology
Radiation
Adenocarcinoma
0.14
0.10
0.52
Adenocarcinoma
Chemotherapy
0.03
0.02
0.37
Adenocarcinoma
No Treatment
0.07
0.05
0.41
Adenocarcinoma
Radiation + Surgery
1.55
0.52
2.65
Adenocarcinoma
Radiation + Chemotherapy
0.04
0.03
0.38
Adenocarcinoma
Surgery + Chemotherapy
0.23
0.13
0.80
Radiation +Surgery + Chemotherapy Adenocarcinoma
0.21
0.12
0.75
Small
Cell*
Surgery*
1.00
Radiation
Squamous
0.28
0.19
0.66
Squamous
Chemotherapy
0.04
0.03
0.38
Squamous
No Treatment
0.11
0.08
0.45
Squamous
Radiation + Surgery
1.92
0.64
3.01
Squamous
Radiation + Chemotherapy
0.08
0.06
0.42
Squamous
Surgery + Chemotherapy
0.22
0.13
0.79
Squamous
Radiation +Surgery + Chemotherapy
0.22
0.13
0.76
Surgery*
Small Cell*
1.00
Radiation
Large Cell
0.30
0.21
0.69
Chemotherapy
Large Cell
0.06
0.04
0.41
No Treatment
Large Cell
0.13
0.10
0.48
Large Cell
Radiation + Surgery
1.64
0.55
2.75
Large
Cell
Radiation + Chemotherapy
0.10
0.07
0.44
Large Cell
Surgery + Chemotherapy
0.34
0.19
0.92
Large
Cell
Radiation +Surgery + Chemotherapy
0.29
0.17
0.84
Surgery*
Small Cell*
1.00
* Signifies Referent or Reference Group. Adjusted for gender, gender*morphology, grade, stage,
gender*stage, stage*grade, marital status, gender*marital status, age group, stage*age group, and
race.
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Table 47-b: Main Effect of Race
Extracted From the Full Model (MLR1)
Odds Ratios and 95% Confidence Intervals by Treatment Group
Treatment Type (Outcome)
Radiation
Chemotherapy
No Treatment
Radiation + Surgery
Radiation + Chemotherapy
Surgery + Chemotherapy
Radiation +Surgery + Chemotherapy
Surgery*

Main Effect
Race
White
White
White
White
White
White
White
Other *

Odds Ratio

95% LCI

95% UCI

0.99
0.67
0.86
0.88
0.83
1.31
0.85
1

0.62
0.45
0.59
0.43
0.56
0.62
0.46
-

1.46
1.08
1.23
1.58
1.23
2.05
1.48
-

Radiation
Black
1.74
1.06
2.23
Black
Chemotherapy
0.82
0.53
1.25
Black
No Treatment
1.32
0.89
1.72
Black
Radiation + Surgery
0.94
0.44
1.69
Black
Radiation + Chemotherapy
1.22
0.80
1.63
Black
Surgery + Chemotherapy
1.34
0.62
2.12
Black
Radiation +Surgery + Chemotherapy
0.84
0.43
1.51
Surgery*
Other *
1
* Signifies Referent or Reference Group. Adjusted for gender, morphology, gender*morphology,
stage, grade, gender*stage, stage*grade, marital status, gender*marital status, age group, and
stage*age group.

Section 2: Multinomial Logistic Regression Interaction Terms
The next section lists the results that contain statistically significant interaction
terms for the full model (Tables 48 – 51). In Table 48, the OR’s and the 95% confidence
intervals are given for the interaction term of gender and stage. In this research, the
overall gender effect is reported later in this chapter which utilizes the results of the main
effect of gender and the interaction term of gender*stage. Also the results from Table 48
are compared later in the next section ―Multinomial versus Binomial Logistic Regression
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Models‖.
The Odds Ratios and 95% Confidence Intervals are given in Table 49 for the
treatment groups and the interaction term of gender and marital status. The moderating
variable of gender demonstrated the interaction effect varied according to the level of
marital status in the interaction term (gender*marital status). Once again the statistics
will not be discussed for Table 49 as this is covered in section five in the ―Gender Effect‖
portion of this chapter
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Table 48: Gender and Stage Interaction Terms
Significant Terms Extracted From the Full Model (MLR1)
Odds Ratios and 95% Confidence Intervals by Treatment Group
Interaction Term
Treatment Type (Outcome)

Odds Ratio

95%
LCI

95%
UCI

Gender
Stage
Female
Radiation
I
1.35
1.05
1.60
Female
Radiation
II
0.91
0.65
1.23
Female
Radiation
III
1.04
0.81
1.29
Male*
IV*
Surgery*
1
Female
I
Chemotherapy
1.53
1.14
1.82
Female
II
Chemotherapy
1.03
0.74
1.35
Female
III
Chemotherapy
1.29
1.02
1.52
Male*
IV*
Surgery*
1
No Treatment
Female
I
1.12
0.91
1.33
No Treatment
Female
II
1.16
0.89
1.41
No Treatment
Female
III
1.14
0.91
1.36
Male*
IV*
Surgery*
1
Radiation + Surgery
Female
I
0.95
0.61
1.39
Radiation + Surgery
Female
II
0.94
0.60
1.39
Radiation + Surgery
Female
III
1.07
0.72
1.47
Male*
IV*
Surgery*
1
Radiation + Chemotherapy
Female
I
1.17
0.91
1.42
Radiation + Chemotherapy
Female
II
0.99
0.76
1.27
Radiation + Chemotherapy
Female
III
1.26
1.02
1.48
Male*
IV*
Surgery*
1
Surgery + Chemotherapy
Female
I
0.99
0.67
1.38
Surgery + Chemotherapy
Female
II
0.84
0.53
1.30
Surgery + Chemotherapy
Female
III
1.25
0.86
1.63
Male*
IV*
Surgery*
1
Radiation +Surgery + Chemotherapy
Female
I
0.62
0.38
1.11
Radiation +Surgery + Chemotherapy
Female
II
0.68
0.43
1.14
Radiation +Surgery + Chemotherapy
Female
III
1.27
0.90
1.61
Male*
IV*
Surgery*
1
Note: * = The reference group LCI = Lower Confidence Interval, UCI = Upper Confidence
Interval
** Adjusted for morphology, grade, stage*grade, marital status, gender*marital status, age group,
stage*age group, and race

183

Table 49: Gender and Marital Status Interaction Terms
Significant Terms Extracted From the Full Model (MLR1)
Odds Ratios and 95% Confidence Intervals by Treatment Group
Interaction Term
Odds Ratio 95% LCI 95% UCI
Marital
Gender
Status
Female
Radiation
Single
0.73
0.53
1.05
Female
Radiation
Married
0.88
0.71
1.10
Radiation
Female
Separated
1.67
0.69
2.56
Radiation
Female
Divorced
0.67
0.49
0.97
Male*
Surgery*
Widowed*
1
Chemotherapy
Female
Single
1.12
0.82
1.44
Chemotherapy
Female
Married
1.10
0.89
1.32
Chemotherapy
Female
Separated
2.47
1.03
3.35
Chemotherapy
Female
Divorced
1.04
0.77
1.34
Male*
Surgery*
Widowed*
1
No Treatment
Female
Single
0.76
0.58
1.02
No Treatment
Female
Married
0.94
0.78
1.12
No Treatment
Female
Separated
1.89
0.85
2.69
No Treatment
Female
Divorced
0.75
0.58
1.00
Male*
Surgery*
Widowed*
1
Radiation + Surgery
Female
Single
0.75
0.42
1.33
Radiation + Surgery
Female
Married
0.70
0.46
1.12
Radiation + Surgery
Female
Separated
0.65
0.10
2.47
Radiation + Surgery
Female
Divorced
0.65
0.37
1.20
Male*
Surgery*
Widowed*
1
Radiation + Chemotherapy
Female
Single
0.83
0.62
1.14
Radiation + Chemotherapy
Female
Married
0.78
0.63
0.99
Radiation + Chemotherapy
Female
Separated
1.59
0.71
2.40
Radiation + Chemotherapy
Female
Divorced
0.74
0.56
1.02
Male*
Surgery*
Widowed*
1
Surgery + Chemotherapy
Female
Single
1.50
0.83
2.08
Surgery + Chemotherapy
Female
Married
0.86
0.56
1.29
Surgery + Chemotherapy
Female
Separated
1.52
0.35
3.00
Surgery + Chemotherapy
Female
Divorced
0.69
0.40
1.25
Male*
Surgery*
Widowed*
1
Radiation +Surgery + Chemotherapy
Female
Single
1.38
0.78
1.95
Radiation +Surgery + Chemotherapy
Female
Married
1.07
0.72
1.47
Radiation +Surgery + Chemotherapy
Female
Separated
2.27
0.57
3.65
Radiation +Surgery + Chemotherapy
Female
Divorced
1.42
0.84
1.93
Male*
Surgery*
Widowed*
1
Note: * = The reference group LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
** Adjusted for morphology, grade, stage, stage*grade, gender*stage, age group, stage*age group, and race
Treatment Type (Outcome)
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Table 50 displays the results for the interaction term of stage and age group for
treatment groups containing statistically significant ORs. The moderating variable of age
group at the time of diagnosis demonstrated interaction between stage (independent
variable) and the treatment group (outcome) based on the level of the moderator. Lung
cancer cases with stage I lung cancer were 78% less likely to receiving radiation therapy
treatments for Age Group V (OR = 0.22, 95% CI 0.13 – 0.75) and 63% less likely for
Age Group VI (OR = 0.37, 95% CI 0.24 – 0.79) as compared to receiving surgery. This
result was expected as radiation alone as a treatment for early stage lung cancer would
not be the standard of care. For the other age groups with stage I lung cancer receiving
radiation, the results were not statistically significant. Clinically, it would be predicted
that the odds ratios for the youngest age group or Age Group 4 with early stage lung
cancer would demonstrate a statistically significant decrease in the probability of
receiving radiation alone but the results were not statistically significant (Table 50).
For stage I lung cancer cases receiving radiation in combination with
chemotherapy, there was a trend demonstrated that as age increased the ORs approached
1.00. Overall there was a decrease likelihood of being treated with chemotherapy
combined with radiation. For early stage disease the youngest age group was 85% less
likely to receive chemotherapy combined with radiation with the oldest age group (age
group VII) being 32% less likely to receive radiation in combination with chemotherapy
after controlling for gender, morphology, gender*morphology, grade, gender*stage,
stage*grade, gender*marital status, marital status, and race. As shown in Table 50,
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overall, the younger the early stage lung cancer case was, the less likely the lung cancer
case had of being treated with radiation or radiation in combination with chemotherapy as
compared to receiving surgery.

Table 50: Stage and Age Group at Diagnosis Interaction Terms
Significant Terms Extracted From the Full Model (MLR1)
Odds Ratios and 95% Confidence Intervals by Treatment Group
Interaction Term
Odds Ratio 95% LCI 95% UCI
Stage
Age Group
Radiation
I
4
0.08
0.03
1.14
Radiation
I
5
0.22
0.13
0.75
Radiation
I
6
0.37
0.24
0.79
Radiation
I
7
0.69
0.47
1.08
Surgery*
IV*
8*
1
Radiation
III
4
0.31
0.14
1.08
Radiation
III
5
0.48
0.29
0.97
Radiation
III
6
0.71
0.46
1.13
Radiation
III
7
0.87
0.58
1.28
IV*
Surgery*
8*
1
Radiation + Chemotherapy
I
4
0.15
0.07
0.92
Radiation + Chemotherapy
I
5
0.27
0.16
0.79
Radiation + Chemotherapy
I
6
0.42
0.26
0.88
Radiation + Chemotherapy
I
7
0.68
0.44
1.13
IV*
Surgery*
8*
1
Note: * = The reference group; LCI = Lower Confidence Interval, UCI = Upper Confidence
Interval Age Groups: 4 = (> 40 - < 50 yrs), 5 = (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 < 80 yrs), 8 = (> 80 - < 90 yrs).** Adjusted for gender, morphology, gender*morphology, grade,
gender*stage, stage*grade, gender*marital status, marital status, and race
Treatment Type (Outcome)

Table 51 contains the results for the interaction terms of stage and grade. There
were no statistically significant ORs for Stage II at any level of Grade (the moderating
variable) and was not presented in Table 51. Stage I and Stage III with the moderating
variable of Grade that contained statistically significant results for a treatment group are
listed. After adjustment for gender, morphology, gender*stage, stage*age group, marital
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status, gender*marital status, age group, and race, grade II stage I lung cancer cases as
compared to other lung cancer cases were 65% less likely to receive chemotherapy (OR =
0.35, 95% CI 0.20 – 0.93). This particular result was not unexpected as early stage
disease, as the standard of care is not to receive chemotherapy as the only treatment for
lung cancer; grade moderated the relationship between stage and the treatment received.
Stage III grade I lung cancer cases as compared to other lung cancer cases were 7
times more likely (OR = 7.03, 95% CI 1.50 – 8.58) to receive radiation in combination
with surgery after adjustment for gender, morphology, gender*stage, stage*age group,
marital status, gender*marital status, age group, and race. The moderating effect of grade
on the independent and the outcome relationship was highly significant for stage III grade
I but this relationship was not significant for stage III with grade II or III. When
considering just the ORs and not the confidence intervals this could be suggestive of a
treatment difference base on grade as there was a trend of decreasing ORs with an
increasing grade.
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Table 51: Stage and Grade at Diagnosis Interaction Terms
Significant Terms Extracted From the Full Model (MLR1)
Odds Ratios and 95% Confidence Intervals by Treatment Group

Treatment Type (Outcome)
Chemotherapy
Chemotherapy
Chemotherapy
Surgery*
Radiation + Chemotherapy
Radiation + Chemotherapy
Radiation + Chemotherapy
Surgery*

Interaction Term
Stage
Grade
I
I
I
II
I
III
IV*
IV*
I
I
I
IV*

I
II
III
IV*

Odds
Ratio

95%
LCI

95%
UCI

0.69
0.35
0.35
1.00

0.35
0.20
0.20
-

1.37
0.93
0.90
-

0.34
0.29
0.30
1.00

0.17
0.17
0.18
-

1.01
0.83
0.82
-

III
I
Radiation + Surgery
7.03
1.50
8.58
Radiation + Surgery
III
II
2.83
0.75
4.16
Radiation + Surgery
III
III
2.45
0.66
3.76
Surgery*
IV*
IV*
1.00
Note: * = The reference group; LCI = Lower Confidence Interval, UCI = Upper Confidence
Interval
** Adjusted by gender, morphology, gender*morphology, gender*stage, gender*marital status,
marital status, age group, stage*age group, and race.

Section 3: Multinomial Logistic Regression Assessment of Fit
The comparison of the residual analysis results for the multinomial logistic
regression models for the individual treatment are given next three tables (Figures 11 –
13). The results are given for the treatment groups of radiation therapy, chemotherapy, no
treatment, radiation + surgery, radiation + chemotherapy, surgery + chemotherapy, and
radiation + chemotherapy + surgery. The Pearson residual is the residual divided by the
variance for a particular observation and is the individual contribution to the Pearson Chi
Square statistic. The deviance residuals are a measure of the amount of deviance
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contributed by the individual observation. In each distribution, the residuals are centered
about zero, do not demonstrate a distinctive trend, and are similar for each treatment
outcome. From the observed data of the residual patterns, the determination was made
that the multiple logistic regression model was appropriate as a model for the research
lung cancer data set.

Figure 11: Pearson and Deviance Residual Analysis
Treatment Groups I, II, III with Treatment Group VIII (Surgery) as Reference
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Figure 12: Pearson and Deviance Residual Analysis
Treatment Groups IV and V with Treatment Group VIII (Surgery) as Reference
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Figure 13: Pearson and Deviance Residual Analysis
Treatment Groups VI and VII with Treatment Group VIII (Surgery) as Reference

Section 4: The Random Effect Component
The statistical testing and analysis used in testing Hypothesis I also included a
multinomial logistic regression model with a random effects component to investigate
any random effect of state may have had on the model results. The method used in SAS
was the Proc Glimmix procedure that utilizes statistical modeling approach to account for
random effects. The ―random effect‖ procedure fit a random adjustment to the intercept
of the model for the eight states in the cancer data set and estimates the variance of those
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adjustments separately for each level of the response variable, treatment group. In the
Proc Glimmix procedure, the overall random effect of state was evaluated and in Table
52, the estimates of the variance are given. Because the variances do not demonstrate a
wide range of variability, the random effect of eight states with respect to which
treatment the lung cancer cases received meaning the heterogeneity (differences) was
minimal.

Table 52: Random Effect of State
Covariance Parameter Estimates: Intercept Method

Subject
Random Effect

Group
Treatment Group

State
Radiation
State
Chemotherapy
State
No Treatment
State
Radiation + Chemotherapy
State
Radiation + Surgery
State
Surgery + Chemotherapy
State
Radiation + Chemotherapy + Surgery
Note: Surgery is the reference treatment group

Estimate

Standard
Error

0.340
0.247
0.094
0.091
0.331
0.101
0.024

0.175
0.126
0.050
0.060
0.168
0.061
0.016

When comparing the model without the random effect of state ―Type III Analysis
of Effects‖ for the full multinomial logistic regression model (Table 46) with the
multinomial logistic regression model ―Type III Analysis of Effects‖ (Table 53)
generated with a random effect of state; there were no significant differences in the pvalues of the independent and interaction terms. Therefore, evaluating the Type III tests
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for the model with and without the random effect, as the p-values did not change, the
overall conclusions drawn during the Hypothesis I testing could be that the random effect
is not influencing the conclusions but the random effect should be account for/assessed.

Table 53: Type 3 Analysis of Effects Main Effects and Interaction Terms*
Multinomial Logistic Regression Model (MLR2)
(Random Effect of State)

Effect
Gender
Morphology
Gender*Morphology
Grade
Stage
Gender*Stage
Stage*Grade
Marital Status
Gender*Marital Status
Age Group
Stage*Age Group
Race

DF
7
21
21
21
21
21
63
28
28
28
84
14

F Value
1.24
71.78
1.45
21.00
150.00
2.16
2.77
12.76
1.70
39.88
2.67
5.40

Pr > F
0.2739
<.0001
0.0851
<.0001
<.0001
0.0015
<.0001
<.0001
0.0115
<.0001
<.0001
<.0001

Note: Age Group and Marital Status at defined on/at Date of Diagnosis
* indicates interaction term

Section 5: Overall Effect of Interaction on the Outcome
By convention, the Odds Ratios (ORs) for the main effects and interaction terms
are reported in the literature as a statistic used to evaluate the effect of the independent
variables on the outcome of interest. In this section, the overall effect of interaction on
the outcome of interest, treatment type received was also examined. In this research, the
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ORs for the interaction effect on the treatment received was also evaluated in order to
perform a more complete assessment of the relationship between the overall effect
variables with the outcome. In determining the overall effect on the outcome, main
effects and statistically significant interaction term variables that contained the variables
of interest were included. In the equation below, the expression used to determine the
overall interaction effect from the full model (variables listed in Table 46) is given as:

Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI +
5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 9
stageI* age_groupI + 10 morphologyI + 11 raceI + others

Over the next section and in Appendix IV, the method used to calculate the Odds
Ratios and 95% Confidence Internals are given for the variable combinations of gender,
stage, marital status, grade and age group. The summary of the overall effect variable
combinations are given in Table 54. The statistically significant results for the overall
interaction effects are given in Tables 55 through 57-b.
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Table 54: Overall Variable Effect on Lung Cancer (LC) Treatment Received
Overall Interaction
Effect Variable
Gender
Stage

Marital Status
Grade
Age Group

Interaction Term

Odds Ratios

Gender1*StageI
Gender1*Marital Status1
StageI*Gender1
Stage1*GradeI
StageI* Age Group1
Marital Status1*Gender1
Grade1*StageI
Age Group1*StageI

OR = exp (1 + 6)
OR = exp (1 + 7)
OR = exp (2 + 6)
OR = exp (2 + )
OR = exp (2 + )
OR = exp (3 + 7)
OR = exp (4 + 8).
OR = exp (5 + 9)

Note: Considering only Gender 1, Stage I, Grade I, Marital Status 1, Age Group 1 in this example;
where Gender 1 = female, Age Group 1 = Age Group IV, and Marital Status 1 = Single

As previously discussed, a multinomial logistic regression model was utilized
having eight treatment groups (Y). Surgery was the reference treatment group; therefore
there were seven possible outcome categories or levels. Also, there were four categories
for stage (Stage IV = reference) and five categories for marital status (Marital Status V
(Widowed) = reference). An example is given next to show how the ―Gender Effect‖
Odds Ratios were calculated with the 95% Confidence Intervals for one of the treatment
groups. In the equations below, the treatment group is radiation (with surgery as the
reference) with gender = 1 for females and gender = 0 for males given for stageI and
marital_statusI. The effect of gender on the probability of receiving radiation therapy as
a treatment, given that the patient is at stageI, is determined as:
Female: Logit (Y=Radiation|gender=1, stageI) =  + 1 + 2 stageI + 3 marital_statusI +
4 *stageI + 5* marital_statusI
Male: Logit (Y=Radiation|gender=0, stageI) =  +2 stageI + 3 marital_statusI
By subtracting the Logit for males from Logit for females, the following equation
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is given as:
Logit (Y=Radiation |gender=1, stageI) = 1 + 4 *stageI

+ 5* marital_statusI

Next, at the variable stageI which is coded as 1 for stage I and 0 for stage IV
(reference), the results are:
Logit (Y=Radiation |gender=1, stageI=1) = 1 + 4
Logit (Y=Radiation |gender=1, stageI=0) = 1

+ 5* marital_statusI
+ 5* marital_statusI

Marital_statusI appears in both logits whether stageI is 1 or 0. In other words, it
does not matter whether the patient is single or married. This can also be stated as when
the interaction between gender and stageI is examined, marital_status I is fixed or
controlled for. For estimating the effect of gender (female as compared to male) on the
probability of receiving radiation treatment, given that the patient is at stage I (stage=1)
and after adjusting for marital_status I , the resultant equation for the Odds Ratio is given
as: OR = exp (1 + 4). The Odds Ratios were calculated by exponentiating the beta
coefficients for gender (female) plus the beta coefficient for the interaction term of
gender (female)*stageI. The 95% lower (LCI) and upper (UCI) confidence intervals were
calculated with the following equation:
LCI, UCI = exp ((1 + 4) + (1.96* [(var (1) +var (4) + 2covar (1, 4)] 0.5))
For each of the six other possible outcomes (treatment groups) remaining, each
outcome (chemotherapy, no treatment, radiation + surgery, radiation + chemotherapy,
surgery + chemotherapy, radiation + chemotherapy + surgery) would have twenty
possible results (ORs and 95% CIs) based on the level of stage for a total of 21 possible
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outcomes.
As shown in Table 55 on the next page, females with stage I as compared with
males with stage I are 1.71 times more likely to receive a combination of chemotherapy
and radiation therapy versus receiving surgery alone (OR = 1.71, 95%CI 1.06 – 2.78)
after adjustment. In other words for patients with stage 1 lung cancer, females are 1.71
times more likely to receive a combined chemotherapy and radiation therapy than males
do. After adjustment, stage 3 females as compared to males with stage 3 were 1.85 times
more likely to receive radiation therapy in combination with chemotherapy versus
receiving surgery alone for the treatment of lung cancer (OR = 1.854, 95%CI 1.151 –
2.986). The results for females with stage II versus males with stage II lung cancer were
not statistically significant. Also, none of the other six treatment types demonstrated
statistically significant results.

Table 55: Interaction Effect of Gender on LC Treatment Received
Gender and Gender*Stage
Treatment Group 5 (Radiation Therapy in Combination with Chemotherapy)
Odds Ratio

95% LCI

95% UCI

Females with Stage I
(Treatment Group 5)

1.71

1.06

2.78

Females with Stage II
(Treatment Group 5)

1.46

0.88

2.41

Females with Stage III
(Treatment Group 5)

1.85
1.15
2.99
Reference for Gender = Males, Reference for Treatment Group = Surgery, Reference for Stage = Stage IV
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Next, the effect of gender on the probability of receiving radiation therapy as a
treatment, given that the patient is at marital_statusI, is determined as:
Female: Logit (Y=Radiation|gender=1, marital_statusI) =  + 1 + 2 stageI + 3
marital_statusI + 4 *stageI + 5* marital_statusI
Male: Logit (Y=Radiation|gender=0, marital_statusI) =  +2 stageI + 3 marital_statusI
By subtracting the Logit for males from Logit for females, the following equation
is given as:
Logit (Y=Radiation |gender=1, stageI) = 1 + 4 *stageI + 5* marital_statusI
At the variable marital_statusI which is coded as 1 for marital_statusI and 0 for
marital_statusI (V = reference), the results are:
Logit (Y=Radiation |gender=1, marital_statusI =1) = 1
Logit (Y=Radiation |gender=1, marital_statusI =0) = 1

+ 4 *stageI
+ 4 *stageI

+ 5

Thus, from above stageI appears in both logits whether marital_statusI is 1 or 0.
That is, it does not matter whether the patient is stage 1 or stage III. Another way of
stating this fact is that when the interaction between gender and marital_statusI is looked
at, stageI is fixed or controlled for. For estimating the effect of gender (female as
compared to male) on the probability of receiving radiation treatment, given that the
patient is at marital_statusI and after adjusting for stageI (stage=1), the resultant equation
for the Odds Ratio is given as: OR = exp (1 + 5).
For each of the six other possible outcomes (treatment groups) remaining, each
outcome (chemotherapy, no treatment, radiation + surgery, radiation + chemotherapy,
surgery + chemotherapy, radiation + chemotherapy + surgery) would have OR’s and 95%
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CIs based on the level of marital status for a total of 28 possible outcomes. The overall
gender effect from gender and the interaction term of gender*marital status was also
calculated for the treatment received. There were no statistically significant results.

Overall Effect of Stage on the Treatment Received
In the next three tables (Tables 56-a, 56-b, 56-c), the statistically significant ORs
and 95% CIs for the interaction effect of ―stage‖ on the outcome are given. In Table 56a, the interaction between stage and gender is examined with grade and age group at the
time of diagnosis being controlled for. As noted in the table, all the ORs demonstrate a
decrease probability to receive a particular treatment for females as compared to males.
Females as compared to males with stage 1 and stage 2 lung cancer are less likely to
receive one of the seven treatment types. The ORs range from 0.008 to 0.137 for stage 1
and 0.023 to 0.929 for stage II lung cancer. After adjustment, females versus males with
stage I lung cancer are 86.3% less likely to receive a combination of surgery and
chemotherapy (OR = 0.137, 95% CI 0.103 – 0.782). For stage 2 lung cancer, females as
compared to males are 73.1% less likely to receive surgery in combination with
chemotherapy (OR = 0.269, 95% CI 0.191 – 0.380). Stage 3 lung cancer females versus
males after controlling for grade and age group, result in four treatment types (radiation,
chemotherapy, no treatment and radiation in combination with chemotherapy) in which
females can be up to 98% less likely to receive one of those four particular treatments.
For example, females versus males with stage 3 lung cancer are 91.6% less likely to
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receive radiation alone as their treatment for lung cancer (OR = 0.84, 95% CI 0.070 –
0.102) after adjustment. Also, contrary to the previous tables being presented with two
significant figures, to see the variability between the statistics, the tables (Tables 56-a
through Table 56-f-2) are presented to the third significant figure.

Table 56-a: Interaction Effect of Stage on LC Treatment Received
Stage and Stage*Gender
Treatment Type (Outcome)

Stage

Gender

OR

Radiation

I

Female

95% LCI

95% UCI

0.019

0.016

0.023

Chemotherapy

0.008

0.006

0.009

No Treatment

0.019

0.016

0.022

Radiation + Surgery

0.074

0.054

0.103

Radiation + Chemotherapy

0.013

0.011

0.015

Surgery + Chemotherapy

0.137

0.103

0.182

Radiation +Surgery + Chemotherapy

0.032

0.022

0.046

0.029

0.022

0.037

Chemotherapy

0.023

0.018

0.029

No Treatment

0.037

0.030

0.044

Radiation + Surgery

0.329

0.235

0.461

Radiation + Chemotherapy

0.047

0.038

0.058

Surgery + Chemotherapy

0.269

0.191

0.380

Radiation +Surgery + Chemotherapy

0.189

0.133

0.267

0.084

0.070

0.102

Chemotherapy

0.092

0.077

0.109

No Treatment

0.092

0.078

0.108

Radiation

Radiation

II

III

Female

Female

Radiation + Chemotherapy
0.019
0.016
0.023
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Treatment Group = Surgery, Reference for Stage = Stage IV, Reference for Gender = Males
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The statistically significant ORs and 95%CIs for Table 56-b-1, 56-b-2, and 56-b-3
are given for the effect of stage on the probability of receiving a particular lung cancer
given the lung cancer case is at a specific grade. After adjustment, for stage 1 grade 1
lung cancer cases as compared to stage 4 grade 4 lung cancer cases, stage 1 grade 1 lung
cancer cases are 98.9% less likely to receive chemotherapy alone (OR = 0.011, 95% CI
0.007 – 0.017) or 88.1% less likely to receive radiation in combination with surgery (OR
= 0.119, 95% CI 0.050 – 0.286). For grade 2 stages 1 though 3 (Table 56-b-2), once
again there is a decreased probability to receive a particular treatment based on the ―stage
effect‖ as compared to receiving surgery alone as the treatment for lung cancer. For stage
1 grade 2 and stage 2 grade 2, there are seven treatment types given as possible outcomes
with four treatment types (radiation chemotherapy no treatment and radiation in
combination with chemotherapy) for stage 3 grade 2. In Table 56-b-3, there are seven
treatment type outcomes for stage 1 grade 3 and stage 2 grade 3 and five treatment
outcomes for stage 3 grade 3. For all ―Stage Effects‖ in Tables 56-b-1through 56-b-3
there is a decrease probability to receive the particular treatment type listed, in other
words for effect of stage does not increase the probability of receiving a treatment type.
Also as the stage of the lung cancer patient increases there is a trend of increasing ORs.
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Table 56-b-1: Overall Interaction Effect of Stage on LC Treatment Received
Stage and Stage*Grade (Grade I)
Treatment Type (Outcome)

Stage

Grade

OR

95% LCI

Radiation

I

I

0.025

0.017

0.037

Chemotherapy

0.011

0.007

0.017

No Treatment

0.032

0.024

0.045

Radiation + Surgery

0.119

0.050

0.286

Radiation + Chemotherapy

0.012

0.008

0.020

Surgery + Chemotherapy

0.126

0.067

0.238

Radiation +Surgery + Chemotherapy

0.070

0.028

0.172

0.047

0.027

0.083

Chemotherapy

0.028

0.015

0.053

No Treatment

0.050

0.032

0.076

Radiation + Chemotherapy

0.061

0.037

0.101

Surgery + Chemotherapy

0.312

0.146

0.668

Radiation +Surgery + Chemotherapy

0.150

0.044

0.503

0.221

0.138

0.352

Chemotherapy

0.129

0.077

0.215

No Treatment

0.184

0.123

0.274

Radiation

Radiation

II

III

I

I

95% UCI

Radiation + Chemotherapy
0.474
0.314
0.716
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Treatment Group = Surgery, Reference for Stage = Stage IV, Reference for Grade = Grade IV
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Table 56-b-2: Interaction Effect of Stage on LC Treatment Received
Stage and Stage* Grade (Grade II)
Treatment Type (Outcome)

Stage

Grade

OR

Radiation

I

II

0.016

0.013

0.019

Chemotherapy

0.005

0.004

0.007

No Treatment

0.018

0.015

0.021

Radiation + Surgery

0.081

0.057

0.116

Radiation + Chemotherapy

0.010

0.008

0.013

Surgery + Chemotherapy

0.095

0.068

0.133

Radiation +Surgery + Chemotherapy

0.038

0.025

0.058

0.039

0.030

0.050

Chemotherapy

0.023

0.017

0.031

No Treatment

0.037

0.030

0.046

Radiation + Surgery

0.340

0.234

0.495

Radiation + Chemotherapy

0.051

0.040

0.065

Surgery + Chemotherapy

0.277

0.190

0.402

Radiation +Surgery + Chemotherapy

0.247

0.165

0.369

0.086

0.069

0.106

Chemotherapy

0.065

0.052

0.082

No Treatment

0.077

0.064

0.094

Radiation

Radiation

II

II

III

II

95% LCI

95% UCI

Radiation + Chemotherapy
0.183
0.151
0.222
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Treatment Group = Surgery, Reference for Stage = Stage IV Reference for Grade = Grade IV
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Table 56-b-3: Interaction Effect of Stage on LC Treatment Received
Stage and Stage* Grade (Grade III)
Treatment Type (Outcome)

Stage

Grade

OR

95% LCI

95% UCI

Radiation

I

III

0.016

0.014

0.019

Chemotherapy

0.005

0.004

0.006

No Treatment

0.017

0.015

0.020

Radiation + Surgery

0.069

0.050

0.094

Radiation + Chemotherapy

0.010

0.009

0.012

Surgery + Chemotherapy

0.169

0.128

0.224

Radiation +Surgery + Chemotherapy

0.039

0.028

0.054

0.023

0.018

0.028

Chemotherapy

0.019

0.015

0.024

No Treatment

0.030

0.025

0.036

Radiation + Surgery

0.315

0.233

0.426

Radiation + Chemotherapy

0.041

0.034

0.049

Surgery + Chemotherapy

0.298

0.215

0.414

Radiation +Surgery + Chemotherapy

0.237

0.178

0.316

0.072

0.061

0.085

Chemotherapy

0.072

0.061

0.084

No Treatment

0.081

0.070

0.095

Radiation + Surgery

0.665

0.513

0.863

Radiation

Radiation

II

III

III

III

Radiation + Chemotherapy
0.162
0.139
0.188
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Treatment Group = Surgery, Reference for Stage = Stage IV, Reference for Grade = Grade IV
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Next in Tables 56-c-1 through 56-c-3, the effect of stage on the probability of the
treatment received given the patient is at age group I are given. For stage 1, there are
seven possible outcomes with ORs ranging from 0.003 to 0.324 for age group 4, six
outcomes for age group 5 (ORs range from 0.007 to 0.084), and 7 possible treatment
outcomes for age group 6 and 7. Note that these results are based on comparing the
reference group of surgery for the treatment type, age group 8 as the reference for the age
group at the time of diagnosis and stage 4 as the reference group for stage. Table 56-c-2
gives the statistics for stage 2 and age groups 4 through 7. There are 5 treatment
outcomes dependent upon the effect of stage (Stage 2 and age groups 4, 5, and 6) and
four treatment groups for stage 2 in age group 7 with the ORs ranging from 0.038 to
0.080. Stage 2 age group 7 lung cancer cases have a 92.0% less likely probability to
receive radiation therapy alone (OR = 0.080, 95% CI 0.35 = 0.182) versus receiving
surgery after controlling for gender and grade. For stage 3, there are five possible
treatment outcomes for age group 4 and 5 with age group 6 and 7 having four treatment
types given with statistically significant ORs (Table 56-c-3). For age groups 6 and 7, the
treatment types are radiation, chemotherapy, no treatment and radiation in combination
with chemotherapy. The effect of stage on the treatment type received was to decrease
the probability of receiving the treatment given in the tables. It is interesting to report
that the effect of stage does not increase the probability of receiving a particular treatment
type given stage 1, 2 or 3.
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Table 56-c-1: Interaction Effect of Stage on LC Treatment Received
Stage and Stage*Age Group (Stage I)
Treatment Type (Outcome)
Age Group Stage Odds Ratio 95% LCI
95% UCI
Radiation
4
I
0.003
0.001
0.010
Chemotherapy
0.004
0.002
0.011
No Treatment
0.016
0.007
0.033
Radiation + Surgery
0.079
0.018
0.354
Radiation + Chemotherapy
0.010
0.004
0.022
Surgery + Chemotherapy
0.324
0.107
0.979
Radiation + Chemotherapy + Surgery
0.073
0.021
0.258
Radiation
5
0.008
0.004
0.017
Chemotherapy
0.007
0.004
0.013
No Treatment
0.017
0.009
0.030
Radiation + Surgery
0.075
0.021
0.271
Radiation + Chemotherapy
0.018
0.010
0.032
Radiation + Chemotherapy + Surgery
0.084
0.030
0.235
Radiation
6
0.014
0.007
0.026
Chemotherapy
0.013
0.007
0.022
No Treatment
0.024
0.014
0.040
Radiation + Surgery
0.129
0.038
0.443
Radiation + Chemotherapy
0.027
0.016
0.047
Surgery + Chemotherapy
0.308
0.132
0.716
Radiation + Chemotherapy + Surgery
0.104
0.039
0.279
Radiation
7
0.026
0.014
0.049
Chemotherapy
0.014
0.008
0.025
No Treatment
0.024
0.014
0.041
Radiation + Surgery
0.130
0.038
0.445
Radiation + Chemotherapy
0.045
0.027
0.076
Surgery + Chemotherapy
0.315
0.133
0.744
Radiation + Chemotherapy + Surgery
0.137
0.052
0.365
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Treatment Group = Surgery, Reference for Age Group = 8, Reference for Stage = Stage IV
Age Groups: 4 = (> 40 - < 50 yrs), 5 = (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 = (>
80 - < 90 yrs)
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Table 56-c-2: Interaction Effect of Stage on LC Treatment Received
Stage and Stage*Age Group (Stage II)
Treatment Type (Outcome)
Age Group Stage Odds Ratio 95% LCI
95% UCI
Radiation
4
II
0.009
0.003
0.034
Chemotherapy
0.012
0.004
0.040
No Treatment
0.024
0.010
0.060
Radiation + Chemotherapy
0.014
0.005
0.038
Radiation + Chemotherapy + Surgery
0.092
0.011
0.739
Radiation
5
0.025
0.010
0.062
Chemotherapy
0.020
0.008
0.050
No Treatment
0.026
0.012
0.055
Radiation + Chemotherapy
0.025
0.011
0.058
Radiation + Chemotherapy + Surgery
0.106
0.015
0.746
Radiation
6
0.043
0.018
0.098
Chemotherapy
0.037
0.015
0.087
No Treatment
0.037
0.018
0.076
Radiation + Chemotherapy
0.039
0.017
0.086
Radiation + Chemotherapy + Surgery
0.131
0.019
0.906
Radiation
7
0.080
0.035
0.182
Chemotherapy
0.042
0.018
0.099
No Treatment
0.038
0.019
0.077
Radiation + Chemotherapy
0.064
0.029
0.141
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Treatment Group = Surgery, Reference for Age Group = 8, Reference for Stage = Stage IV
Age Groups: 4 = (> 40 - < 50 yrs), 5 = (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 =
(> 80 - < 90 yrs)
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Table 56-c-3: Interaction Effect of Stage on LC Treatment Received
Stage and Stage*Age Group (Stage III)
Treatment Type (Outcome)
Age Group Stage Odds Ratio 95% LCI
95% UCI
Radiation
4
III
0.013
0.004
0.043
Chemotherapy
0.034
0.012
0.098
No Treatment
0.061
0.027
0.139
Radiation + Chemotherapy
0.048
0.019
0.119
Radiation + Chemotherapy + Surgery
0.168
0.032
0.874
Radiation
5
0.034
0.016
0.073
Chemotherapy
0.055
0.025
0.119
No Treatment
0.066
0.034
0.126
Radiation + Chemotherapy
0.087
0.043
0.177
Radiation + Chemotherapy + Surgery
0.193
0.044
0.849
Radiation
6
0.058
0.029
0.115
Chemotherapy
0.101
0.050
0.205
No Treatment
0.094
0.051
0.172
Radiation + Chemotherapy
0.135
0.070
0.261
Radiation
7
0.109
0.056
0.212
Chemotherapy
0.116
0.058
0.232
No Treatment
0.096
0.053
0.175
Radiation + Chemotherapy
0.222
0.116
0.426
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Treatment Group = Surgery, Reference for Age Group = 8, Reference for Stage = Stage IV
Age Groups: 4 = (> 40 - < 50 yrs), 5 = (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 = (>
80 - < 90 yrs)

Overall Effect of Marital Status on the Treatment Received
For the effect of marital status on the probability of receiving a particular
treatment given that the patient is female, Table 56-d demonstrates statistically significant
ORs and 95% CIs for married, separated and divorced patients. Females versus males
that were married were 48.2% less likely to receive radiation (OR = 0.518, 95%CI 0.388
– 0.690) or 45.3% less likely to receive no treatment (OR = 0.547, 95% CI 0.433 –
0.691). Married females versus married males were 2.144 more likely to receive surgery
in combination with chemotherapy after adjustment. Also divorced females as compared
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to males that were divorced were 1.738 time more likely to receive surgery in
combination with chemotherapy. There was a probability of receiving no treatment for
females versus males that were separated by as much as 72.8% (OR = 0.493, 95% CI
0.274 – 0.887).

Table 56-d: Interaction Effect of Marital Status on LC Treatment Received
Marital Status and Marital Status *Gender
Treatment Type (Outcome)

Gender

Marital Status

Odds Ratio

95% LCI

95% UCI

Radiation

Female

Married

0.518

0.388

0.690

No Treatment

0.547

0.433

0.691

Surgery + Chemotherapy

2.144

1.335

3.444

0.493

0.274

0.887

No Treatment

Female

Separated

Surgery + Chemotherapy
Female
Divorced
1.738
1.012
2.985
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Treatment Group = Surgery, Reference for Age Group = 8, Reference for Marital Status =
Widowed

Overall Effect of Grade on the Treatment Received
In examining the effect of grade on the probability of receiving a particular
treatment type, for stage 1, 2, and 3, there is a decreased probability in all instances listed
in Table 56-e-1. For stages 1, 2 and 3, there are seven possible treatment outcomes for
grade 1. As the severity of the grade increase, there are less treatment types given as
outcomes that are statistically significant. For grade 2 stage 1, there are two statistically
significant ORs/95% CIs for the treatment types of chemotherapy and radiation in
combination with chemotherapy. In Table 56-e-3, the effect of grade 3 on the probability
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of the treatment type received are given. For grade 3 stage 1 there 1 treatment type listed
that is statistically significant (radiation in combination with chemotherapy) and three
treatment types for stage 2 grade 3 and stage 3 grade 3. The ORs for grade 3 range from
a minimum 0.385 to a maximum of 0.570.

Table 56-e-1: Overall Interaction Effect of Grade on LC Treatment Received
Grade and Stage*Grade (Grade I)
Treatment Type (Outcome)
Stage
Grade
Odds Ratio 95% LCI
95% UCI
Radiation
I
I
0.445
0.267
0.741
Chemotherapy
0.254
0.157
0.411
No Treatment
0.526
0.372
0.744
Radiation + Surgery
0.320
0.113
0.901
Radiation + Chemotherapy
0.127
0.080
0.202
Surgery + Chemotherapy
0.331
0.179
0.613
Radiation + Chemotherapy + Surgery
0.300
0.118
0.761
Radiation
II
0.297
0.168
0.528
Chemotherapy
0.129
0.076
0.218
No Treatment
0.299
0.191
0.469
Radiation + Surgery
0.224
0.065
0.765
Radiation + Chemotherapy
0.107
0.066
0.173
Surgery + Chemotherapy
0.247
0.108
0.565
Radiation + Chemotherapy + Surgery
0.158
0.053
0.472
Radiation
III
0.327
0.187
0.572
Chemotherapy
0.130
0.079
0.211
No Treatment
0.295
0.191
0.457
Radiation + Surgery
0.190
0.056
0.644
Radiation + Chemotherapy
0.112
0.071
0.178
Surgery + Chemotherapy
0.434
0.193
0.973
Radiation + Chemotherapy + Surgery
0.159
0.055
0.462
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Treatment Group = Surgery, Reference for Stage = Stage IV, Reference for Grade = Grade IV
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Table 56-e-2: Overall Interaction Effect of Grade on LC Treatment Received
Grade and Stage*Grade (Grade II)
Treatment Type (Outcome)
Stage
Grade
Odds Ratio 95% LCI
95% UCI
Chemotherapy
I
II
0.380
0.211
0.682
Radiation + Chemotherapy
0.210
0.118
0.373
Radiation
II
0.496
0.313
0.786
Chemotherapy
0.193
0.128
0.290
No Treatment
0.431
0.312
0.596
Radiation + Chemotherapy
0.177
0.125
0.251
Surgery + Chemotherapy
0.343
0.197
0.600
Radiation + Chemotherapy + Surgery
0.322
0.145
0.716
Radiation
III
0.545
0.331
0.897
Chemotherapy
0.194
0.127
0.296
No Treatment
0.426
0.293
0.618
Radiation + Chemotherapy
0.186
0.126
0.273
Radiation + Chemotherapy + Surgery
0.326
0.139
0.765
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Treatment Group = Surgery, Reference for Stage = Stage IV, Reference for Grade = Grade IV

Table 56-e-3: Overall Interaction Effect of Grade on LC Treatment Received
Grade and Stage*Grade (Grade III)

Treatment Type (Outcome)
Stage
Grade
Odds Ratio 95% LCI
95% UCI
Radiation + Chemotherapy
I
III
0.434
0.246
0.765
Chemotherapy
II
0.401
0.255
0.632
Radiation + Chemotherapy
0.366
0.245
0.547
Surgery + Chemotherapy
0.325
0.168
0.627
Chemotherapy
III
0.403
0.278
0.584
Radiation + Chemotherapy
0.385
0.277
0.533
Surgery + Chemotherapy
0.570
0.331
0.982
Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Treatment Group = Surgery, Reference for Stage = Stage IV, Reference for Grade = Grade IV
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Overall Effect of Age Group on the Treatment Received
In the next two tables, Tables 57-a and 57-b, the effect of age group of the
probability of receiving a particular treatment type given the patient is at stageI are given.
These tables display statistics that show not only a decreased probability of receiving a
specific treatment but also an increased probability to receive a particular treatment based
on the overall interaction effect of age group. For age group 4 and 5, there is an
increased probability to receive surgery + chemotherapy as well as radiation +
chemotherapy + surgery for all stages (stages 1, 2, and 3). For stage 1 age group 4
patients, there is a 5.716 times increased in the risk to receive surgery in combination
with chemotherapy and a 7.975 increase risk to receive radiation in combination with
surgery plus chemotherapy. Of all age groups, the maximum risk (OR = 11.377, 95% CI
3.387 – 38.214) to receive a particular treatment (radiation + chemotherapy + surgery) is
for age group 4 stage 3 lung cancer patients. There is a decrease probability to receive
radiation or no treatment for age groups 4, 5, 6, and 7 for all three stages of lung cancer
(Tables 57-a and 57-b) after adjustment. The ORs range from 0.044 for age group 6
stage 1 to 0.382 for age group 4 stage 3. Age group seven is the only age group that lists
ORs that a show a decreased risk to receive a given treatment type. This could be
indicative of that as patients’ age - patients are not treated as aggressively.
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Table 57-a: Interaction Effect of Age Group on LC Treatment Received
Age Group and Stage*Age Group (Age Group 4 and Age Group 5)
Treatment Type (Outcome)

Stage

Age Group

OR

Radiation

I

4

0.085

0.035

0.210

No Treatment

0.278

0.191

0.406

Surgery + Chemotherapy

5.716

2.930

11.150

Radiation + Chemotherapy + Surgery

7.975

2.419

26.285

0.225

0.118

0.429

No Treatment

0.299

0.171

0.525

Radiation + Surgery

3.260

1.136

9.356

Surgery + Chemotherapy

7.375

2.851

19.082

Radiation + Chemotherapy + Surgery

9.164

2.650

31.688

0.382

0.219

0.667

No Treatment

0.426

0.255

0.712

Radiation + Surgery

5.636

2.084

15.245

Radiation + Chemotherapy

2.313

1.313

4.074

Surgery + Chemotherapy

5.429

2.212

13.328

Radiation + Chemotherapy + Surgery

11.377

3.387

38.214

Radiation

Radiation

Radiation

II

4

III

4

0.057

0.020

0.161

0.340

0.138

0.837

No Treatment

0.211

0.112

0.397

Radiation + Chemotherapy

0.409

0.195

0.859

Surgery + Chemotherapy

3.110

1.140

8.488

Radiation + Chemotherapy + Surgery

4.624

1.194

17.914

0.150

0.103

0.217

Chemotherapy

0.542

0.339

0.867

No Treatment

0.226

0.179

0.286

Surgery + Chemotherapy

4.013

2.243

7.181

Radiation + Chemotherapy + Surgery

5.314

1.841

15.343

0.254

0.173

0.371

No Treatment

0.322

0.233

0.445

Radiation + Surgery

4.125

1.822

9.338

Surgery + Chemotherapy

2.954

1.427

6.116

Radiation + Chemotherapy + Surgery

6.597

2.162

20.129

Radiation

5

95% UCI

Chemotherapy

Radiation

I

95% LCI

II

5

III

5

Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Treatment Group = Surgery, Reference for Age Group = 8, Reference for Stage = Stage IV
Age Groups: 4 = (> 40 - < 50 yrs), 5 = (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 = (> 80 - < 90 yrs)
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Table 57-b: Interaction Effect of Age Group on LC Treatment Received
Age Group and Stage*Age Group (Age Group 6 and Age Group 7)
Treatment Type (Outcome)

Stage

Age Group

OR

Radiation

I

6

0.044

0.016

0.122

Chemotherapy

0.252

0.104

0.611

No Treatment

0.187

0.101

0.345

Radiation + Chemotherapy

0.250

0.121

0.516

Surgery + Chemotherapy

2.915

1.111

7.650

0.115

0.072

0.184

Chemotherapy

0.402

0.233

0.692

No Treatment

0.201

0.141

0.288

Radiation + Chemotherapy

0.457

0.292

0.714

Surgery + Chemotherapy

3.762

1.793

7.892

0.196

0.152

0.251

No Treatment

0.286

0.241

0.340

Radiation + Chemotherapy

0.705

0.520

0.954

Surgery + Chemotherapy

2.769

1.579

4.856

Radiation + Chemotherapy + Surgery

3.002

1.063

8.476

0.045

0.016

0.125

Chemotherapy

0.206

0.085

0.500

No Treatment

0.220

0.120

0.403

Radiation + Chemotherapy

0.161

0.078

0.331

0.119

0.075

0.188

Chemotherapy

0.329

0.192

0.564

No Treatment

0.236

0.166

0.335

Radiation + Chemotherapy

0.294

0.189

0.457

0.201

0.145

0.280

Chemotherapy

0.608

0.395

0.938

No Treatment

0.336

0.258

0.438

Radiation

Radiation

Radiation

Radiation

Radiation

II

6

III

6

I

7

II

7

III

7

95% LCI

Note: OR = Odds Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Treatment Group = Surgery, Reference for Age Group = 8, Reference for Stage = Stage IV
Age Groups: 4 = (> 40 - < 50 yrs), 5 = (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 = (> 80 - < 90 yrs)
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95% UCI

Hypothesis I Conclusion

In conclusion, in testing Hypothesis I, the null hypothesis of no differences in
treatment outcomes between men and women, was rejected as there were statistically
significant results when the overall gender effect was examined. A multinomial logistic
regression model was used to test Hypothesis I for differences between men and women
with the same histological type, stage, and grade of lung cancer and the treatment they
received.
When considering the random effect that state may have made on the conclusions,
the reported estimates of the variances demonstrated that there was minimal
heterogeneity due to the states with regard to which treatment modality the lung cancer
cases received. Also when comparing the p-values for the Type III tests for the model
with and without the random effect, the overall conclusions drawn during Hypothesis I
testing did not change. Although it could be said the random effect was not influencing
the overall conclusions, the random effect should be assessed for the possible impact on
the resultant analyses.
Lastly, when the overall interaction effect of gender, stage, grade, marital status
and age groups on the treatment received was examined, a complete assessment of the
outcome was given. For example, utilizing gender and the interaction terms of
gender*stage and gender*marital status, statistically significant ORs and 95% CIs were
demonstrated for an increased or risk to receive a particular treatment modality based on
gender and a specific stage classification.
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Hypothesis II
There is a statistically significant difference in survival between women with lung
cancer as compared to the survival of men with lung cancer.
Introduction and Survival Analysis
During hypothesis testing, the purpose for Hypothesis 2 was to examine if there
was or was not an association between gender and survival without adjustment for the
other research covariates in the lung cancer data set. To test Hypothesis II and assess the
relationship between gender groups and survival, a non-parametric survival method, the
Life Table (Actuarial) method was utilized. The life table method is appropriate for
large data sets with grouped data and the observation times are subdivided into intervals
of fixed length. Table 58 lists the results of the survival distribution function generated
by the Life Table method. Although three test statistics (the log-rank, the Wilcoxon, and
-2Log (LR)) were generated for the survival distribution function, the log-rank test
statistic was selected as the standard reporting statistic. This particular statistic gives
equal weight to every lung cancer case death time. The other two statistics adjust for
differences in the survival distribution function depending upon the time of the death in
the time, i.e. the event (death) will be weighted. The log-rank test statistic was
significant with a p-value less than 0.0001 which could be interpreted as a difference
existed in survival between men and women.
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Table 58: Lung Cancer Survival
Survival Distribution Function
Testing the Equality over Gender

Test
Log-Rank

Life Table Method
ChiChi-Square
Square DF*
P Value
213.70
1
<.0001
*DF = Degrees of Freedom

The graph of the survival function or cumulative survival, S(t) for Life Table
method is shown below in Figure 14. As displayed in the graph, with no adjustment,
females had an increased probability of survival and survived longer than males. The
shape of the curves for the survival probability for males and females in Figure 14 were
not the same, i.e. the curves did not overlay and did not cross. ―If‖ the survival curves for
females and males did overlay, this would suggest that there was no difference with a
resultant ―failure to reject‖ the null hypothesis. In Figure 14, any crossing of the genderspecific survival curves could indicate changes in the survival patterns between males
and females or possible interaction. Also shown in Figure 14 after 10 months, the
difference between the curves were approximately parallel over the 5 year time period;
this suggested that the proportionality assumption was not violated meaning the hazard or
risk of death did not change over time between the male and female lung cancer cases.
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Figure 14: Life Table Method
Survival Distribution Function

Table 59 displays the summary of the number of lung cancer case that lived (no
event = censored) and the number of lung cancer cases that died (event occurred =
uncensored). During survival statistical testing it was important to evaluate the number
of cases that died and the number of cases that lived in the data set because if the number
of lung cancer cases that lived were disproportional between the two groups (females and
males) the resultant statistics could be biased and subsequent interpretations for
Hypothesis II could be limited. Table 59 gives the total number of females and male
lung cancer cases in the lung cancer data set; overall 33.31% of the female lung cancer
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cases did not die and 25.47% of the male lung cancer cases did not die over the study 5
year time period. In Table 59, although fewer males lived as compared to females
(6333males vs. 6661females) when examining Table 59-a, the differences in the number of
females and males that lived in time intervals (1 month intervals) was not
disproportionate. Overall, the survival time consisted of 60 time intervals of one month,
examples (Table 59-a) for the early time intervals and later time intervals are given for
number of cases that died (d), the number of cases that survived (c) and the effective
number of lung cancer cases at risk (n) in each time interval, I (one month). Therefore,
the difference between the number of female and male lung cancer cases that lived (c)
would not impact or limit the interpretation of the survival results from Hypothesis II
testing.

Table 59: Survival Data for Lung Cancer Cases
Lung Cancer Distribution Summary

Gender
Female
Male
Total

Total
Total Died
19994 13333
24869 18536
44863 31869
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Total
Lived
6661
6333
12994

Percent
Lived
33.31
25.47
28.96

Table 59-a: Extracted Life Table Survival Parameter Results
Life Table Model for the Lung Cancer Data Set
Time Interval
(months)
Lower, Upper

Females

Males

0
1
2
3
4
56
57
58
59

1
2
3
4
5
57
58
59
60

Number
Failed
(Died)
d
2665
1310
1082
967
821
7
4
4
1265

0
1
2
3
4
56
57
58
59

1
2
3
4
5
57
58
59
60

3672
1877
1617
1445
1215
7
5
9
1394

Number
Censored
(Lived)
c
1436
656
452
379
363
12
11
10
619

Effective
Sample
Size
n
19276.0
15565.0
13701.0
12203.5
10865.5
1926.0
1907.5
1893.0
1574.5

1278
641
459
375
360
3
18
11
526

24230.0
19598.5
17171.5
15137.5
13325.0
1971.5
1954.0
1934.5
1657.0

Note: Originally there were 60 time intervals of 1 month

In Table 60, the results for the quartile estimates and the 95% confidence intervals
for the survival probabilities with the mean survival times are given for males and
females lung cancer cases. The confidence intervals are reported because each estimate
of the survival probability contains random variation resulting in an inherent imprecision.
When evaluating the ―Quartile Percents‖, the 50th percentile is of the greatest of interest
as it represents the median survival time. The median survival time is defined as the
survival time for a cumulative survival function of 0.5. The median survival time for the
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data set cannot be interpreted as that ―point in time‖ where 50% of the lung cancer cases
survived; this would only be true if there were no censored observations prior to that
―point in time‖, which was not the case. Females had a median survival of 7.69 months
with a 95% confidence interval of 7.46 to 7.95 months. The median survival time for
males was 6.30 months with a 95% confidence interval of 6.17 to 6.44 months; this was
1.39 months less than the female median survival time. Also shown in Table 60, the
mean survival time for females is 19.83 months whereas the mean (or average) survival
time for males was 16.37 months; females for this data set ―on average‖ lived
approximately 3.01 months longer than the males.

Table 60: Gender Survival Estimates (in months)
Summary Statistics of the Lung Cancer Distribution
Quartile
Point
Percent Estimate
Female
75
34.29
50
7.69
25
2.63
Male

75
50
25

19.70
6.31
2.23

95% LCI

95% UCI

Mean Standard
Error

31.56
7.46
2.53

37.41
7.95
2.73

19.83

0.19

18.85
6.17
2.14

20.46
6.44
2.30

16.37

0.15

*LCI = Lower Confidence Interval, UCI = Upper Confidence Interval

Another test statistic generated with the Life Table Method is the cumulative
hazard function, CHF. The cumulative hazard function corresponds to the total number
of deaths over an interval of time. In Figure 15, the graph of the cumulative hazard
function is representative for the overall study time of 60 months. The x-axis for the
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overall time is annotated in ten month time intervals which are further subdivided into
one month survival time intervals as noted on the graph as a circle (o) for females and a
plus (+) for males. The cumulative hazard function illustrates the probability for the
outcome of interest, death and how that probability changes with time. The cumulative
probability of death increased for both females and males over the time interval in Figure
15 with males having an increase in the probability of death as compared to females.

Figure 15: Cumulative Hazard Function for the Life Table Model
Female and Males Lung Cancer Cases
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When examining the cumulative hazard function plot a comprehensive
representation of how the hazard is changing over time cannot be completely ascertained.
Survival data are not normal and therefore to view the cumulative hazard function
transforming the data with a logarithmic function allows for a more complete
examination of the hazard between males and females. As shown in Figure 16, after the
6transformation of the data, the hazard is shown to remain constant between males and
females over the time under study (see Figure 16). This was important to examine
(constant hazard) to ensure the assumption of proportionality was not violated, i.e. the
probability of death was constant over the study time period between males and females.

Figure 16: Transformation of the Cumulative Hazard Function
Female and Males Lung Cancer Cases
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Hypothesis II Conclusion
In conclusion, for Research Question Two, the null hypothesis was rejected as
there were statistically significant differences in gender specific survival. Women lung
cancer cases had an increased probability of survival (a survival advantage) versus men
with lung cancer. It is reported in the literature that there is a distinct survival advantage
for women with lung cancer as compared to men with lung cancer. This result of
increased survival for women was verified during Hypothesis II testing and analyses;
these results are consistent with published literature.

Hypothesis III
Women with the same histological type, stage, grade of lung cancer, and the same
treatment modality differ significantly in survival as compared to men with the same
histological type, stage, and grade of lung cancer, and the same treatment modality.
Introduction
The third aim in testing the hypothesis of this research study was to expand the
investigation of lung cancer treatment differences for females versus males in order to
answer the research question of whether differences in treatment assignment based on
gender altered survival. For lung cancer cases, females have been shown to have a
distinct survival advantage relative to males8, 15, 17. The statistical modeling approaches
that demonstrate this survival advantage for females do not account for any effects due to
moderating variables on the relationship or association between the independent variable
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of gender and survival. The intent was to determine under which conditions females
demonstrated or did not demonstrate a survival advantage as compared to males by
investigating differences in gender-specific survival for men and women lung cancer
cases grouped or stratified by treatment modality, histologic type, stage, grade and other
research covariates and by expanding the modeling approach to include interaction terms.
The research statistical approach to test Hypothesis 3 was to employ Survival
Analysis or ―Time-to-Event‖ Analysis. This technique can be applied to evaluate data
that are censored (the research study event is not observed) and are not normal (lack of
normality) due to censoring. Under the conditions described in this research, the lung
cancer data from the eight cancer registries were right censored. Right censoring is
defined as the non-observance of the study event, i.e. death, during a specified time
range. During the specified time frame (1-1-2000 through 12-31-2004) under study, any
non-observed event (death) would classify that individual lung cancer case as censored.
As stated in Chapter Three, the model selected to examine the relationship
between survival and the covariates was the Cox Proportional Hazards model. This
particular model is categorized as semi-parametric as the baseline hazard is not specified
but other assumptions such as time-invariant covariates across the study period are
assumed. Time-invariant covariates imply that the ratio of the hazard for any two
observations is similar across the period of study. Prior to hypothesis testing with the
Cox Proportional Hazards statistical model, the first step to answer Research Question
Three was to perform a preliminary ―Exploratory Univariate Survival Analysis‖ for the
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individual categorical independent variables. Commonly the ―Kaplan-Meier Survival
Method’ is utilized but due to the large number of lung cancer cases with many failures in
the data set (N =44,863) the ―Life Table Survival Method‖ was selected for the
preliminary analyses3. This initial or preliminary testing was done to evaluate the
survival function and shape of the survival curves for each covariate over survival time.
The survival curves for the groups or strata of the individual covariates were utilized to
examine the proportionality between the strata (groups) for each variable. When the
groups or strata for the independent variable are proportional, the curves of the survival
function graphs between the strata appear approximately parallel (the lines of the graphs
do not diverge or do not cross). After evaluating the survival function curves between
gender vs. survival time, stage vs. survival time, grade vs. survival time, and morphology
vs. survival time for the lung cancer cases diagnosed over the 5 year study period, it was
determined that utilization of the Cox Proportional Hazard model was appropriate as the
proportionality assumption held for gender, stage, grade, and morphology over survival
time. There were some overlapping survival curves for independent variables of age
group at diagnosis, marital status at diagnosis, race, and treatment group over time which
could have been problematic as the assumption of proportionality (constant hazard) could
possibly be violated making the Cox Proportional Hazard model inappropriate to use with
the lung cancer data set. The initial non-proportionality concern was addressed later in
this section with the variables (age group at diagnosis, marital status at diagnosis, race,
3

Information from ―Analyzing Survival Data from Clinical Trials and Observational Studies‖ by Ettore
Marubini and Maria Grazia Valsecchi; section 3.3.2., page 54.
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and treatment group) being tested via residual analysis (results are shown in Figures 13
and 14).
During the initial phase of univariate survival analysis, the statistics generated by
the ―Test of Equality over Strata‖ were used to evaluate any inequality across the strata
for each independent categorical variable. The lifetest procedure generated log-rank test
statistic, with the p-values (<0.0001) being significant for gender, stage, grade,
morphology, race, marital status at diagnosis, age group at diagnosis, and treatment
group. Table 61 contains the some of the results for the Life Table Method ―Tests of
Equality over the Strata‖ and as noted above the p-values are significant. A possible
limitation of the statistical analysis for this data set for the highly significant p-values
may not just be a result of a true null hypothesis (no difference) but rather may be
attributed to the extremely large sample size (N = 44,863) influencing the statistics.

Table 61: Life Table - Test of Equality over Strata
Parameter
Gender
Stage
Grade
Morphology

Test

Chi-Square Pr > Chi-Square

Log-Rank
Log-Rank
Log-Rank
Log-Rank

206.90
502.70
844.80
417.80

< 0.0001
< 0.0001
< 0.0001
< 0.0001

The next phase in testing Hypothesis 3 was assessing the research question by
fitting the data to the Cox Proportional Hazard model which is a semi-parametric
mathematical equation (the procedure in SAS is referred to as ―PROC PHREG‖). During

227

the model build or selection of the covariates and interaction terms to be included in the
final model, the ―Stepwise‖ procedure was utilized in a forward selection (alpha = 0.05)
and backward elimination of the variable or interaction term if the significance level of
0.05 was not met. Four variables (gender, stage, grade, and morphology) were coded to
remain in the model during the stepwise procedure without having to meet the entry and
exit specifications of 0.05 as these were the primary variables under study. At the
completion of the stepwise procedure, the final model was assessed by examining the pvalues for the main effect variables and the variable combinations for the interaction
terms. Interaction terms were included in the final model so the effect of moderating
variables that could impact the relationship between the independent variables and
survival were identified. Below in Table 61-a, the results of the Type III testing for the
final model are given. As shown Table 61-a, there were a total of six main effects
variables and ten interaction terms.
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Table 61-a: The Cox Proportional Hazards Model (CPHM1)
Type 3 Tests - Final Model

Effect
Gender
Morphology
Gender * Morphology
Grade
Grade * Morphology
Stage
Stage * Morphology
Age Group
Stage * Age Group
Race
Treatment Type
Gender * Treatment Type
Treatment Type * Morphology
Treatment Type * Grade
Treatment Type * Stage
Treatment Type * Age Group
Treatment Type * Race

DF
1
3
3
3
9
3
9
4
12
2
7
7
21
21
21
28
14

Note: Age Group at defined on/at Date of Diagnosis
* indicates interaction term
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Wald
Chi-Square
34.54
17.21
8.61
3.81
29.34
92.72
20.69
64.69
22.99
4.14
20.54
23.01
73.18
61.24
147.33
104.76
34.35

Pr > ChiSq
<.0001
0.0006
0.0350
0.2823
0.0006
<.0001
0.0141
<.0001
0.0278
0.1259
0.0045
0.0017
<.0001
<.0001
<.0001
<.0001
0.0018

The extracted equation or expression from the Cox Proportional Hazards model would
be:

Hazard Rate = exp (1genderI + 2morphologyI + 3gradeI + 4stageI + 5age_groupI +
6raceI + 7treatment_typeI + 8 genderI * morphologyI + 9 gradeI * morphologyI +
10 stageI * morphologyI + 11 stageI * age_groupI + 12 genderI*treatment_typeI +
13 treatment_typeI * morphologyI+ 14 treatment_typeI * grade I +
15treatment_typeI* stageI + 16treatment_typeI* age_groupI +
17treatment_typeI*raceI + others)

The next three sections for Hypothesis III include 1) the interaction terms
analysis, 2) the residuals analysis (model assessment), and 3) gives the results for the
overall interaction effect on the probability of survival. It was important to include the
interaction terms analysis so a comparison of the results could be made to the overall
interaction effect on the outcome.

Section 1: Cox Proportional Hazards Model Interaction Terms
In the next six tables (Tables 62- 67), the results of the final Cox Proportional
Hazards Model (CPHM1) are given for the interaction terms extracted from the full
model that contained statistically significant results. When there were associations
between the independent variable and the outcome of interest, survival, the relationship
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varied at different levels dependent upon the effect modifier. Interaction terms included
in the statistical model (when appropriate) allowed for the opportunity to examine a more
complete overview of the relationship between an independent variable and the outcome
and how that relationship changes based on the moderating variable (effect modifier). As
stated previously during Hypothesis II testing, in the majority of the currently published
literature of gender-specific survival, gender is evaluated as a main effect without
interaction terms. The survival estimates based on the information presented in that
literature are reported favorably for women relative to men8, 15, 17. In testing Hypothesis
II, the results were consistent with the published literature that found females have a
survival advantage over men. Part of the research investigation of gender-specific
survival was to verify that the results obtained from the lung cancer data set were
consistent with other research results published in the current literature.
The investigation of gender-specific survival was expanded during Hypothesis III
testing. After adjustment for covariates, the relationship between gender-specific survival
and the treatment received was analyzed. As shown in the following tables (Tables 62
through 67), there were increased hazard or increase risk of death based on treatment
received. The overall gender effect reported later in this section on survival will include
the results for the terms containing gender; therefore the statistics for Table 62 will not be
reviewed here.
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Table 62: Hazard Ratios and 95% Confidence Intervals
Interaction Term of Treatment Group and Gender
Extracted from the Cox’s Proportional Hazard’s Final Model (CPHM1)

Interaction Terms**
Hazard Ratio
95% LCI
95% UCI
Gender
Treatment Group
(Moderator)
Female
Radiation
1.18
1.09
1.29
Female
Chemotherapy
1.16
1.07
1.26
Female
No Treatment
1.13
1.05
1.21
Female
Radiation + Surgery
1.13
0.96
1.34
Female
Radiation + Chemotherapy
1.18
1.09
1.27
Female
Surgery + Chemotherapy
1.11
0.93
1.33
Female
Radiation + Surgery + Chemotherapy
1.07
0.92
1.25
Male*
Surgery*
1.00*
LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, * = designates reference
** Adjusted for morphology, gender * morphology, grade, grade * morphology, stage, stage *
morphology, age group, stage * age group, race, morphology * treatment type, grade * treatment type,
stage * treatment type, age group * treatment type, and race * treatment type

The results displayed in Table 63 are for the interaction term of treatment group
and stage; stage is the moderator in this interaction term extracted from the full CPH
model. For the first treatment group of radiation therapy, lung cancer cases with stage 3
were at a 20.0% decreased risk for death than those lung cancer cases receiving surgery
after controlling for gender, morphology, gender * morphology, grade, grade *
morphology, stage * morphology, age group, stage * age group, race, gender * treatment
type, morphology * treatment type, grade * treatment type, age group * treatment type,
and race * treatment type. There are no trends or overall significant findings
demonstrated for an increased or decreased risk in this treatment group (radiation) based
on stage 1 or stage 2 for this disease. In the case of chemotherapy (treatment group 2),
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there is a decreasing risk of death as stage increases. For stage 1 lung cancer cases
receiving chemotherapy the risk of death was 1.68 times greater than those lung cancer
cases receiving surgery after controlling for gender, morphology, gender * morphology,
grade, grade * morphology, stage * morphology, age group, stage * age group, race,
gender * treatment type, morphology * treatment type, grade * treatment type, age group
* treatment type, and race * treatment type.
Stage 2 lung cancer cases receiving chemotherapy were 1.44 times more likely to
die than those lung cancer cases receiving surgery after adjustment. Later stage lung
cancer cases (stage 3) receiving chemotherapy were 7.0% less likely to die than those
lung cancer cases receiving surgery after adjustment, although this was not statistically
significant (HR = 0.93, 95% CI 0.81 - 1.06). After controlling for gender, morphology,
gender * morphology, grade, grade * morphology, stage * morphology, age group, stage
* age group, race, gender * treatment type, morphology * treatment type, grade *
treatment type, age group * treatment type, and race * treatment type, stage 1 (HR = 1.68,
95% CI 1.41 - 1.99) and stage 2 (HR = 1.44, 95% CI 1.19 - 1.74) lung cancer cases were
shown to be at a greater risk or hazard for death as opposed to lung cancer cases
receiving surgery alone. These findings are of particular interest as clinically early stage
disease is associated with a decreased hazard for death and later stage disease has
decreased survival. Evaluation of the effects of the moderator (stage) in the relationship
between treatment and survival after adjustment in the full model for this data set
demonstrated that early stage lung cancer cases receiving chemotherapy had decreased
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survival.
For the next treatment group of ―no treatment‖, early stage lung cancer cases
(stage 1) that received no treatment were 16.0% more likely to die (HR = 1.16, 95 % CI
1.02 - 1.32) than those lung cancer cases receiving surgery alone after controlling for
gender, morphology, gender * morphology, grade, grade * morphology, stage *
morphology, age group, stage * age group, race, gender * treatment type, morphology *
treatment type, grade * treatment type, age group * treatment type, and race * treatment
type. The risk of death increased by 46.0% for stage 2 lung cancer cases as compared to
other lung cancer cases (HR = 1.46, 95 %CI 1.25 - 1.70) versus receiving surgery alone
after adjustment. Although the hazard ratio decreased for stage 3 disease, the result
shown in Table 63 for stage 3 lung cancer cases receiving no treatment was not
statistically significant (HR = 0.93, 95% CI = 0.82 - 1.06). Once again it would be
expected that later stage disease would have increased mortality; this was association was
not demonstrated for those lung cancer cases in the no treatment group.
The only statistically significant hazard ratio in treatment group 4 (radiation in
combination with surgery) in Table 63, was for stage 3 lung cancer cases. Lung cancer
cases receiving radiation plus surgery were 26.0% less likely to die than those lung
cancer cases receiving surgery after controlling for gender, morphology, gender *
morphology, grade, grade * morphology, stage * morphology, age group, stage * age
group, race, gender * treatment type, morphology * treatment type, grade * treatment
type, age group * treatment type, and race * treatment type. This result indicated that for
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later stage disease the treatment combination of radiation and surgery improved survival.
For early stage disease (Stage 1 and 2) lung cancer cases receiving chemotherapy plus
radiation did not demonstrate a decrease in the risk of death (Table 63). On the contrary,
stage 1 lung cancer cases receiving this treatment combination were 43.0% more likely to
die with stage 2 lung cancer cases being 31.0% more likely to die than those lung cancer
cases receiving surgery after adjustment. The trend of increasing stage having a
decreased risk for death for the radiation plus chemotherapy treatment group was further
demonstrated as stage 3 had an 11.0% decrease in the risk for death versus lung cancer
cases receiving surgery after adjustment. These results suggest that stage moderated the
relationship between the treatment group and survival: earlier stage lung cancer cases
have decreased survival when the treatment for the disease consists of radiation in
combination with chemotherapy. For the last two treatment groups (surgery +
chemotherapy and radiation + chemotherapy + surgery) in Table 63, the only significant
hazard ratio was for stage 1 lung cancer cases receiving all three treatment modalities of
radiation, chemotherapy and surgery (HR = 1.79, 95% CI 1.31 – 2.44) as compared to
lung cancer cases receiving surgery after controlling for gender, morphology, gender *
morphology, grade, grade * morphology, stage * morphology, age group, stage * age
group, race, gender * treatment type, morphology * treatment type, grade * treatment
type, age group * treatment type, and race * treatment type. This treatment group
(radiation + surgery + chemotherapy) with stage 1 disease had the highest risk for death
(79.0%) as compared to all the other treatment groups as shown in Table 63.
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Table 63: Hazard Ratios and 95% Confidence Intervals
Interaction Term of Treatment Group and Stage
Extracted from the Cox’s Proportional Hazard’s Final Model (CPHM1)
Hazard
Ratio

Interaction Terms**

95% LCI
95% UCI
Stage
Treatment Group
(Moderator)
Radiation
I
1.03
0.89
1.19
Chemotherapy
I
1.68
1.41
1.99
No Treatment
I
1.16
1.02
1.32
Radiation + Surgery
I
1.28
0.97
1.68
Radiation + Chemotherapy
I
1.43
1.22
1.66
Surgery + Chemotherapy
I
1.25
0.95
1.64
Radiation + Surgery + Chemotherapy
I
1.79
1.31
2.44
Surgery*
IV*
1.00
Radiation
II
1.10
0.92
1.32
Chemotherapy
II
1.44
1.19
1.74
No Treatment
II
1.46
1.25
1.70
Radiation + Surgery
II
1.07
0.82
1.41
Radiation + Chemotherapy
II
1.31
1.11
1.54
Surgery + Chemotherapy
II
1.01
0.72
1.41
Radiation + Surgery + Chemotherapy
II
1.27
0.95
1.71
Surgery*
IV*
1.00
Radiation
III
0.80
0.69
0.92
Chemotherapy
III
0.93
0.81
1.06
No Treatment
III
0.93
0.82
1.06
Radiation + Surgery
III
0.74
0.59
0.92
Radiation + Chemotherapy
III
0.89
0.78
1.01
Surgery + Chemotherapy
III
0.90
0.71
1.14
Radiation + Chemotherapy
III
1.31
1.11
1.54
Radiation + Surgery + Chemotherapy
III
0.95
0.77
1.17
Surgery*
IV*
1.00
LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, * = designates reference
** Adjusted for gender, morphology, gender * morphology, grade, grade * morphology, stage *
morphology, age group, stage * age group, race, gender * treatment type, morphology * treatment
type, grade * treatment type, age group * treatment type, and race * treatment type

Table 64 exhibits only one statistically significant hazard ratio for the interaction
term of treatment group and grade. Grade I lung cancer cases receiving chemotherapy
had an increased risk of death with a hazard ratio of 1.51 (95% CI 1.12 - 2.03) relative to
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lung cancer cases receiving surgery after controlling for gender, morphology, gender *
morphology, grade * morphology, stage, stage * morphology, age group, stage * age
group, race, gender * treatment type, morphology * treatment type, grade * treatment
type, age group * treatment type, and race * treatment type.

For this data set and as

shown in Table 64, there was only one statistically significant hazard ratio which may
have been due to chance alone versus being truly significant for the relationship between
treatment modality of chemotherapy and decreased survival moderated by the grade of
disease.
The hazard ratios and the 95% confidence intervals for the interaction term of
treatment group and morphology are displayed in Table 65. Morphology moderated the
relationship between the independent variable treatment group and the outcome, survival.
The finding that morphology acted as a moderator was consistent with clinical practices
of treating a disease based on cell type with a particular treatment regimen. The statistics
demonstrated that the treatment selection based on cell type could decrease survival or
may not increase survival. There were only three treatment groups (radiation,
chemotherapy, and radiation in combination with chemotherapy) with statistically
significant results meaning for a particular treatment group the hazard ratio and the
confidence interval for that hazard ratio did not include 1. For each of those three
treatment groups, the hazard ratios demonstrated an increased risk for death or decreased
survival for the lung cancer cases. Lung cancer cases with adenocarcinoma receiving
radiation were 45.0% more likely to die (HR = 1.45, 95% CI 1.03 – 2.04) as compared to
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the other treatment groups with adenocarcinoma after controlling for gender, gender *
morphology, grade, grade * morphology, stage, stage * morphology, age group, stage *
age group, race, gender * treatment type, stage * treatment type, grade * treatment type,
age group * treatment type, and race * treatment type. The hazard ratio increased by 65%
(HR = 1.65, 95% CI 1.17 – 2.33) for squamous cell lung cancer cases receiving radiation
with a hazard ratio for large cell carcinoma increasing by 61% (HR = 1.61, 95% CI 1.14
– 2.28) relative to lung cancer cases receiving surgery after adjustment. For
adenocarcinoma lung cancer cases receiving chemotherapy, the risk of death increased by
42.0% than those lung cancer cases receiving surgery after adjustment. The hazard ratio
for squamous cell lung cancer receiving chemotherapy was 1.51 meaning there was a
51.0% increase in the risk of death as compared to lung cancer cases receiving surgery
after controlling for gender, gender * morphology, grade, grade * morphology, stage,
stage * morphology, age group, stage * age group, race, gender * treatment type, stage *
treatment type, grade * treatment type, age group * treatment type, and race * treatment
type. Radiation in combination with chemotherapy demonstrated the same trend of
decreased survival for the lung cancer morphological types of adenocarcinoma,
squamous cell, and large cell carcinoma. Adenocarcinoma lung cancer cases receiving
radiation plus chemotherapy were 48.0% (HR = 1.48, 95% CI 1.08 – 2.02) more likely to
die with large cell lung cancer cases having a 62.0% increase risk for death (HR = 1.62,
95% CI 1.18 – 2.24) than those lung cancer cases receiving surgery after adjustment.
According to the statistics, chemotherapy, radiation, and chemotherapy in combination
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with radiation decreased survival for all three lung cancer types. In Table 65, the hazard
ratios for radiation in combination with surgery was the one treatment group that did
increase in survival (HR’s less than 1.00) for all three NSCLC types (adenocarcinoma,
squamous, and large cell) as compared lung cancer cases receiving surgery but these
results were not statistically significant as the 95% confidence intervals did include 1.
For all other treatment groups (no treatment, surgery plus chemotherapy, and radiation in
combination with surgery plus chemotherapy) listed in Table 65, the results were not
statistically significant therefore an association between the treatment group and survival
moderated by morphology was not demonstrated.
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Table 64: Hazard Ratios and 95% Confidence Intervals
Interaction Term of Treatment Group and Grade
Extracted from the Cox’s Proportional Hazard’s Final Model (CPHM1)
Hazard
Ratio

Interaction Terms**

95% LCI
95% UCI
Grade
Treatment Group
(Moderator)
Radiation
I
1.03
0.76
1.41
Chemotherapy
I
1.51
1.12
2.03
No Treatment
I
1.05
0.81
1.38
Radiation + Surgery
I
0.66
0.34
1.27
Radiation + Chemotherapy
I
1.26
0.94
1.67
Surgery + Chemotherapy
I
1.22
0.69
2.17
Radiation + Surgery + Chemotherapy
I
0.92
0.5
1.71
Surgery*
IV*
1
Radiation
II
0.93
0.71
1.23
Chemotherapy
II
1.09
0.84
1.41
No Treatment
II
1.06
0.84
1.36
Radiation + Surgery
II
0.89
0.52
1.53
Radiation + Chemotherapy
II
1.12
0.88
1.44
Surgery + Chemotherapy
II
0.97
0.6
1.59
Radiation + Surgery + Chemotherapy
II
0.97
0.61
1.54
Surgery*
IV*
1
Radiation
III
0.92
0.7
1.2
Chemotherapy
III
0.89
0.7
1.14
No Treatment
III
1
0.79
1.26
Radiation + Surgery
III
0.91
0.54
1.55
Radiation + Chemotherapy
III
0.98
0.77
1.24
Surgery + Chemotherapy
III
0.98
0.61
1.56
Radiation + Surgery + Chemotherapy
III
0.82
0.52
1.28
Surgery*
IV*
1
LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, * = designates reference
** Adjusted for gender, morphology, gender * morphology, grade * morphology, stage, stage *
morphology, age group, stage * age group, race, gender * treatment type, morphology *
treatment type, stage * treatment type, age group * treatment type, and race * treatment type
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Table 65: Hazard Ratios and 95% Confidence Intervals
Interaction Term of Treatment Group and Morphology
Extracted from the Cox’s Proportional Hazard’s Final Model (CPHM1)
Hazard
Ratio

Interaction Terms**
Treatment Group

95% LCI

95% UCI

Morphology
(Moderator)

Radiation
Adenocarcinoma
1.45
1.03
2.04
Chemotherapy
Adenocarcinoma
1.42
1.04
1.95
Adenocarcinoma
1.07
0.79
1.46
No Treatment
Radiation + Surgery
Adenocarcinoma
0.72
0.31
1.65
Radiation + Chemotherapy
Adenocarcinoma
1.48
1.08
2.02
Surgery + Chemotherapy
Adenocarcinoma
1.03
0.61
1.72
Radiation + Surgery + Chemotherapy
Adenocarcinoma
1.53
0.92
2.55
Surgery*
Small Cell*
1
Radiation
Large Cell
1.61
1.14
2.28
Chemotherapy
Large Cell
1.43
1.03
1.97
No Treatment
Large Cell
1
0.72
1.37
Radiation + Surgery
Large Cell
0.82
0.35
1.91
Radiation + Chemotherapy
Large Cell
1.62
1.18
2.24
Surgery + Chemotherapy
Large Cell
0.97
0.57
1.66
Radiation + Surgery + Chemotherapy
Large Cell
1.43
0.84
2.42
Surgery*
Small Cell*
1
Radiation
Squamous
1.65
1.17
2.33
Chemotherapy
Squamous
1.51
1.1
2.07
No Treatment
Squamous
1.16
0.85
1.58
Radiation + Surgery
Squamous
0.84
0.36
1.93
Radiation + Chemotherapy
Squamous
1.63
1.19
2.23
Surgery + Chemotherapy
Squamous
1.04
0.62
1.77
Radiation + Surgery + Chemotherapy
Squamous
1.58
0.94
2.64
Surgery*
Small Cell*
1
LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, * = designates reference
** Adjusted for gender, gender * morphology, grade, grade * morphology, stage, stage * morphology,
age group, stage * age group, race, gender * treatment type, grade * treatment type, stage * treatment
type, age group * treatment type, and race * treatment type

The hazard ratios for the interaction term of treatment group and age group in
Table 66 displayed that age was a moderator in the association between the treatment
received and survival. Also in Table 66, the hazard ratios did not exhibit an increasing or
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decreasing trend between the type of treatment received and survival. For all levels of
age group (4, 5, 6, and 7) lung cancer cases receiving radiation therapy as a treatment
modality were at increased risk for death as compared to lung cancer cases receiving
surgery after controlling for gender, morphology, gender * morphology, grade, grade *
morphology, stage, stage * morphology, stage * age group, race, gender * treatment type,
stage * treatment type, grade * treatment type, morphology * treatment type, and race *
treatment type. Lung cancer cases in age group 4 that received radiation were 1.38 times
more likely to die than those lung cancer cases receiving surgery after adjustment. All
other age groups, 5 (HR = 1.51, 95% CI 1.27 – 1.81), 6 (HR = 1.27, 95% CI 1.10 – 1.46),
and 7 (HR = 1.19, 95% CI 1.05 – 1.36) were at increased risk for death versus lung
cancer cases receiving surgery after adjustment.
The risk of death increased by 22.0% for lung cancer cases in age group 5
receiving chemotherapy (HR = 1.22, 95% CI 1.03 – 1.45) versus lung cancer cases
receiving surgery after adjustment (Table 66). The variation of that risk was as small as
3.0% to a maximum risk for death of 45.0%. In Table 66, the no treatment group
demonstrated a trend of decreasing risk of death with the HRs ranging from 1.65 to 1.23;
as the lung cancer case became older the hazard ratio decreased but this was not
statistically significant. The only other treatment group with a statistically significant
hazard ratio was the treatment group of radiation in combination with chemotherapy
(Table 66). Lung cancer cases that received radiation in combination with chemotherapy
were 31.0% more likely to die (HR = 1.31, 95% CI 1.11 - 1.56) relative to lung cancer
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cases receiving surgery after adjustment. For all age groups in the other three treatment
groups of 1) radiation plus surgery, 2) surgery in combination with chemotherapy, and 3)
radiation plus surgery plus chemotherapy, the risk of death or hazard ratio was not
statistically significant as compared to lung cancer cases receiving surgery after
controlling for gender, morphology, gender * morphology, grade, grade * morphology,
stage, stage * morphology, stage * age group, race, gender * treatment type, stage *
treatment type, grade * treatment type, morphology * treatment type, and race * treatment
type. Age group moderated the relationship between treatment group and survival with
the no treatment group overall having the highest risk of death. Possible explanations of
the no treatment group having the highest risk would include 1) those particular lung
cancer cases did not receive one of the seven treatments for lung cancer because they
were too sick for treatment or 2) the lung cancer case may have refused treatment for
their disease. Of the last four treatment groups (Radiation + Surgery, Radiation +
Chemotherapy, Surgery + Chemotherapy, and Radiation + Chemotherapy + Surgery)
shown in Table 66, the only treatment group moderated by age group that demonstrated a
statistically significant hazard ratio was for the radiation in combination with
chemotherapy treatment group. Lung cancer cases in age group 5 were at a 31.0 %
increased risk versus lung cancer cases receiving surgery after adjustment.
The last table (Table 67) in the Hypothesis 3 section 1 lists the hazard ratios for
the interaction term of treatment group and race extracted from the full model. After
controlling for gender, morphology, gender * morphology, grade, grade * morphology,
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stage, stage * morphology, age group, stage * age group, gender * treatment type,
morphology * treatment type, grade * treatment type, stage * treatment type, and age
group * treatment type, white and black lung cancer cases receiving radiation had an
increased hazard for death or decreased survival with white lung cancer cases having a
38.0% (HR = 1.38, 95% CI 1.04 – 1.84) increased risk for death and black lung cancer
cases having a 27.0% (HR = 1.51, 95% CI 1.27 – 1.81) increased risk for death than
other lung cancer cases receiving surgery. For lung cancer cases receiving
chemotherapy, black lung cancer cases demonstrated the only statistically significant
relationship between the treatment type and survival. After adjustment, black lung cancer
cases receiving chemotherapy alone were 22.0% more likely to die as compared to other
lung cancer cases receiving surgery alone (HR = 1.22, 95% CI 1.03 – 1.45).
For white lung cancer cases receiving no treatment there was a 65.0% increase in
the risk of death (HR = 1.65, 95%CI 1.28 - 2.14) and for black lung cancer cases
receiving no treatment the hazard ratio was 1.60 (95%CI 1.37 - 1.87) as compared to
other lung cancer cases receiving surgery after controlling for gender, morphology,
gender * morphology, grade, grade * morphology, stage, stage * morphology, age group,
stage * age group, gender * treatment type, morphology * treatment type, grade *
treatment type, stage * treatment type, and age group * treatment type. Once again as
demonstrated in Table 66 (interaction term of treatment group and age group), the ―no
treatment group‖ had the highest risk of death but in this case (Table 67) race was the
moderator between treatment group and survival.
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Black lung cancer cases receiving a combination of radiation and chemotherapy
had a 1.31 times increase in the risk of death with a hazard ratio varying as low as 11.0%
to a maximum of 56.0% (95% confidence interval of 1.11 to 1.56) versus other lung
cancer cases receiving surgery after adjustment. For all other treatment groups, i.e.
radiation + surgery, surgery + chemotherapy, and radiation + surgery + chemotherapy,
the results were not statistically significant. Although when just evaluating the hazard
ratios for radiation in combination with surgery and chemotherapy, there was a decreased
risk of death for both white (HR = 0.73, 95%CI 0.39 – 1.35) and black lung (HR = 0.72,
95%CI 0.41 – 1.27) cancer cases.
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Table 66: Hazard Ratios and 95% Confidence Intervals
Interaction Term of Treatment Group and Age Group
Extracted from the Cox’s Proportional Hazard’s Final Model (CPHM1)
Hazard
Ratio

Interaction Terms**

95% LCI
95% UCI
Age Group
Treatment Group
(Moderator)
Radiation
4
1.38
1.04
1.84
Chemotherapy
4
1.1
0.84
1.43
No Treatment
4
1.65
1.28
2.14
Radiation + Surgery
4
0.93
0.56
1.54
Radiation + Chemotherapy
4
1.24
0.96
1.61
Surgery + Chemotherapy
4
0.99
0.57
1.72
Radiation + Surgery + Chemotherapy
4
0.73
0.39
1.35
Surgery*
8*
1
Radiation
5
1.51
1.27
1.81
Chemotherapy
5
1.22
1.03
1.45
No Treatment
5
1.6
1.37
1.87
Radiation + Surgery
5
1.23
0.87
1.73
Radiation + Chemotherapy
5
1.31
1.11
1.56
Surgery + Chemotherapy
5
1.05
0.67
1.65
Radiation + Surgery + Chemotherapy
5
0.72
0.41
1.27
Surgery*
8*
1
Radiation
6
1.27
1.1
1.46
Chemotherapy
6
1.1
0.95
1.28
No Treatment
6
1.53
1.35
1.73
Radiation + Surgery
6
1.04
0.77
1.41
Radiation + Chemotherapy
6
1.13
0.98
1.32
Surgery + Chemotherapy
6
1.01
0.66
1.54
Radiation + Surgery + Chemotherapy
6
0.75
0.43
1.3
Surgery*
8*
1
Radiation
7
1.19
1.05
1.36
Chemotherapy
7
1
0.87
1.15
No Treatment
7
1.23
1.1
1.38
Radiation + Surgery
7
1.07
0.8
1.44
Radiation + Chemotherapy
7
1.08
0.93
1.24
Surgery + Chemotherapy
7
0.88
0.57
1.34
Radiation + Surgery + Chemotherapy
7
0.64
0.37
1.11
Surgery*
8*
1
LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, * = designates reference
Age Groups: 4 ( > 40 - < 50 years old) , 5 ( > 50 - < 60 years old), 6 (> 60 - < 70 years old), 7 ( >
70 - < 80 years old), 8 ( > 80 - < 90 years old)
** Adjusted for gender, morphology, gender * morphology, grade, grade * morphology, stage,
stage * morphology, stage * age group, race, gender * treatment type, morphology * treatment
type, grade * treatment type, stage * treatment type, and race * treatment type
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Table 67: Hazard Ratios and 95% Confidence Intervals
Interaction Term of Treatment Group and Race
Extracted from the Cox’s Proportional Hazard’s Final Model (CPHM1)
Hazard
Ratio

Interaction Terms**

95% LCI
95% UCI
Race
Treatment Group
(Moderator)
Radiation
White
1.38
1.04
1.84
Chemotherapy
White
1.1
0.84
1.43
No Treatment
White
1.65
1.28
2.14
Radiation + Surgery
White
0.93
0.56
1.54
Radiation + Chemotherapy
White
1.24
0.96
1.61
Surgery + Chemotherapy
White
0.99
0.57
1.72
Radiation + Surgery + Chemotherapy
White
0.73
0.39
1.35
Surgery*
Other*
1
Radiation
Black
1.51
1.27
1.81
Chemotherapy
Black
1.22
1.03
1.45
No Treatment
Black
1.6
1.37
1.87
Radiation + Surgery
Black
1.23
0.87
1.73
Radiation + Chemotherapy
Black
1.31
1.11
1.56
Surgery + Chemotherapy
Black
1.05
0.67
1.65
Radiation + Surgery + Chemotherapy
Black
0.72
0.41
1.27
Surgery*
Other*
1
LCI = Lower Confidence Interval, UCI = Upper Confidence Interval, * = designates reference
** Adjusted for gender, morphology, gender * morphology, grade, grade * morphology, stage, stage
* morphology, age group, stage * age group, gender * treatment type, morphology * treatment type,
grade * treatment type, stage * treatment type, and age group * treatment type

Section 2: Residuals
The next two figures are the residual plots for the independent variables versus
the log of time in months (Figures 13 and 14). A residual for a ―variable‖ is defined as
the difference between the actual value and the estimated value for all units or individuals
given for that particular ―variable‖ contained in the model equation. These plots were
generated to assess the overall fit of the Cox Proportional Hazard model to the lung
cancer data. When the requirements or assumptions for the semi-parametric Cox247

proportional Hazards model are met, the model would be appropriate or correctly
estimate the behavior of the data. Validating or corroborating the final Cox Proportional
Hazard model results via residual analysis established that the initial non-proportional
covariates (age group at diagnosis, race, and treatment group) were independent of
survival time for that period under study. If the residuals exhibited a trend, e.g. increased
over time for the covariates of interest, the hazard ratio or relative risk could be
overestimated (overestimation could lead to inflated coefficient estimates) and those
covariates would not be time-invariant across the study period. As the residual plots for
the covariates over survival time for the 5 year study time did not demonstrate any trends,
the use of the Cox Proportional Hazards model was appropriate. Residual analysis was
also performed to evaluate the proportionality and constant hazard assumptions for the
remaining covariates and interaction terms - no trends were seen with residuals and the
values fell about zero (Figures 17 and 18).
In Figure 17, the Schoenfeld residuals for the independent variable (gender)
versus the log of survival time in months are displayed; the residuals produced during the
statistical testing were weighted and smoothed over time. There is no trend of increasing
or decreasing residual patterns for gender over the log of survival time meaning the
requirement of time-invariance held true; the model accurately estimated the lung cancer
data behavior for females and males. As noted on the x-axis for Figure 17, time was
transformed into the log of survival time due to the nature of survival data (nonnormalcy) due to the effects of censoring. If the transformation of survival time was not
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done, the residual pattern could be inappropriately displayed and interpreted incorrectly.

Figure 17: Residual Testing of the Lung Cancer Distribution
Gender versus the Log of Time in Months

The next figure (Figure 18) includes the Schoenfeld residuals plots for all eight
independent research variables. Although the displays in Figure 18 of the residual plots
are minimized as compared to the display of the single variable, gender as shown in
Figure 17, the intent was to illustrate any overall trend in the residual plots for gender,
stage, grade, morphology, race, age group, treatment group, and marital status versus the
log of survival time. The residual patterns did not increase or decrease over time (no
slope) and were centered about zero as expected; the difference on average between the
estimated and actual data point for the residual should fall or be located along the zero
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axis value. There is no trend of increasing or decreasing residual patterns for the
individual independent variables over the log of survival time meaning the assumption of
proportionality and constant hazard was not violated and that the model accurately
estimated the lung cancer data behavior for females and males.

Figure 18: Residual Testing for the Lung Cancer Distribution
Independent Variables versus the Log of Time in Months

Section 3: Overall Effect of Interaction on Survival
The final assessment for the overall effect on survivorship is presented in this
section. Utilizing the SAS command ―contrast‖ in the PHREG model statement, the
Hazard Ratios and 95% Confidence Intervals were calculated for the variables of gender,
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morphology, stage, grade, race, and treatment type and the statistically significant
interaction terms. In the following equation, the variables that were evaluated for the
overall effect are given. The variables given in the equation were extracted from the full
Cox’ Proportional Hazards model (Table 61-a) that contained statistically significant
interaction terms:

Hazard Rate = exp (1genderI + 2morphologyI + 3gradeI + 4stageI + 5age_groupI +
6raceI + 7treatment_typeI + 8 genderI * morphologyI + 9 gradeI * morphologyI +
10 stageI * morphologyI + 11 stageI * age_groupI + 12 genderI*treatment_typeI +
13 treatment_typeI * morphologyI+ 14 treatment_typeI * grade I +
15treatment_typeI* stageI + 16treatment_typeI* age_groupI +
17treatment_typeI*raceI + others)

In Table 68, the statistically significant Hazard Ratio combinations for the
statistically significant interaction terms are listed by gender, morphology, stage, grade,
race, and treatment type. Following Table 68, an example of the method used to
calculate the Hazard Ratios for the overall effect of gender on the probability or risk for
death for a given morphological lung cancer type is reviewed.
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Table 68: Overall Effect on Survival
Hazard Ratio Combinations
Overall Effect Variable
Gender

Interaction Term
Gender1*Morphology1
Gender1 and Treatment Type1

Hazard Ratios
HR = exp (1 + 8)
HR = exp (1 + 12)

Morphology1 and Gender1
Morphology1 and Grade1

HR = exp (2 + 8)
HR = exp (2 + 9)

Grade

Grade1 and Morphology1
Grade1 and Treatment Type1

HR = exp (3 + 9)
HR = exp (3 + 17)

Stage

Stage1 and Morphology1
Stage1 and Treatment Type1
Stage1 and Age Group1

HR = exp (4 + 10)
HR = exp (4 + 15)
HR = exp (4 + 11)

Age Group1and Treatment Type1
Age Group1 and Stage1

HR = exp (5 + 16)
HR = exp (5 + 11)

Race1 and Treatment Type1

HR = exp ( + 17)

Treatment Type1 and Gender1
Treatment Type1 and Morphology1
Treatment Type1 and Grade1

HR = exp (7 + 12)
HR = exp (7 + 13)
HR = exp (7 + 14)

Treatment Type1 and Stage1
Treatment Type1 and Age Group1
Treatment Type1 and Race1

HR = exp (7 + 15)
HR = exp (7 + 16)
HR = exp (7 + 17)

Morphology

Race
Treatment Type

Note: Considering only Gender 1 (female), Stage I, Grade I, Race I (white), Age Group 1 (Age Group IV
(> 40 - < 50 yrs. old)), Morphology 1, Treatment Type 1(radiation) in this example.
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Evaluating the Overall Effect of Gender on Survival

From the equation below, the gender and the statistically significant interaction terms
containing gender are identified (bolded).
Hazard Rate = exp (1genderI + 2morphologyI + 3gradeI + 4stageI + 5age_groupI +
6raceI +  7treatment_typeI + 8 genderI * morphologyI + 9 gradeI * morphologyI +
10 stageI * morphologyI + 11 stageI * age_groupI +  12 genderI*treatment_typeI +
13 treatment_typeI * morphologyI+ 14 treatment_typeI * grade I +
15treatment_typeI* stageI + 16treatment_typeI* age_groupI +
17treatment_typeI*raceI + others)
From the equation above, the following equation results when examining of the
overall effect of gender on survival:
Hazard Rate = exp (1genderI + 2morphologyI + 7treatment_typeI + 8 genderI *
morphologyI + 12 genderI*treatment_typeI)

Gender and Morphology
Female: HR (gender =1, morphologyI) = exp (1 + 2morphologyI + 7treatment_typeI +
8 * morphologyI + 12 *treatment_typeI )
Male: HR (gender =0, morphologyI) = exp (

+ 2morphologyI + 7treatment_typeI )

Subtracting male from female given morphologyI, the following equation is given as:
Female: HR (gender =1, morphologyI) = exp (1 + 8 * morphologyI + 12
*treatment_typeI)
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Then looking at morphologyI for morphology 1 = 1 and morphologyI for morphology 4 =
0, the following equation is given as:
Female: HR (gender =1, morphologyI = 1) = exp (1 + 8 + 12 *treatment_typeI)
Female: HR (gender =1, morphologyI = 0) = exp (1
+ 12 *treatment_typeI)

Note that any treatment type does not affect the outcome under the conditions as
stated above. The Hazard Ratio is then calculated for females as compared to males
adjusting for morphology and controlling for treatment group as:
HR = exp (1 + 8)
In Table 69-a the effect of gender on the probability of survival based on the
morphological lung cancer type demonstrate an increase survival for all three non-small
cell lung cancer types for females as compared to males controlling for treatment type.
After adjustment, females versus males with large cell lung cancer are 25% more likely
to survive (HR = 0.75, 95% CI 0.70 – 0.81), whereas females with squamous cell
carcinoma are 18% more likely to survive as compared to males with squamous cell
carcinoma (HR = 0.82, 95% CI 0.76 – 0.87).
The effect of gender on the probability of survival (Table 69-b) shows an overall
increase in survival given the treatment types of chemotherapy, no treatment, radiation +
chemotherapy, and radiation + chemotherapy + surgery. The hazard ratios range from a
minimum of 0.83 to a maximum of 0.92. Females versus males receiving radiation in
combination with chemotherapy and surgery are 17% more likely to survive (HR = 0.83,
95% CI 0.72 – 0.97) and 8% more likely to die when females as compared to males
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receive radiation plus chemotherapy after adjustment. The statistics demonstrate that for
a particular treatment combination statistically significant survivorship is exhibited for
females versus males.

Table 69-a: Overall Effect of Gender on Survival
Hazard Ratios and 95% Confidence Intervals
Gender and Gender*Morphology
Gender
Female

Morphology
Adenocarcinoma
Squamous Cell
Large Cell

HR
0.76
0.82
0.75

95% LCI
0.71
0.76
0.70

95% UCI
0.80
0.87
0.81

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Gender = Male, Reference for Morphology = Small Cell Lung Cancer

Table 69-b: Overall Effect of Gender on Survival
Hazard Ratios and 95% Confidence Intervals
Gender and Gender* Treatment Type
Gender
Female

Treatment Type
Chemotherapy
No Treatment
Radiation + Chemotherapy
Radiation + Chemotherapy + Surgery

HR
0.91
0.88
0.92
0.83

95% LCI
0.85
0.82
0.86
0.72

95% UCI
0.97
0.94
0.98
0.97

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Gender = Male, Reference for Treatment Type = Surgery
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Evaluating the Overall Effect of Morphology on Survival
In Tables 69-c through 69-e the overall effect of morphology on the risk of
survival are given. After adjustment, the risk of death is decreased for squamous cell
carcinoma lung cancer cases by 425% and 40% for large cell lung cancer cases as
compared to small cell lung cancer cases that are female (Table 69-c). In Table 69-d,
large cell (HR = 0.50, 95% CI 0.28 – 0.88) and squamous cell carcinoma (HR = 0.51,
95% CI 0.29 – 0.89) are at an increase risk for survival given that those patients are grade
1.

For the overall effect of morphology on the probability of survival in Table 69-e,

four of five the treatment types are statistically significant for an increased survival with
the HRs ranging from a minimum of 0.44 to a maximum HR of 0.65. The only HR in
Table 69-e that demonstrates a decreased survival or increase risk of death is the
morphologic lung cancer type of adenocarcinoma when those patients receive radiation in
combination with chemotherapy (HR = 1.24, 95% CI 1.04 – 1.49) after adjustment.

Table 69-c: Overall Effect of Morphology on Survival
Hazard Ratios and 95% Confidence Intervals
Morphology and Morphology *Gender
Morphology
Squamous Cell
Large Cell

Gender
Female

HR
0.59
0.60

95% LCI
0.42
0.43

95% UCI
0.82
0.83

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval,
Reference for Morphology = Small Cell Lung Cancer, Reference for Gender = Male
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Table 69-d: Overall Effect of Morphology on Survival
Hazard Ratios and 95% Confidence Intervals
Morphology and Morphology*Grade
Morphology
Squamous Cell
Large Cell
Large Cell

Grade
I
I
III

HR
0.50
0.51
0.54

95% LCI
0.28
0.29
0.32

95% UCI
0.88
0.89
0.92

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence
Interval, Reference for Morphology = Small Cell Lung Cancer, Reference for Grade = IV

Table 69-e: Overall Interaction Effect of Morphology on Survival
Hazard Ratios and 95% Confidence Intervals
Morphology and Morphology*Treatment Type
Morphology
Adenocarcinoma
Squamous Cell
Squamous Cell
Squamous Cell
Large Cell

Treatment Type
Radiation + Chemotherapy
No Treatment
Radiation + Surgery
Surgery + Chemotherapy
Radiation + Surgery

HR
1.24
0.65
0.44
0.62
0.45

95% LCI
1.04
0.53
0.20
0.39
0.20

95% UCI
1.49
0.80
0.97
0.99
0.99

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval,
Reference for Morphology = Small Cell Lung Cancer, Reference for Treatment Type = Surgery
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Evaluating the Overall Effect of Grade on Survival
In the next two tables (Table 69-f and Table 69-g) the effect of grade on the risk
of death are given based on morphology and treatment type. Grade I (HR = 0.64, 95% CI
0.49 – 0.83) and grade III (HR = 0.68, 95% CI 53 – 0.88) demonstrate an increase risk of
survival for patients that have adenocarcinoma as compared to small cell lung cancer
after adjustment. The HR for Grade II adenocarcinoma lung cancer cases was not
statistically significant. In Table 69-g, the effect of grade given the treatment type
received shows a decrease survival for grade II and III lung cancer cases receiving
chemotherapy and a decrease survival for grade III patients receiving radiation in
combination with chemotherapy. The risk of death ranges from a minimum HR of 1.38
to a maximum HR of 1.66. Grade II versus grade IV lung cancer patients are 1.414
times more likely to die when they receive chemotherapy (HR = 1.41, 95% CI 1.03 –
1.95) versus receiving surgery for the treatment of their lung cancer. After adjustment,
for patients with Grade II lung cancer, the risk of death increases by 38% when receiving
radiation in combination with chemotherapy and 66% when receiving chemotherapy
(Table 69-g).
Table 69-f: Overall Effect of Grade on Survival
Hazard Ratios and 95% Confidence Intervals
Grade and Grade*Morphology
Grade
I
III

Morphology
Adenocarcinoma
Adenocarcinoma

HR
0.64
0.68

95% LCI
0.49
0.53

95% UCI
0.84
0.88

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval,
Reference for Morphology = Small Cell Lung Cancer, Reference for Grade = IV
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Table 69-g: Overall Effect of Grade on Survival
Hazard Ratios and 95% Confidence Intervals
Grade and Grade*Treatment Type
Grade
II
III
III

Treatment Type
Chemotherapy
Chemotherapy
Radiation + Chemotherapy

HR
1.41
1.66
1.38

95% LCI
1.03
1.34
1.12

95% UCI
1.95
2.05
1.69

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval,
Reference for Treatment Type = Surgery, Reference for Grade = IV

Evaluating the Overall Effect of Stage on Survival

In Tables 69-h, 69-i, and 69-j, the statistics for the effect of stage on the
probability of survival given morphology, treatment type and age group at the time of
diagnosis are given. In Table 69-h, for all stages of lung cancer (stages 1 through 3) there
is an increase risk of survival for the morphologic types of adenocarcinoma, squamous
cell, and large cell lung cancer as compared to small cell carcinoma after adjustment.
The HRs range from a minimum of 0.41 for stage 1 adenocarcinoma patients to a
maximum of 0.78 for stage 2 large cell lung cancer patients. Also for all stages of cases
with squamous cell lung carcinoma the risk of an increased survival ranges from an HR
of 0.52 to a maximum HR of 0.61 (Table 69-h). There is an increase risk of survival for
stage 1 lung cancer cases receiving six of the seven possible treatment types based on
surgery as the reference group and after adjustment (Table 69-i). Stage 1 lung cancer
patients versus stage 4 lung cancer patients are 57% more likely to survive when they
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receive radiation therapy alone and 31% more likely to survive when they (stage I lung
cancer patients) receive chemotherapy for the treatment of their lung cancer. Comparing
the effect of stage II lung cancer patients receiving radiation therapy alone, there is a 45%
increased risk of survival (HR 0.55, 95% CI 0.44 – 0.69) after adjustment. Also for stage
III versus stage IV lung cancer cases, there is a 29% increased risk of survival when
receiving radiation therapy alone. Noted in Table 69-i, the percent increased risk of
survival decreases with increasing stage; this same trend is exhibited for the no treatment
group. The HRs for the no treatment group increase from 0.48 for stage 1, 0.62 for stage
II and 0.79 for stage III lung cancer cases. This can be interpreted as the percent increase
in survivorship values decreases with increasing stage. For stage I lung cancer case
receiving no treatment there is a 52% increased risk of survival, stage II lung cancer cases
have a 38% increased risk of survival and for stage III lung cancer cases there is a 21%
increased risk of survival (table 69-i).
The statistically significant hazard ratios and 95% confidence intervals for the
overall effect of stage on the risk of death given an age group is shown in Table 69-j. For
all stage of lung cancer, there is a decrease risk of death or increased survivorship for the
four age groups 4 though 7 as compared to age group 8 and after adjustment. The HRs in
Table 69-j range from 0.33 to 0.67 with a trend of increasing HRs with increasing age
group for each of the four age groups listed.
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Table 69-h: Overall Effect of Stage on Survival
Hazard Ratios and 95% Confidence Intervals
Stage and Stage*Morphology

Stage
I
II
III
I
II
III
I
II
III

Morphology
Adenocarcinoma

Squamous Cell

Large Cell

HR
0.41
0.47
0.43
0.52
0.61
0.55
0.67
0.78
0.70

95%
LCI
0.35
0.41
0.37
0.41
0.47
0.43
0.55
0.64
0.57

95%
UCI
0.47
0.55
0.50
0.67
0.78
0.71
0.81
0.95
0.86

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence
Interval, Reference for Morphology = Small Cell Lung Cancer, Reference for Stage = IV
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Table 69-i: Overall Effect of Stage on Survival
Hazard Ratios and 95% Confidence Intervals
Stage and Stage*Treatment Type

Stage
I

II

III

Treatment Group
Radiation
Chemotherapy
No Treatment
Radiation +Surgery
Radiation + Chemotherapy
Surgery + Chemotherapy
Radiation
No Treatment
Radiation +Surgery
Radiation + Chemotherapy
Surgery + Chemotherapy
Radiation
No Treatment

HR
0.43
0.70
0.48
0.53
0.59
0.52
0.55
0.62
0.68
0.76
0.67
0.70
0.79

95%
LCI
0.36
0.58
0.41
0.39
0.50
0.39
0.44
0.51
0.50
0.61
0.48
0.60
0.69

95%
UCI
0.51
0.83
0.56
0.71
0.70
0.69
0.69
0.77
0.94
0.96
0.92
0.83
0.91

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence
Interval, Reference for Treatment Group = Surgery, Reference for Stage = Stage IV
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Table 69-j: Overall Effect of Stage on Survival
Hazard Ratios and 95% Confidence Intervals
Stage and Stage*Age Group
Stage
1

2

3

Age Group
4
5
6
7
4
5
6
7
4
5
6
7

HR
0.35
0.33
0.36
0.41
0.45
0.43
0.46
0.53
0.58
0.55
0.59
0.67

95% LCI
0.26
0.28
0.30
0.35
0.33
0.34
0.37
0.42
0.43
0.45
0.49
0.57

95% UCI
0.47
0.40
0.43
0.49
0.63
0.55
0.58
0.67
0.77
0.67
0.70
0.80

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval,
Reference for Stage = Stage 4, Reference for Age Group = 8, Age Groups: 4 = (> 40 - < 50 yrs),
5 = (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 = (> 80 - < 90 yrs)

Evaluating the Overall Effect of Age Group at Time of Diagnosis on Survival
In the next tables, 69-k and 69-l, the effect of age group on the risk of survival is
given for treatment type and stage.
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Table 69-k: Overall Effect of Age Group on Survival
Hazard Ratios and 95% Confidence Intervals
Age Group and Age Group*Treatment Type

Age Group
4

5

6
7

Treatment Type
Radiation
Chemotherapy
Radiation +Surgery
Radiation + Chemotherapy
Radiation + Chemotherapy + Surgery
Chemotherapy
Radiation +Surgery
Radiation + Chemotherapy
Radiation + Chemotherapy + Surgery
Radiation + Chemotherapy + Surgery
No Treatment

HR
0.83
0.66
0.56
0.74
0.44
0.64
0.54
0.72
0.43
0.51
1.35

95%
LCI
0.69
0.57
0.35
0.65
0.24
0.48
0.33
0.55
0.23
0.28
1.05

95%
UCI
0.99
0.75
0.89
0.86
0.79
0.84
0.91
0.95
0.80
0.95
1.74

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Treatment Group = Surgery, Reference for Age Group = 8, Age Groups: 4 = (> 40 < 50 yrs), 5 = (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 = (> 80 - < 90 yrs)
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Table 69-l: Overall Effect of Age Group on Survival
Hazard Ratios and 95% Confidence Intervals
Age Group and Age Group*Stage
Age Group
4

5

6

7

Stage
I
II
III
I
II
III
I
II
III
I
III
III

HR
0.51
0.48
0.52
0.49
0.47
0.50
0.59
0.56
0.61
0.69
0.66
0.71

95% LCI
0.40
0.37
0.40
0.37
0.41
0.43
0.46
0.48
0.55
0.53
0.56
0.62

95% UCI
0.64
0.63
0.66
0.65
0.53
0.59
0.77
0.66
0.67
0.90
0.76
0.80

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Stage = Stage 4, Reference for Age Group = 8, Age Groups: 4 = (> 40 - < 50 yrs), 5
= (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 = (> 80 - < 90 yrs)

Evaluating the Overall Effect of Race on Survival

In Table 69-m, the statistically significant HRs and 95%CIs for the overall effect
of race on the probability of survival given treatment type are given. For white versus
other lung cancer cases, there is a 1.43 times increased risk of death when the patient
receives chemotherapy and a 1.91 times increase in the risk of death when that case
receives no treatment. For black lung cancer cases versus other lung cancer cases, the
risk of death increases from 1.57 times when they receive chemotherapy alone to a 2.10
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times increase in the risk of death when the patient receives no treatment.

Table 69-m: Overall Effect of Race on Survival
Hazard Ratios and 95% Confidence Intervals
Race and Race*Treatment Type
Race
White
Black

Treatment Type
Chemotherapy
No Treatment
Chemotherapy
No Treatment

HR
1.43
1.91
1.57
2.10

95% LCI
1.07
1.46
1.15
1.57

95% UCI
1.90
2.50
2.14
2.82

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Race = 3 (or Other), Reference for Treatment Group = Surgery

Evaluating the Overall Effect of Treatment Type on Survival

In the next five tables, the effect of treatment type received for the probability of survival
given morphology, grade, stage, age group and race. There were no statistically
significant HRs and 95% CIs when the overall effect of treatment on the risk of survival
was evaluated for gender. For the treatment type of chemotherapy (Table 69-n), the risk
of survival was increased by 48% when the patient had large cell lung cancer versus
small cell lung cancer (HR = 0.52, 95% CI 0.30 – 0.91). In Table 69-o, for the treatment
type effect of chemotherapy, there was a decrease in the risk of death for both grade 1
and grade 3 lung cancer. There was an increase in survivorship of 49.8% for grade 1
patients receiving chemotherapy (HR = 0.50, 95% CI 0.27 – 0.94) and a 49% increase in
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survival for grade 3 patients receiving chemotherapy. All other
treatment types did not present statistically significant HRs with 95%CIs. The effect of
treatment type on the risk of death given the stage (Table 69-p) of lung cancer
demonstrated an decreased risk of survival for those stage 1 cases receiving
chemotherapy alone (HR = 0.51, 95% 0.28 - 0.90) but a 2.10 times increased risk for
death when stage 2 lung cancer cases received radiation alone as their treatment for lung
cancer. For those lung cancer patient receiving chemotherapy in age groups 5 and 7, the
risk of survival increased by as much as 79% (Table 69-q). In age group 6, when the
treatment was radiation therapy alone versus surgery, the risk of death increased 2.07
times (HR = 2.07, 95% CI 1.04 – 4.13) after adjustment. In the last table (Table 69-r),
the overall effect of treatment type on the risk of survival given raceI, shows that for
black and white lung cancer cases, when the treatment was chemotherapy the risk of
death decreases by as much as 77%.
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Table 69-n: Overall Effect of Treatment Type on Survival
Hazard Ratios and 95% Confidence Intervals
Treatment Type and Treatment Type*Morphology
Treatment Type
Chemotherapy

Morphology
Large Cell

HR
0.52

95% LCI
0.30

95% UCI
0.91

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence
Interval, Reference for Treatment Group = Surgery, Reference for Morphology = Small Cell
Lung Cancer

Table 69-o: Overall Effect of Treatment Type on Survival
Hazard Ratios and 95% Confidence Intervals
Treatment Type and Treatment Type*Grade
Treatment Type
Chemotherapy
Chemotherapy

Grade
I
III

HR
0.50
0.51

95% LCI
0.27
0.28

95% UCI
0.94
0.94

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence
Interval, Reference for Treatment Group = Surgery, Reference for Grade = Grade IV

Table 69-p: Overall Effect of Treatment Type on Survival
Hazard Ratios and 95% Confidence Intervals
Treatment Type and Treatment Type*Stage
Treatment Type
Chemotherapy
Radiation

Stage
I
II

HR
0.51
2.10

95% LCI
0.28
1.08

95% UCI
0.90
4.06

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval,
Reference for Treatment Group = Surgery, Reference for Stage = Stage 4
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Table 69-q: Overall Effect of Treatment Type on Survival
Hazard Ratios and 95% Confidence Intervals
Treatment Type and Treatment Type*Age Group
Treatment Type
Chemotherapy
Radiation
Chemotherapy

Age Group
5
6
7

HR
0.53
2.07
0.45

95% LCI
0.29
1.04
0.21

95% UCI
0.98
4.13
0.97

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Stage = Stage 4, Reference for Age Group = 8, Age Groups: 4 = (> 40 - < 50 yrs), 5
= (> 50 - < 60 yrs), 6 = (> 60 - < 70 yrs), 7 = (> 70 - < 80 yrs), 8 = (> 80 - < 90 yrs)

Table 69-r: Overall Effect of Treatment Type on Survival
Hazard Ratios and 95% Confidence Intervals
Treatment Type and Treatment Type*Race
Treatment Type
Chemotherapy
Chemotherapy

Race
White
Black

HR
0.41
0.53

95% LCI
0.23
0.38

95% UCI
0.75
0.75

Note: HR = Hazard Ratio, LCI = Lower Confidence Interval, UCI = Upper Confidence Interval
Reference for Race = 3, Reference for Treatment Group = Surgery
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Hypothesis III Conclusion
After evaluating the results generated during Hypothesis 3 testing, the decision
was made to reject the null hypothesis because statistically significant differences existed
in survival between women and men after controlling for covariates and interaction
terms. The final CPH model included stratification based on gender, stage, grade,
morphology and treatment type as well as investigating main effects and the effect of
moderating variables on the association between independent variables and survival.
The additional information obtained by utilizing a statistical model that included
interaction terms served to reveal increased hazard ratios that demonstrated female and
male lung cancer cases had survival patterns that were moderated by the treatment type
received. When the overall effect was examined, survival differences were exhibited.
Females as compared to males had an increased risk of survivorship specific to different
treatment types and lung cancer type. Of all the treatment groups, the greatest increased
survival was for women versus men being treated with radiation in combination with
surgery and chemotherapy (HR = 0.83, 95% CI 0.72 – 0.98). The hazard ratios based on
the gender effect demonstrated an increase in survivorship for females versus males. But
when the hazard ratios for the interaction term for gender and treatment type received
were examined, females were at a decreased survival by as much as 18%. Without
consideration of the overall effect of gender this survival advantage would not have been
identified and the results could have been misinterpreted.
In conclusion, female lung cancer cases have been reported in the literature to
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have increased survival as well as decreased survival as compared to males with lung
cancer. Without the modeling approach presented in this research, specific treatment
regimens and the importance of that treatment on survivorship would not have been
ascertained for females as compared to males. The answer to the research question of
―Does the lung cancer treatment received impact gender-specific survival‖ has been
presented for this data set. The research results found that gender does play a role in
some of the lung cancer treatment selected and that selection impacts gender specific
survival.
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CHAPTER V: DISCUSSION
Introduction
Chapter 5 summarizes the results of this research with 1) an assessment of the
major findings for the statistical analyses of the three hypotheses tested, 2) comparison of
the key findings with current literature for consistency 3) an evaluation of the key
findings for inconsistencies with current literature, 4) a review of the strengths and the
weakness of the research study, 5) a presentation of the significant research findings as it
relates to the importance in Public Health and lastly, 6) and future directions. The
purpose of this research was to investigate if any differences in lung cancer treatment
received were based on gender, and whether any associated treatment differences
impacted gender-specific survival. To examine the relationship between gender-specific
treatment and survival, the first research question to answer was if differences in lung
cancer treatment (the outcome variable) existed based on gender (an independent
variable). The question of gender-specific lung cancer treatments was important to
address as a first step in the investigation as there are no published quantitative results
that show whether there is a statistically significant difference regarding the lung cancer
treatment received by women as compared to men12, 40-45. The selection of a particular
lung cancer treatment is a clinical decision based on standardized recommendations
which considers several parameters including morphologic type, stage, and grade of lung
cancer4, 9, 13. Each morphologic type of lung cancer has its own medical intervention that
can include any combination of surgery, radiation therapy, and/or chemotherapy. A
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particular lung cancer treatment may vary depending upon other differences such as comorbidities or regional differences, e.g. physician preferences, physician training,
insurance.

Assessment of the Major Findings
The procedures and methods presented in this research concerning genderspecific treatment differences, to the author’s knowledge, have not been published in the
literature. Any differences in lung cancer treatment for females relative to males were
important to ascertain as those differences could affect survival. The research questions
were designed to investigate if gender-specific treatment differences changed the
relationship between female survival and male survival for the data analyzed in this
dissertation. A novel approach was used to evaluate the overall interaction effect and that
impact on the treatment received and survival. To the author’s knowledge this approach
has not been published in the literature as it pertains to lung cancer treatment and
survival. For example, the overall gender effect was calculated from the beta coefficients
for the main effect of gender plus the beta coefficients of the statistically significant
interaction term containing gender. When the beta coefficients were added and
exponentiated the Odds Ratios for treatment received and Hazard Ratios for survival
were generated. From this information, differences in specific lung cancer treatments and
gender specific survival could be ascertained.
Upon examination of the Odds Ratios from the Multinomial Logistic Regression
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model, it was determined that the recommended standard of care for the treatment of
primary lung cancer was not always adhered to for females versus males. For example,
the ORs were statistically significant for stage I female lung cancer cases; those patients
had as much as a 2.78 times increased probability of receiving radiation in combination
with chemotherapy versus the standard of care, surgery. Surgery is the primary modality
for the treatment of early stage lung cancer (stage I); radiation plus chemotherapy is an
adjunct or secondary treatment and the treatment modality could vary based on gender.
When the hazard ratios were assessed some of the treatment decisions for the lung
cancer cases affected males’ survival by increasing their risk for death relative to females.
Depending upon the treatment received and morphologic lung cancer type, males as
compared to females could have an increased hazard for death with the hazard ranging
from 8 % to 29%. These results demonstrated that males had a statistically significant
decrease in survival when the overall gender effect was taken into account. Without the
statistical approach utilized in this research, misinterpretation of gender specific
treatment and survival could have been made. Evaluating just the main effects and/or
interaction effects can give results that conflict with the overall effect a variable
contributes to the outcome.

Hypothesis I
Hypothesis I stated that there was a treatment difference based on gender when
adjusted for the research covariates. The outcome variable of interest was treatment
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group which included eight different lung cancer treatment options. The eight lung
cancer treatment groups were classified as 1) radiation therapy, 2) chemotherapy, 3) no
treatment received, 4) radiation plus surgery, 5) radiation in combination with
chemotherapy, 6) surgery plus chemotherapy, 7) radiation plus chemotherapy plus
surgery and 8) surgery.
The statistics for the data analyzed in this dissertation demonstrated that some
females as compared to males depending upon stage and marital status did not receive the
same lung cancer treatment modality. The standard of care as outlined in the article by
Collins, et. al. (2007) is to treat a later stage lung cancer with chemotherapy or a
combination of chemotherapy and radiation. Treatment decisions are based on the
standards of care established by the medical community are overseen by several
organizations such as the American Medical Association, the American College of
Surgeons, the National Cancer Institute, and the American College of Radiology 33. The
statistical analyses found that some of the treatment selection for stage I and III was
gender dependent. The null hypothesis of no differences in treatment outcomes between
men and women was rejected as there were statistically significant differences between
gender and the lung cancer treatment received.

Hypothesis II
The major finding for Hypothesis II (there was a statistically significant
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difference in survival for female lung cancer cases as compared to the survival for male
lung cancer cases) was the unadjusted gender-specific survival patterns were comparable
to the published literature 14-17. Female lung cancer cases had an increased probability of
survival (increased survivorship) as compared to males. The mean survival time for
females was 19.8 months whereas the mean survival time for males was 16.4 months;
females for this data set ―on average‖ lived approximately 3.0 months longer than the
males; these results were statistically significant. Women were at a lower risk to
experience the event (death) as compared to men for the selected five year time range
under study. Comparing these results to the literature, Ouellette et. al. (1998), ―Lung
Cancer in Women as Compared to Men: Stage, Treatment, and Survival‖ 8, also found
gender differences in survival. Women were found to live, on average, 12 months longer
than men. The authors concluded there was a significant survival difference between
men and women with lung cancer with women having a survival advantage over men.
For the data analyzed in this dissertation, the null hypothesis of no difference was
rejected as it was determined that there was a statistically significant increase in survival
in women with lung cancer as compared to the survival of men with lung cancer.

Hypothesis III
Univariate and multivariate survival analysis were included in the statistical
methods to test Hypothesis Three. Hypothesis III stated that women with the same
histological type, stage, grade of lung cancer, and the same treatment modality differ
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significantly in survival as compared to men with the same histological type, stage, and
grade of lung cancer, and the same treatment modality. The gender effect demonstrated a
decreased risk of death for females versus males dependent upon the treatment received
and the morphologic lung cancer type. After adjustment, females versus males with
large cell lung cancer could exhibit a 30% increase in the probability of survival (HR =
0.75, 95% CI 0.70 – 0.81) and a 29% increase in survival for females versus males with
adenocarcinoma. Based on the statistical analyses with the overall gender effect, females
exhibited a distinct survival advantage when the type of treatment received and
morphological lung cancer type was examined. The majority of the literature17, 27, 40 that
was reviewed males are at increased risk of death as compared to females with lung
cancer. The cited articles do not take into account any effect of gender on survival.
Comparisons were made to the statistics generated by models cited in the literature that
did not mention any adjustment for interaction terms demonstrated females had a survival
advantage as compared to males17, 27, 41. For example, in the article by Ringer, et. al.
(2005), the statistics used for the primary outcome of survival were given as the ChiSquare and Student t test. Although survival rates (%) were given for lung cancer
patients by stage of disease, histologic type, and by gender, there was no mention of
interaction. Fu, et. al. (2007) 12 reported on a model that included interaction terms; the
only interaction term that was statistically significant was gender and age. The authors
found that women and men that were age 50 or greater demonstrated increased survival
as compared to women less than 50 years of age.
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For Hypothesis III, the null hypothesis of no difference was rejected as the results
of the statistical testing supported statistically significant differences in gender specific
survival.

Comparison and Consistency of Key Findings with the Current Literature
When comparing the characteristics of the lung cancer cases, Radzikowska, et. al.,
(2002), investigated demographic factors (gender, age, and smoking) and factors
connected with the disease (histology, performance status, stage, treatment and survival)
for lung cancer patients. Women were found to be more likely to have adenocarcinoma
and SCLC as compared to men. Squamous cell cancer was the predominant type of lung
cancer among men, and less than ten percent of men had adenocarcinoma. This was
consistent with research findings of this dissertation, Kowski, et al., (2010);
adenocarcinoma was the most prevalent histological type for women (17.8%) whereas
squamous cell lung cancer included the greatest number of males (19.4%). Radzikowska,
et. al., (2002) found that 21.6% of all females had adenocarcinoma of the lung. There
was a 2.2% difference for the number of females with adenocarcinoma when both lung
cancer data sets were compared.
Fu, et. al. (2007)12 evaluated the survival rates for men and women who received
one of five treatment groups (surgery alone, radiotherapy alone, surgery + radiotherapy,
no surgery or radiotherapy, unknown) utilizing the life table method. With this method,
for patients receiving surgery as part of their treatment, females had an increased survival
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as compared to men12. For females and males that underwent surgery in combination
with radiation therapy, females had an increase in survival by as much as 66%. This
increase in survivorship for women receiving radiotherapy in combination with surgery
was also demonstrated by Kowski, et. al. (2010) with the Cox Proportional Hazards
model. Women as compared to men receiving radiotherapy in combination with surgery
were 1.08 times more likely to survive (HR = 0.92, 95% CI 0.86 – 0.98). Although each
of the authors utilized different statistical methods, both found similar results of a
decrease survivorship for men versus females when treatment type was evaluated.
There were other areas of agreement (consistency) in this research with cited
literature8, 15, 17, 27, 167 that reported women with lung cancer survive longer than men with
lung cancer. Analyses of data among females demonstrated statistically significant
increased survivorship in the unadjusted survival rates as compared to males utilizing the
Life Table method (non-parametric). Lung cancer mortality rates are higher in men as
compared to women 3, 10. This was consistent with the research findings during
Hypothesis II testing.

Comparison of the Key Findings with the Current Literature for Inconsistency
The article, Ouellette, et. al. (1998), ―Lung Cancer in Women as Compared to
Men: Stage, Treatment, and Survival‖ 8, found gender differences in survival were not
significant. This was inconsistent with the statistical analyses addressing Hypothesis II in
this research which found females having a survival advantage. When stratified analysis
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based on stage of disease was assessed by Ouellette, et. al. (1998); women were found to
live, on average, 12 months longer than men. The authors concluded there was a
statistically significant survival difference after adjusting by stage between men and
women with lung cancer with women having a survival advantage over men. In
comparison to the increased survivorship of women after adjustment for stage, published
by Ouellette, et. al. (1998), this dissertation, Kowski, et. al. (2010) did not find a
statistically significant relationship between gender, stage and survival when the overall
gender effect was considered. These differences in survival were demonstrated utilizing
a semi-parametric statistical model - the Cox Proportional Hazards model. When the
statistics were assessed for the overall gender effect on survival, there were no
statistically significant hazard ratios that included gender and stage.
Ringer, et al. (2005) in the article "Influence of sex on lung cancer histology,
stage, and survival in a Midwestern United States Tumor Registry." identified differences
between men and women with regard to lung cancer type, stage at diagnosis, and
survival. Women were found to have a decreased survival with late stage lung cancer as
compared to men 27 but there was no expansion of the results based on any analysis that
included the type of treatment received for women and men. Kowski, et. al. (2010)
research results for the lung cancer cases demonstrated an inconsistency based on the
treatment received. Females versus males with lung cancer were at a statistically
significant increased risk of survival when they were treated with radiation in
combination with surgery (HR = 0.92, 95% CI 0.86 – 0.98), chemotherapy alone (HR =
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0.91, 95% CI 0.85 – 0.97), radiation in combination with chemotherapy and surgery (HR
= 0.83, 95% CI 0.72 – 0.97) or if no treatment was received (HR = 0.88, 95% CI 0.82 –
0.94) as compared to receiving surgery alone.
Survival rates were shown to be independent of lung cancer morphology as cited
in the article by Visbal, et. al. (2004)17. The survival rates presented in this dissertation
demonstrated a statistically significant difference for the 4 major lung cancer
morphologic types. When the gender effect was considered, females versus males with
squamous cell lung cancer receiving surgery alone demonstrated an increase risk of
survival (HR = 0.82, 95% CI 0.76 – 0.87). Also, females versus males with large cell
lung cancer receiving radiation therapy alone were 1.11 times more likely to survive (HR
= 0.89, 95% CI 0.82 – 0.96). This research expanded the investigation to include the
possible effect of stage, grade, treatment type, age group, marital status, and race for each
morphologic lung cancer type.
The article ―Women and Lung Cancer: Epidemiology, tumor biology, and
emerging trends in clinical research‖ by Belani, et.al. (2007), noted gender specific
differences in cancer prognosis 41. Belani compared several studies examining
histological types of lung cancer and gender differences. For example, the authors noted
that the major histologic type of lung cancer was adenocarcinoma with ratio between
males to females being 1.0 to 1.341. Belani, et. al. (2007) further reported that males as
compared to females have a greater proportion of squamous cell carcinoma
approximately 1.7 to 1.0. As reported in the previous section, adenocarcinoma was the
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most prevalent histological type for females (17.8%) whereas squamous cell lung cancer
included the greatest number of males (19.4%). The difference in the distribution for the
morphologic types could have resulted from differences in the data analyzed in this
dissertation for Kowski, et. al. (2010) versus the data sets Belani, et. al. (2007) examined
as those lung cancer cases were from different studies.

Study Limitations
Different types of bias or systematic error can be initiated in the design phase, the
data collection phase, the analysis phase or during the publication phases for the research
study. Several possible limitations in this research were experienced in the initial phase
of data collection. The data that were collected was secondary data. Secondary data can
be subject to measurement error. This bias could have been introduced by errors made
during data collection by the cancer registries. As the cancer registries collected the data
in a standardized format, this particular limitation was considered to be minimal.
Initially, all cancer registries that were members of NAACCR from the four
geographic regions of the US were possible candidates for inclusion into the study. From
the NAACCR cancer registries, cancer registries were selected that met and maintained
quality standards for the years of study (2000 – 2004). Once it was established that a
cancer registry followed the standardized procedures for NAACCR, two state cancer
registries were randomly selected from each geographic region. Also, there were
differences for each state cancer registry IRB protocol for the release of data. This may
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have introduced a selection bias in that some of the states that were selected randomly
from each geographic region would not release the data; another state had to be selected
from the region. Selection bias is minimal when the samples are selected randomly and
although this was the intent for this research, a completely random selection of the cancer
registries that supplied lung cancer cases for the data set was not achievable; this may
have limited the external validity of the study results due to a systematic or random error
bias.
Another limitation was the limited access over which variables could be obtained
from the cancer registries. Patient anonymity was a major concern limiting the number
of variables that could be obtained for the research study. Also variations due to changes
in the characteristics of the lung cancer population may have been introduced by
geographic differences, e.g. different patterns of care specific to a region, environmental
differences, e.g. an increase in lung cancer cases due to radon and these random
variations may have limited the interpretation of the study results.
When evaluating the statistical analyses, one of the limitations could be identified
as some of the lower bounds of the confidence intervals were minimally statistically
significant, i.e. some of the lower bounds of the confidence intervals did approach one.
The statistics were reported and standardized on the level of significance to the hundreds;
therefore these results were still reported as statistically significant. Not all subgroup
analyses resulted in statistically significant findings, which could be interpreted as a
possible limitation if statistically significant results for all subgroups were anticipated.
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Without the subgroup analyses, the information on treatment and gender specific survival
differences between could not be determined or examined.
One of the major limitations for comparative purposes was that the current
literature8, 15, 17, 27, 167 does not addressed treatment differences based on gender.
Contrary to the current literature, gender specific survival differences, were demonstrated
when females and males were stratified by lung cancer type (morphology), stage, grade
and treatment type and when the effect of moderating variables were accounted for in the
statistical models. The authors Belani, et. al. (2007) expressed an urgent need to increase
research and funding to improve lung cancer care, in particular for women 41, their
recommendation was based on limited information as difference in treatment modality by
gender only included studies focused on surgery alone or radiation therapy alone. For
this research presented in this dissertation, the major treatment types for lung cancer were
critical for a valid assessment. As demonstrated in the statistical analyses, there are
statistically significant differences in the treatments women receive as compared to men
based on stage for the data analyzed in this dissertation.

Study Strengths
The data from the eight cancer registries for this research was acquired over a
year and a half time period. Strength in the study design included the large population
size (power) and quality of data. Each cancer registry that was included in the data set
met national standards as outlined by NAACCR decreasing any discrepancies with data
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collection and data quality. In the design phase, strength of this study was in the protocol
for the selection of the state cancer registries which minimized selection bias by the
random selection of the cancer registries. Error due to random variations in the
characteristics of lung cancer cases was accounted for by assessing random effects during
the statistical testing phase. Possible random variations in the lung cancer cases due to
geographic or environmental differences that may have invalidated the results were
addressed comparing a random effects model to a fixed effects model. No effect on the
association between for the outcome and independent variables were seen for the data
analyzed in this dissertation when the two models were compared. A particular strength
of the study statistical testing included a more complete assessment of gender-specific
survival adjusted for treatment type, stage, morphology, grade and interaction terms.
Studies have not been published in the literature (to the author’s knowledge) utilizing a
statistical modeling approach which included these variables with interaction terms.
Temporal differences due to changes in treatment regimens for the treatment of lung
cancer were minimized as the time range of this study was 5 years (01-01-2000 though
12-31-2004), as the standards of care did not change over this time period. Also there
were no coding changes introduced by NACCR for lung cancer during the study time
range, so any misclassification error would be thought as minimal.
Expanding upon the strength of the methods utilized, initially, during the model
criteria development, different classifications (strata) for lung cancer treatments were
identified. Other independent variables were selected for inclusion into the statistical
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model (the Multinomial Logistic Regression model) to answer question one.
Stratification based on the independent variables of gender, morphology, stage, grade,
age, race and marital status was utilized in the statistical model but this approach is unlike
statistical models in other currently published studies12, 40-45. This research model
identified possible moderating variables that could have affected a lung cancer treatment
based on the overall gender effect. The fixed effects were accounted for in the first
model for the multinomial logistic regression model (MLR1). Another important aspect
in answering Research Question I was to investigate possible random effects. A random
effects component was included in a second multinomial logistic regression (MLR2)
model. The decision to test for possible changes in the associations between the outcome
and independent variables due to random effects was based on previous risk factors cited
in the literature (Chapter Two) which included the environment10, 172 and geographic
variations10. Possible random effects due to these and other risk factors may have
introduced differences in the lung cancer cases from the state cancer registries located in
the four geographic regions of the United States. Any differences in the association
between the outcome and covariates due to the fixed effects versus random effects would
have to be identified as the resultant statistics could be biased and could have included
invalid interpretations.
After the assessment of gender-specific treatment differences as outlined in
Question One during Hypothesis I testing, Research Questions Two and Three then
expanded the study of survival based on gender differences and other covariates. Other
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covariates included the treatment received, age, morphologic lung cancer type, grade and
stage. Research Question Two examined survival rates between males and females
without any statistical adjustment for additional covariates in the model. The
investigation of the unadjusted lung cancer survival for the data analyzed in this
dissertation over the five year time interval served a two-fold purpose. First, an initial
assessment of the unadjusted gender-specific survival associated with these data had to be
made without the effects of the covariates on the outcome. Secondly, an evaluation of
the survivorship for these data was necessary so a comparison of the gender specific
survival patterns reported in the literature could be made. In the literature, females with
lung cancer have been reported to have a survival advantage relative to males with lung
cancer3, 10; consistency with the published literature would add to the external validity of
the findings for this research. For example, although interpretations of the unadjusted
results were limited in scope, the individuals comprising the research lung cancer data set
could be representative of the lung cancer cases in the US if the lung cancer data set
survival patterns were consistent with gender-specific lung cancer survival results
published in the literature3, 10.
Other study’s strengths in the methodology to answer to the final research
question during Hypothesis III statistical testing utilized univariate and multivariate
survival analysis. Univariate survival analysis was comprised of evaluating the statistics
and graphs generated during the non-parametric technique for the Life Table Method.
Each independent variable was tested separately to evaluate the proportionality
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assumption between the strata of the independent variable versus survival time. The
proportionality assumption infers that the hazard or risk of failure (death) is constant over
survival time. For the assumption of proportionality to hold true, the graphs between the
survival curves and the strata of the independent variable will be parallel; any
overlapping, diverging or converging lines of the graphs can be cause for concern as this
could violate the basic statistical assumptions for a semi-parametric model.
The semi-parametric method, the Cox’s Proportional Hazards model, was selected
to assess the multivariable relationship between the outcome (survival time) and the
independent variables with the inclusion of interaction terms. In order to obtain a model
with the inclusion and exclusion of variables and variable combination for second order
interaction terms, the stepwise procedure was used. Included in the evaluation of the
model fit, any non-proportionality concerns for a non-constant hazard over survival time
were addressed via residual analysis. Residual analysis was used to test for trends; any
resultant trends in the residual plots for the individual variables would be displayed as
increasing or decreasing slopes over the log of survival time. If a trend was displayed for
a variable over the log of survival time, the model would be inappropriate for the variable
selected or the model would ―not fit the data‖ properly as the associated hazard for the
variable was not constant over the survival time.
The reported relationship in the literature between gender and survival is
inconsistent. Contrary to some of the articles published in the literature8, 15, 17, 27, 167 ,
with women having increased survivorship as compared to men, in some circumstances
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this research found female had a survival disadvantage as compared to males. Treatment
differences based on gender were demonstrated and that those treatment differences
changed the association for gender-specific survival when adjustments for the covariates
and interaction terms were taken into account in the model. When the overall gender
effect was considered for the treatment received, morphologic lung cancer type and
survival, this research design and resultant findings supports the literature27 in which
females have an increased survivorship as compared to men.

Public Health Importance
Finding the most effective treatment for increasing lung cancer survival has
immense public health consequences. Finding the most effective treatment includes
many factors that must be accounted for but can be difficult to ascertain. Prior to
investigating effective treatments that increase survival, the examination of treatment
differences based on key factors for lung cancer would have to be made. This would
include any treatment for lung cancer that differed on the basis of gender. The clinical
pathways for the care of lung cancer patients is standardized but when quantifiable
techniques were utilized, differences in the standard of care for lung cancer patients were
demonstrated to be gender dependent. For example, the standard of care for early stage
lung cancer is surgery. For this data set, surgery was not consistently shown to be the
first treatment choice for early stage lung cancer. For example, separated females with
stage I lung cancer versus separated males with stage I were 2.82 times more likely to
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receive chemotherapy alone (OR = 2.82, 95% CI 1.17 – 6.80) as compared to receiving
surgery alone. For later stage disease, divorced females as compared to divorced males
with stage III lung cancer were 1.57 times more likely to receive radiation in combination
with surgery and chemotherapy (OR = 1.57, 95% CI 1.07 – 2.30) versus receiving
surgery alone. For later stage disease, radiation therapy in combination with
chemotherapy or chemotherapy alone is the standard treatment recommendation.
Building on this information of gender differences in lung cancer treatments,
when the overall gender effect was assessed for survival, lung cancer type and the
treatment received, males versus females had a statistically significant decrease in
survival. Gender specific survivorship was demonstrated to be statistically significant
when adjusted for grade, grade*morphology, stage, stage*morphology, age group,
stage*age group, race, treatment type*morphology, treatment type*grade, treatment
type*stage, treatment type*age group, and treatment type*race. When the gender effect
for survival was assessed, females compared to males had a statistically significant
survival advantage for six of the seven treatment groups. For the other treatment group
of radiation therapy in combination with chemotherapy, the result for the gender effect on
survival was not statistically significant. Generally, lung cancer cases receive a specific
treatment for lung cancer regardless of gender; this was not the case for the data analyzed
for this dissertation. For males versus female lung cancer cases, differences in the type of
treatment received could increase the risk of death or decrease survival time. The
associated gender differences with treatment selection were tested with multiple
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modeling techniques resulting in the same conclusion, there is a statistically significant
difference in the way female and male lung cancer cases are treated. The methods and
statistical analyses outlined in this research identify the impact of treatment decisions on
female and male survival in particular for early stage lung cancer.
The costs associated with lung cancer care are enormous according to the
National Heart Lung & Blood Institute (NHLBI). Lung cancer costs shows medical
expenditures as approximately 10 billion annually, according to the Centers for Medicare
and Medicaid Services (CMS) 115. Over 13% of the total cancer care costs for 2006 were
attributed to lung cancer. The non-medical total or personal care exceeded 250 billion for
the same time period. If it is possible to assess the most effective treatment, there could
be an increase in survival and a decrease in healthcare costs, thereby improving Public
Health.

Future Directions
A first step in the future direction of this research would be a comparative
analysis of an active versus passive cancer registry such as SEER. These data are
collected and compiled independently by SEER registries. Further, the data are publicly
available and issues of patient confidentiality will be minimized. An independent
comparison and verification of the study results would be a necessary next step to verify
that treatment differences based on gender exist. Lastly, a possible future direction, after
validation of the research results presented in this dissertation would be the development
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of a task group to investigate treatment differences based on gender and the subsequent
impact on gender specific survivorship. Several scientific and medical associations such
as the American Medical Association, the American College of Surgeons, the National
Cancer Institute, or the American College of Radiology might possibly accept this role.
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Appendix I: State Demographics
Table 70: Geographic Area: Florida
Profile of Sex and Age Characteristics: 2000
Subject

Number

Percent

Total population

15,982,378

100.0

SEX AND AGE
Male
Female

7,797,715
8,184,663

48.8
51.2

Under 5 years

945,823

5.9

5 to 9 years
10 to 14 years
15 to 19 years
20 to 24 years
25 to 34 years
35 to 44 years

1,031,718
1,057,024
1,014,067
928,310
2,084,100
2,485,247

6.5
6.6
6.3
5.8
13.0
15.5

45 to 54 years
55 to 59 years
60 to 64 years
65 to 74 years
75 to 84 years
85 years and over

2,069,479
821,517
737,496
1,452,176
1,024,134
331,287

12.9
5.1
4.6
9.1
6.4
2.1

38.7

(X)

18 years and over
Male
Female
21 years and over

12,336,038
5,926,729
6,409,309
11,736,378

77.2
37.1
40.1
73.4

62 years and over
65 years and over
Male
Female

3,245,806
2,807,597
1,216,647
1,590,950

20.3
17.6
7.6
10.0

Median age (years)

Legend: (X) Not Applicable
Source: U.S. Census Bureau, Census 2000.
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Table 71: Geographic Area: Idaho
Profile of Sex and Age Characteristics: 2000
Subject

Number

Percent

Total population

1,293,953

100.0

SEX AND AGE
Male
Female

648,660
645,293

50.1
49.9

Under 5 years

97,643

7.5

5 to 9 years
10 to 14 years
15 to 19 years
20 to 24 years
25 to 34 years
35 to 44 years
45 to 54 years

100,756
104,608
110,858
93,994
169,433
192,968
170,248

7.8
8.1
8.6
7.3
13.1
14.9
13.2

60,024
47,505
75,970
51,889
18,057

4.6
3.7
5.9
4.0
1.4

33.2

(X)

18 years and over
Male
Female
21 years and over

924,923
458,934
465,989
860,220

71.5
35.5
36.0
66.5

62 years and over
65 years and over
Male
Female

173,097
145,916
64,161
81,755

13.4
11.3
5.0
6.3

55 to 59 years
60 to 64 years
65 to 74 years
75 to 84 years
85 years and over
Median age (years)

Legend: (X) Not Applicable
Source: U.S. Census Bureau, Census 2000.
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Table 72: Geographic Area: Indiana
Profile of Sex and Age Characteristics: 2000
Subject

Number

Percent

Total population

6,080,485

100.0

SEX AND AGE
Male
Female

2,982,474
3,098,011

49.0
51.0

Under 5 years
5 to 9 years
10 to 14 years
15 to 19 years
20 to 24 years
25 to 34 years
35 to 44 years

423,215
443,273
443,416
453,482
425,731
831,125
960,703

7.0
7.3
7.3
7.5
7.0
13.7
15.8

45 to 54 years
55 to 59 years
60 to 64 years
65 to 74 years
75 to 84 years
85 years and over

816,865
294,169
235,675
395,393
265,880
91,558

13.4
4.8
3.9
6.5
4.4
1.5

35.2

(X)

18 years and over
Male
Female

4,506,089
2,174,756
2,331,333

74.1
35.8
38.3

21 years and over
62 years and over
65 years and over
Male
Female

4,221,426
888,688
752,831
303,797
449,034

69.4
14.6
12.4
5.0
7.4

Median age (years)

Legend: (X) Not Applicable
Source: U.S. Census Bureau, Census 2000.
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Table 73: Geographic Area: Massachusetts
Profile of Sex and Age Characteristics: 2000
Subject

Number

Percent

Total population

6,349,097

100.0

SEX AND AGE
Male
Female

3,058,816
3,290,281

48.2
51.8

Under 5 years
5 to 9 years
10 to 14 years
15 to 19 years
20 to 24 years
25 to 34 years
35 to 44 years

397,268
430,861
431,247
415,737
404,279
926,788
1,062,995

6.3
6.8
6.8
6.5
6.4
14.6
16.7

873,353
310,002
236,405
427,830
315,640
116,692

13.8
4.9
3.7
6.7
5.0
1.8

36.5

(X)

18 years and over
Male
Female

4,849,033
2,289,671
2,559,362

76.4
36.1
40.3

21 years and over
62 years and over
65 years and over
Male
Female

4,587,935
997,277
860,162
341,539
518,623

72.3
15.7
13.5
5.4
8.2

45 to 54 years
55 to 59 years
60 to 64 years
65 to 74 years
75 to 84 years
85 years and over
Median age (years)

Legend: (X) Not Applicable
Source: U.S. Census Bureau, Census 2000.
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Table 74: Geographic Area: Nebraska
Profile of Sex and Age Characteristics 2000
Subject

Number

Percent

Total population

1,711263

100.0

SEX AND AGE
Male
Female

843,351
867,912

49.3
50.7

Under 5 years
5 to 9 years
10 to 14 years
15 to 19 years
20 to 24 years
25 to 34 years
35 to 44 years

117,048
123,445
128,934
134,909
120,331
223,273
263,834

6.8
7.2
7.5
7.9
7.0
13.0
15.4

45 to 54 years
55 to 59 years
60 to 64 years
65 to 74 years
75 to 84 years
85 years and over

225,754
77,584
63,956
115,699
82,543
33,953

13.2
4.5
3.7
6.8
4.8
2.0

35.3

(X)

18 years and over
Male
Female

1,261,021
612,965
648,056

73.7
35.8
37.9

21 years and over
62 years and over
65 years and over
Male
Female

1,180,859
269,893
232,195
95,630
136,565

69.0
15.8
13.6
5.6
8.0

Median age (years)

Legend: (X) Not Applicable
Source: U.S. Census Bureau, Census 2000.
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Table 75: Geographic Area: Oregon
Profile of Sex and Age Characteristics: 2000
Subject

Number

Percent

Total population

3,421,399

100.0

SEX AND AGE
Male
Female

1,696,550
1,724,849

49.6
50.4

Under 5 years
5 to 9 years
10 to 14 years
15 to 19 years
20 to 24 years
25 to 34 years
35 to 44 years

223,005
234,474
242,098
244,427
230,406
470,695
526,574

6.5
6.9
7.1
7.1
6.7
13.8
15.4

45 to 54 years
55 to 59 years
60 to 64 years
65 to 74 years
75 to 84 years
85 years and over

507,155
173,008
131,380
219,342
161,404
57,431

14.8
5.1
3.8
6.4
4.7
1.7

36.3

(X)

18 years and over
Male
Female

2,574,873
1,262,405
1,312,468

75.3
36.9
38.4

21 years and over
62 years and over
65 years and over
Male
Female

2,429,348
513,663
438,177
186,477
251,700

71.0
15.0
12.8
5.5
7.4

Median age (years)

Legend: (X) Not Applicable
Source: U.S. Census Bureau, Census 2000.
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Table 76: Geographic Area: Rhode Island
Profile of Sex and Age Characteristics: 2000
Subject

Number

Percent

Total population

1,048,319

100.0

SEX AND AGE
Male
Female

503,635
544,684

48.0
52.0

Under 5 years
5 to 9 years
10 to 14 years
15 to 19 years
20 to 24 years
25 to 34 years
35 to 44 years

63,896
71,905
71,370
75,445
71,813
140,326
170,310

6.1
6.9
6.8
7.2
6.9
13.4
16.2

45 to 54 years
55 to 59 years
60 to 64 years
65 to 74 years
75 to 84 years
85 years and over

141,863
49,982
39,007
73,684
57,821
20,897

13.5
4.8
3.7
7.0
5.5
2.0

36.7

(X)

18 years and over
Male
Female

800,497
376,436
424,061

76.4
35.9
40.5

21 years and over
62 years and over
65 years and over
Male
Female

748,445
175,111
152,402
60,002
92,400

71.4
16.7
14.5
5.7
8.8

Median age (years)

Legend: (X) Not Applicable
Source: U.S. Census Bureau, Census 2000.
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Table 77: Geographic Area: South Carolina
Profile of Sex and Age Characteristics: 2000
Subject

Number

Percent

Total population

4,012,012

100.0

SEX AND AGE
Male
Female

1,948,929
2,063,083

48.6
51.4

Under 5 years
5 to 9 years
10 to 14 years
15 to 19 years
20 to 24 years
25 to 34 years
35 to 44 years

264,679
285,243
290,479
295,377
281,714
560,831
625,124

6.6
7.1
7.2
7.4
7.0
14.0
15.6

45 to 54 years
55 to 59 years
60 to 64 years
65 to 74 years
75 to 84 years
85 years and over

550,321
206,762
166,149
270,048
165,016
50,269

13.7
5.2
4.1
6.7
4.1
1.3

35.4

(X)

18 years and over
Male
Female

3,002,371
1,432,413
1,569,958

74.8
35.7
39.1

21 years and over
62 years and over
65 years and over
Male
Female

2,814,131
581,573
485,333
196,734
288,599

70.1
14.5
12.1
4.9
7.2

Median age (years)

Legend: (X) Not Applicable
Source: U.S. Census Bureau, Census 2000.
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Appendix II: Lung Cancer Distribution Tables
Table 41: Lung Cancer Distribution - Treatment Group versus Race
Treatment Group
Radiation
I
Chemotherapy
II
Surgery
III
Radiation + Surgery
IV
Radiation + Chemotherapy
V
Surgery + Chemotherapy
VI
Radiation + Surgery +
Chemotherapy
VII
No Radiation, Surgery,
and/or Chemotherapy
VIII

Race
White
Black
Other
White
Black
Other
White
Black
Other
White
Black
Other
White
Black
Other
White
Black
Other
White
Black
Other
White
Black
Other

Frequency Percent
3921
90.1
401
9.2
29
0.7
6026
93.1
383
5.9
63
1.0
11967
94.0
659
5.2
102
0.8
990
93.1
64
6.0
9
0.9
7262
91.3
627
7.9
66
0.8
1166
93.4
75
6.0
8
0.6
1254
93.0
81
6.0
13
1.0
8872
91.5
752
7.8
73
0.8

There were no obvious differences in treatment groups versus and distribution of
race – see Table 41 in Appendix B. The majority of lung cancer cases are White ranging
from 91.3% of all lung cancer cases in Group V (Radiation and Chemotherapy) to 94% of
all lung cancer cases in Group III (Surgery). The classification of ―Other‖ for race
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contained the least amount of lung cancer cases for each treatment group with each
Treatment Group having a minimum of approximately one percent within each treatment
classification (I – VIII).
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Table 42: Lung Cancer Distribution - Treatment Group vs. Marital Status at Diagnosis
Treatment Group
Marital Status Frequency Percent
Single
482
11.1
Radiation
Married
2309
53.1
I
Separated
46
1.1
Divorced
486
11.2
Widowed
1028
23.6
Single
652
10.1
Chemotherapy
Married
3879
59.9
II
Separated
63
1.0
Divorced
734
11.3
Widowed
1144
17.7
Single
1014
8.0
Surgery
Married
8014
63.0
III
Separated
76
0.6
Divorced
1301
10.2
Widowed
2323
18.3
Single
93
8.8
Radiation + Surgery
Married
693
65.2
IV
Separated
6
0.6
Divorced
108
10.2
Widowed
163
15.3
Radiation +
Single
784
9.9
Chemotherapy
Married
4991
62.7
V
Separated
86
1.1
Divorced
982
12.3
Widowed
1112
14.0
Surgery +
Single
103
8.3
Chemotherapy
Married
873
69.9
VI
Separated
9
0.7
Divorced
122
9.8
Radiation + Surgery +
Single
98
7.3
Chemotherapy
Married
934
69.3
VII
Separated
11
0.8
Divorced
148
11.0
Widowed
157
11.7
321

No Radiation, Surgery,
and/or Chemotherapy
VIII

Single
Married
Separated
Divorced
Widowed

1201
5066
70
1039
2321

12.4
52.2
0.7
10.7
23.9

For all treatment groups in Table 42 (Treatment Group vs. Marital Status at
Diagnosis), the greatest percentage of the lung cancer cases were married at the time of
diagnosis ranging from 52.2 percent for Treatment Group VIII to maximum percentage
of 69.9 percent for surgical and chemotherapy, Group VI.
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Table 43: Lung Cancer Distribution - Treatment Group vs. Age Group at Diagnosis
Treatment
Group

Radiation
I

Chemotherapy
II

Surgery
III

Radiation + Surgery
IV

Radiation +
Chemotherapy
V

Surgery +
Chemotherapy
VI

Age Group at
Diagnosis
Frequency Percent
> 40 - < 50
> 50 - < 60
> 60 - < 70
> 70 - < 80
> 80 - < 90

189
573
1093
1675
821

4.3
13.2
25.1
38.5
18.9

> 40 - < 50
> 50 - < 60
> 60 - < 70
> 70 - < 80
> 80 - < 90

404
1192
2061
2225
590

6.2
18.4
31.8
34.4
9.1

> 40 - < 50
> 50 - < 60
> 60 - < 70
> 70 - < 80
> 80 - < 90
> 40 - < 50
> 50 - < 60
> 60 - < 70
> 70 - < 80
> 80 - < 90
> 40 - < 50
> 50 - < 60
> 60 - < 70
> 70 - < 80

442
1662
3893
5366
1365
59
178
358
395
73
666
1743
2705
2361

3.5
13.1
30.6
42.2
10.7
5.6
16.8
33.7
37.2
6.9
8.4
21.9
34.0
29.7

> 80 - < 90
> 40 - < 50
> 50 - < 60
> 60 - < 70
> 70 - < 80

480
92
287
479
350

6.0
7.4
23.0
38.4
28.0
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Radiation + Surgery +
Chemotherapy
VII

No Radiation, Surgery,
and/or Chemotherapy
VIII

> 80 - < 90
> 40 - < 50
> 50 - < 60
> 60 - < 70
> 70 - < 80
> 80 - < 90
> 40 - < 50
> 50 - < 60
> 60 - < 70
> 70 - < 80
> 80 - < 90

41
133
345
485
366
19
367
1199
2462
3666
2003

3.3
9.9
25.6
36.0
27.2
1.4
3.8
12.4
25.4
37.8
20.7

The greatest percentage for age group IV (> 70 - < 80) were found in Treatment
Groups I (38.5), II (34.4), III (42.2), IV (37.2), V (29.7), and VIII (37.8). The remaining
two treatment groups had the highest percentage in the third age group, > 60 - < 70,
Treatment Group VI (38.4) and Treatment Group VII (36.0).
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Appendix III: Chemotherapy Agents
Table 78: Chemotherapy Agents for Lung Cancer

Source: Alexander Spira, M.D., Ph.D., and David S. Ettinger, M.D.; N Engl J Med 2004;
350:379-92.
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Appendix IV: Calculation of the Overall Interaction Effect
Calculation of the overall effect for the treatment type received (variables extracted for
the Multinomial Logistic Regression Model).

Stage
The interaction terms containing stage with the main effects are included in the following
equation that was originally extracted from the full model.
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI +
5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 9
stageI* age_groupI + 10 morphologyI + 11 raceI
The terms that contain stage are identified and include the main effect:
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI +
5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI +
9 stageI* age_groupI + 10 morphologyI + 11 raceI
The following equation results:
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 4 gradeI + 5age_groupI + 6
genderI*stageI + 8 stageI*gradeI + 9 stageI* age_groupI
These terms must be evaluated separately to assess the effect of stage on the outcome. In
other words, as there are three interaction terms with stage, three separate equations
containing stage are calculated for gender, grade and age group. In Part I below, the
example treatment is radiation, stageI (stageI = stage 1 coded as 1 and stage IV coded as
0 (reference). Part II will examine stage and grade and Part III will assess stage and age
group.
Part I: Evaluating stage and gender
Stage I: Logit (Y= Radiation | stageI = 1, genderI) =  + 1 genderI + 2 + 4 gradeI +
5age_groupI + 6 genderI* + 8 *gradeI + 9 * age_groupI
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Stage IV: Logit (Y= Radiation | stageI = 0, genderI) =  + 1 genderI + 4 gradeI +
5age_groupI
Subtracting stage I from stage IV, the following is given:
Logit (Y= Radiation | stageI = 1, genderI) = 2 + 6 genderI* + 8 *gradeI + 9 *
age_groupI
Looking at females as compared to males with gender = 1 for females and gender = 0 for
males.
Logit (Y= Radiation | stageI = 1, genderI = 1) = 2 + 6 + 8 *gradeI + 9 * age_groupI
Logit (Y= Radiation | stageI = 1, genderI = 0) = 2
+ 8 *gradeI + 9 * age_groupI

The Odds Ratio for females with stage 1 lung cancer (grade and age group are fixed or
controlled for) is given as: OR = exp (2 + 6)

Part II: Evaluating stage and grade
Stage I: Logit (Y= Radiation | stageI = 1, genderI) =  + 1 genderI + 2 + 4 gradeI +
5age_groupI + 6 genderI* + 8 *gradeI + 9 * age_groupI
Stage IV: Logit (Y= Radiation | stageI = 0, genderI) =  + 1 genderI + 4 gradeI +
5age_groupI
Subtracting stage I from stage IV, the following is given:
Logit (Y= Radiation | stageI = 1, genderI) = 2 + 6 genderI* + 8 *gradeI + 9 *
age_groupI
Looking at grade I as compared to grade IV with gradeI = 1 for grade I and gradeI = 0 for
grade IV.
Logit (Y= Radiation | stageI = 1, gradeI = 1) = 2 + 6 genderI* + 8 + 9 * age_groupI
Logit (Y= Radiation | stageI = 1, gradeI = 0) = 2 + 6 genderI*
+ 9 * age_groupI
The Odds Ratio for stage 1 grade 1 lung cancer (gender and age group are fixed or
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controlled for) is given as: OR = exp (2 + )
Part III: Evaluating stage and age group
Stage I: Logit (Y= Radiation | stageI = 1, age_groupI) =  + 1 genderI + 2 + 4 gradeI +
5age_groupI + 6 genderI* + 8 *gradeI + 9 * age_groupI
Stage IV: Logit (Y= Radiation | stageI = 0, age_groupI =  + 1 genderI + 4 gradeI +
5age_groupI
Subtracting stage I from stage IV, the following is given:
Logit (Y= Radiation | stageI = 1, age_groupI) = 2 + 6 genderI* + 8 *gradeI + 9 *
age_groupI
Looking at grade I as compared to grade IV with gradeI = 1 for grade I and gradeI = 0 for
grade IV.
Logit (Y= Radiation | stageI = 1, age_groupI = 1) = 2 + 6 genderI* + 8 *gradeI + 9
Logit (Y= Radiation | stageI = 1, age_groupI = 0) = 2 + 6 genderI* + 8 *gradeI +
The Odds Ratio for stage 1 in age group I (gender and grade are fixed or controlled for) is
given as: OR = exp (2 + )

Grade
Given the equation extracted from the full model:
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI +
5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 9
stageI* age_groupI + 10 morphologyI + 11 raceI
The terms that contain grade are identified and include the main effect:
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI +
5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 9
stageI* age_groupI
The following equation results:
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Logit (Y= Treatment | X) =  + 2 stageI + 4 gradeI + 8 stageI*gradeI
Next, the effect of grade on the probability of receiving radiation therapy as a
treatment, given that the patient is at stageI, is determined as:
Grade I: Logit (Y=Radiation|grade=1, stageI) =  + 2 stageI + 4 + 8 *stageI
Grade IV: Logit (Y=Radiation|grade=0, stageI) =  + 2 stageI
By subtracting the Logit for grade IV from Logit for grade I, the following
equation is given as:
Logit (Y=Radiation |grade=1, stageI) = 4 + 8 *stageI
At the variable stageI which is coded as 1 for stageI and 0 for stageI (V =
reference), the results are given as:
Logit (Y=Radiation |grade=1, stageI =1) = 4
Logit (Y=Radiation |grade=1, stageI =0) = 4

+ 8

Estimating the overall effect of grade (grade I as compared to grade IV) on the
probability of receiving radiation treatment, after adjusting for stageI (stage=1) results in
the following equation for the Odds Ratio is given as:
OR = exp (4 + 8).

Marital Status
The interaction terms containing marital status with the main effects are included in the
following equation that was originally extracted from the full model.
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI +
5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 9
stageI* age_groupI + 10 morphologyI + 11 raceI
The terms that contain stage are identified and include the main effect:
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI +  3 marital_statusI + 4 gradeI
+ 5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI +
9 stageI* age_groupI
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The following equation results:
Logit (Y= Treatment | X) =  + 1 genderI + 3 marital_statusI + 7 genderI*
marital_statusI
Evaluating marital_statusI for marital status = I (single) and marital_statusI for marital
status = V (widowed), the following is given:
Marital Status I: Logit (Y= Radiation | marital_statusI = 1, genderI) =  + 1 genderI +
3 + 7 genderI*
Marital Status V: Logit (Y= Radiation | marital_statusI = 0, genderI) =  + 1 genderI

Subtracting marital status I from marital status IV, the following equation results:
Logit (Y= Radiation | marital_statusI = 1, genderI) = 3 + 7 genderI*
Looking at females as compared to males with genderI = 1 for females and gradeI = 0 for
males.
Logit (Y= Radiation | marital_statusI = 1, genderI = 1) = 3 + 7
Logit (Y= Radiation | marital_statusI = 1, genderI = 0) = 3

The Odds Ratio for the overall interaction effect given marital status for females as
compared to males is given as: OR = exp (3 + 7)

Age Group
The interaction terms containing age group with the main effects are included in the
following equation that was originally extracted from the full model.
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI +
5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 9
stageI* age_groupI + 10 morphologyI + 11 raceI
The terms that contain age group are identified and include the main effect:
Logit (Y= Treatment | X) =  + 1 genderI + 2 stageI + 3 marital_statusI + 4 gradeI +
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5age_groupI + 6 genderI*stageI + 7 genderI* marital_statusI + 8 stageI*gradeI + 9
stageI* age_groupI
The following equation results:
Logit (Y= Treatment | X) =  + 2 stageI + 5age_groupI + 9 stageI* age_groupI
For the next example, the treatment group still remains as Radiation alone. Evaluating
age_groupI for age group I = 1 (> 40 - < 50 year) and age_groupI for age group V = 0 (>
80 - < 90 years), the following is given:
Marital Status I: Logit (Y= Radiation | age_groupI = 1, stageI) =  + 2 stageI + 5 + 9
stageI*
Marital Status V: Logit (Y= Radiation | age_groupI = 0, stageI) =  + 2 stageI

Subtracting age group I from age group V, the following equation results:
Logit (Y= Radiation | age_groupI = 1, stageI) = 5 + 9 stageI*
Looking at stage I and stage IV with stageI = 1 for stage I and stageI = 0 for stage IV.
Logit (Y= Radiation | marital_statusI = 1, stageI = 1) = 5 + 9
Logit (Y= Radiation | marital_statusI = 1, stageI = 0) = 5

The Odds Ratio for the overall interaction effect given age group I controlling for stage is
given as: OR = exp (5 + 9)
Logit (Y= Radiation | stageI = 1, grade =1) =  + 1 gender + 2 stageI + 4 gradeI +
5age_groupI + 6 gender*stageI + 8 stageI*gradeI + 9 stage* age_groupI
Logit (Y= Radiation | stageI = 1, age_group =1) =  + 1 gender + 2 stageI + 4 gradeI +
5age_groupI + 6 gender*stageI + 8 stageI*gradeI + 9 stage* age_groupI
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